<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001928" GROUP_ID="STROKE" ID="945499101312162080" MERGED_FROM="" MODIFIED="2012-04-04 14:41:06 +0200" MODIFIED_BY="Hazel Fraser" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2012-04-04 14:41:06 +0200" MODIFIED_BY="Hazel Fraser">
<TITLE>Calcium antagonists for acute ischemic stroke</TITLE>
<CONTACT MODIFIED="2012-04-04 14:41:06 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="16502" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Ming</FIRST_NAME><LAST_NAME>Liu</LAST_NAME><POSITION>Professor of Neurology</POSITION><EMAIL_1>wyplmh@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 8542 3551</PHONE_1><FAX_1>+86 28 8542 3551</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-04-04 14:41:06 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="06102852219372169079100714171047" ROLE="AUTHOR"><PREFIX>Miss</PREFIX><FIRST_NAME>Jing</FIRST_NAME><LAST_NAME>Zhang</LAST_NAME><EMAIL_1>zhangjing0909@163.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY></ADDRESS></PERSON><PERSON ID="4F00216982E26AA2014E8936D578E3EC" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jie</FIRST_NAME><LAST_NAME>Yang</LAST_NAME><EMAIL_1>yangjie1126@163.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology, Nanjing First Hospital</DEPARTMENT><ORGANISATION>Nanjing Medical University</ORGANISATION><CITY>Nanjing</CITY><COUNTRY CODE="CN">China</COUNTRY></ADDRESS></PERSON><PERSON ID="16550974595633821045100714171626" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Canfei</FIRST_NAME><LAST_NAME>Zhang</LAST_NAME><EMAIL_1>zhangcanfei2003@163.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY></ADDRESS></PERSON><PERSON ID="45871479670777096537120120134710" ROLE="AUTHOR"><FIRST_NAME>Xiaoqun</FIRST_NAME><LAST_NAME>Jiang</LAST_NAME><EMAIL_1>xiaoqinybyb@163.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><CITY>Chengdu</CITY><COUNTRY CODE="CN">China</COUNTRY></ADDRESS></PERSON><PERSON ID="26537237396220592566120120134813" ROLE="AUTHOR"><FIRST_NAME>Hongqing</FIRST_NAME><LAST_NAME>Zhou</LAST_NAME><EMAIL_1>shuiyanyoulan@163.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><CITY>Chengdu</CITY><COUNTRY CODE="CN">China</COUNTRY></ADDRESS></PERSON><PERSON ID="16502" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Ming</FIRST_NAME><LAST_NAME>Liu</LAST_NAME><POSITION>Professor of Neurology</POSITION><EMAIL_1>wyplmh@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 8542 3551</PHONE_1><FAX_1>+86 28 8542 3551</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-02-28 15:06:32 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="25" MONTH="1" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="9" MONTH="1" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="9" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2000"/>
</DATES>
<WHATS_NEW MODIFIED="2012-03-16 11:02:23 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-02-28 15:05:37 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>The authorship of this review has changed. The basic conclusion is unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-03-16 11:02:23 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>The searches were updated in January 2012. We have added four new included trials in this update. These four trials included approximately 423 patients. This review now has 34 included trials with a total of 7731 participants. We have also added 'Risk of bias' tables for nearly all the trials included in this review. Specifically, we have added new information to this update, but the conclusions have not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-10-20 09:52:59 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-10-20 09:52:59 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="22" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Netherlands Heart Foundation (D93.014)</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Janssen Pharmaceuticals</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Stichting De Drie Lichten</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-04-03 11:14:51 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-03-16 11:03:05 +0000" MODIFIED_BY="tingting Yuan">
<TITLE MODIFIED="2008-07-22 14:10:24 +0100" MODIFIED_BY="Hazel Fraser">Calcium antagonists for acute ischemic stroke</TITLE>
<SUMMARY_BODY MODIFIED="2012-03-16 11:03:05 +0000" MODIFIED_BY="tingting Yuan">
<P>The majority of ischemic strokes are due to blockage of an artery in the brain by a blood clot. The area of brain supplied by that artery rapidly becomes damaged. Some of the damage to brain cells occurs because of a build-up of calcium ions inside the cells. Calcium antagonists might reduce the damage by preventing calcium ions entering the cells. We searched for trials which assessed the effects of calcium antagonists (given either by mouth or by intravenous injection) in patients with ischemic stroke. We found 34 studies, including 7731 patients, that were suitable for inclusion in the review. There was no difference in deaths or survival free of disability between patients who received calcium antagonists and those who did not. Patients who received calcium antagonists by intravenous injection were slightly worse overall than those who received the drugs by mouth. In conclusion, the authors of this Cochrane review found no evidence that giving calcium antagonists after acute ischemic stroke could save lives or reduce disability.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-03-29 09:48:59 +0100" MODIFIED_BY="tingting Yuan">
<ABS_BACKGROUND MODIFIED="2012-02-28 15:06:33 +0000" MODIFIED_BY="tingting Yuan">
<P>The sudden loss of blood supply in ischemic stroke is associated with the increase of calcium ions within neurons. Inhibiting this increase could protect neurons and hence might reduce neurological impairment, disability and handicap after stroke.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-03-05 10:21:41 +0000" MODIFIED_BY="tingting Yuan">
<P>To determine whether calcium antagonists reduce the risk of death or dependency after acute ischemic stroke. To investigate the influence of different drugs, dosages, routes of administration, time intervals after stroke and trial design on the risk of a primary outcome.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-03-14 15:10:49 +0000" MODIFIED_BY="tingting Yuan">
<P>We searched the Cochrane Stroke Group Trials Register (January 2012), MEDLINE (1950 to December 2011), EMBASE (1980 to December 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library,</I> 2011 issue 4) and four Chinese databases (December 2011): Chinese Biological Medicine Database (CBM-disc), China National Knowledge Infrastructure (CNKI), Chinese scientific periodical database of VIP information and Wanfang Data. We also contacted trialists and researchers.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-02-28 15:07:38 +0000" MODIFIED_BY="tingting Yuan">
<P>All truly randomized trials comparing a calcium antagonist with control in patients with acute ischemic stroke.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-03-16 11:02:39 +0000" MODIFIED_BY="tingting Yuan">
<P>Two authors assessed all trials and extracted the data. We used death or dependency at the end of long-term follow-up (at least three months) in activities of daily living as the primary outcome. Analyses were, if possible, intention-to-treat.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-03-29 09:48:59 +0100" MODIFIED_BY="tingting Yuan">
<P>We included 34 trials including 7731 patients<I>. </I>There was no effect of calcium antagonists on the primary outcome (risk ratio (RR) 1.05; 95% confidence interval (CI) 0.98 to 1.13), or on death at the end of follow-up (RR 1.07, 95% CI 0.98 to 1.17). Comparisons of different doses of nimodipine suggested that the highest doses were associated with poorer outcome.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-03-16 11:03:01 +0000" MODIFIED_BY="[Empty name]">
<P>No evidence is available using calcium antagonists in patients with acute ischemic stroke is effective.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-04-03 11:14:51 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-03-16 11:04:06 +0000" MODIFIED_BY="[Empty name]">
<P>Calcium antagonists may act as neuroprotective drugs by diminishing the influx of calcium ions through the voltage sensitive calcium channels. One Cochrane review published in <I>The Cochrane Library</I> has already demonstrated that calcium antagonists could reduce the risk of a primary outcome and secondary ischemia after aneurysmal subarachnoid hemorrhage (SAH) (<LINK REF="REF-Mees-2008" TYPE="REFERENCE">Mees 2008</LINK>). Of course, there is a difference between the treatment of ischemic stroke and the treatment of SAHs. At the same time, in stroke, medication will be started after the onset of ischemia instead of being given before. In view of the evidence on the existence of an "ischemic penumbra" (<LINK REF="REF-Siesjo-1978" TYPE="REFERENCE">Siesjo 1978</LINK>), where brain tissue may survive in ischemic periods of variable and as yet not precisely determined duration, a therapeutic effect may be present when administration starts up to several hours after stroke onset. Therefore, it is necessary to test whether this kind of drug can play a neuroprotective role and improve neurological impairment.</P>
<CONDITION MODIFIED="2012-03-16 11:03:41 +0000" MODIFIED_BY="tingting Yuan">
<P>Stroke is the second more common cause of death and the leading cause of disability worldwide (<LINK REF="REF-Liu-2007" TYPE="REFERENCE">Liu 2007</LINK>). Approximately 87% of all strokes are ischemic (i.e. due to a blockage of an artery in the brain) (<LINK REF="REF-AHA-2007" TYPE="REFERENCE">AHA 2007</LINK>), which leads to the affected area being starved of oxygen. Massive calcium influx entering into the cells is a final common pathway that leads to cell death (<LINK REF="REF-Siesjo-1989" TYPE="REFERENCE">Siesjo 1989</LINK>). Therefore, it is necessary to test any promising strategy that could help brain cells recover by blocking calcium ions.</P>
</CONDITION>
<INTERVENTION MODIFIED="2012-03-16 11:03:48 +0000" MODIFIED_BY="[Empty name]">
<P>Calcium antagonists reduce the influx of calcium into the cell through blocking calcium channels. Thus, a rationale for the use of calcium antagonists for preventing secondary ischemia is based on the notion that these drugs can counteract the influx of calcium into the vascular smooth-muscle cell, thereby decreasing the rate of vasospasm. Animal experiments have indicated that calcium antagonists administered after cerebral ischemia may be effective in reducing infarct volume and lead to improvements in neurological outcome (<LINK REF="REF-Germano-1987" TYPE="REFERENCE">Germano 1987</LINK>; <LINK REF="REF-Steen-1983" TYPE="REFERENCE">Steen 1983</LINK>). After their introduction into clinical practice it was discovered that calcium antagonists also had neuroprotective properties (<LINK REF="REF-Mees-2008" TYPE="REFERENCE">Mees 2008</LINK>). Calcium antagonists reduce the risk of primary outcome and secondary ischemia after SAH (<LINK REF="REF-Mees-2008" TYPE="REFERENCE">Mees 2008</LINK>), and nimodipine, a typical calcium antagonist, has been shown to be effective in decreasing the occurrence of death and disability (primary outcome) after SAH and traumatic SAH in humans (<LINK REF="REF-Di-Mascio-1994" TYPE="REFERENCE">Di Mascio 1994</LINK>; <LINK REF="REF-Harders-1996" TYPE="REFERENCE">Harders 1996</LINK>; <LINK REF="REF-Pickard-1989" TYPE="REFERENCE">Pickard 1989</LINK>). We wondered whether calcium antagonists could have the same effects in ischemic stroke patients.</P>
</INTERVENTION>
<THEORY MODIFIED="2012-03-16 11:03:58 +0000" MODIFIED_BY="tingting Yuan">
<P>Some meta-analyses with a more limited scope (restricted to nimodipine and completed before some recent trials were available) have been performed (<LINK REF="REF-Di-Mascio-1994" TYPE="REFERENCE">Di Mascio 1994</LINK>; <LINK REF="REF-Gelmers-1990" TYPE="REFERENCE">Gelmers 1990</LINK>; <LINK REF="REF-Mohr-1994" TYPE="REFERENCE">Mohr 1994</LINK>). In these meta-analyses, a beneficial effect of nimodipine was not demonstrated, except in one subgroup analysis. This subgroup analysis (patients treated within 12 hours of stroke onset) suggested that early treatment was effective and might lead to a 38% reduction in the odds of the primary outcome occurring (<LINK REF="REF-Mohr-1994" TYPE="REFERENCE">Mohr 1994</LINK>). Any subgroup analysis showing a beneficial effect should be interpreted with caution, since there is always the danger that it might be a chance finding (<LINK REF="REF-Counsell-1994" TYPE="REFERENCE">Counsell 1994</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2012-03-16 11:04:06 +0000" MODIFIED_BY="tingting Yuan">
<P>Calcium antagonists could protect neurons and hence might reduce neurological impairment, disability and handicap after stroke. Many calcium antagonists have been tested in randomized controlled trials (RCTs) in patients with acute ischemic stroke, but none of these trials have demonstrated a convincing beneficial effect. However, the sample size might be too small to show a result or significant clinical effect. For this reason a systematic review was necessary. The last version of this Cochrane review was published in 2000. Since then more trials have been published. Therefore, we conducted this updated review to provide more up-to-date evidence for clinical practice.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-03-16 11:04:26 +0000" MODIFIED_BY="[Empty name]">
<P>To determine whether using of calcium antagonists in patients with acute ischemic stroke could (1) reduce the number of patients who, at the end of follow-up, are either dead or severely disabled, (2) reduce the risk of death during the treatment period or at the end of follow-up and to make comparisons for different calcium antagonist regimens (different drugs, oral or intravenous administration, different dosages and various time intervals from onset of symptoms until start of treatment) and different trial designs (multicenter placebo-controlled trial, publication status).</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-03-16 11:05:02 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-03-16 11:04:34 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2012-03-05 14:25:10 +0000" MODIFIED_BY="tingting Yuan">
<P>We included all RCTs of calcium antagonists versus control (placebo or standard medical treatment alone). We also included trials comparing different routes of administration (oral versus intravenous administration) and different doses. We excluded trials that were not truly randomized.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-03-05 14:25:25 +0000" MODIFIED_BY="tingting Yuan">
<P>Patients with presumed or definite acute ischemic stroke that were randomized within 14 days after stroke onset. All were confirmed through computerized tomography (CT) or magnetic resonance (MR) scanning. Two studies (<LINK REF="STD-Chandra-1995" TYPE="STUDY">Chandra 1995</LINK>; <LINK REF="STD-Lowe--1989" TYPE="STUDY">Lowe 1989</LINK>) included some hemorrhagic stroke patients (255 patients included in total) but, since we could not extract the information for the ischemic stroke patients only, we included all randomized patients.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-03-16 11:04:28 +0000" MODIFIED_BY="[Empty name]">
<P>We included all types of calcium antagonists, given in any dose, by the intravenous or oral route. These were defined as agents whose principal mode of action is to inhibit the influx of calcium into cells by way of the voltage-sensitive calcium channels.</P>
<P>We excluded trials that were confounded by the treatment or control group receiving another active therapy that had not been factored into the randomization.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-03-16 11:04:34 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-03-16 11:04:34 +0000" MODIFIED_BY="tingting Yuan">
<P>Primary outcome: defined as death (all-cause case fatality) or dependency in activities of daily living at long-term follow-up (at least three months). For assessing dependency, we used the following available functional health scales: the Modified Rankin or Oxford Handicap Scale (dependency &gt; 3) (<LINK REF="REF-Bamford-1989" TYPE="REFERENCE">Bamford 1989</LINK>), Glasgow Outcome Scale (dependency &lt; 4) (<LINK REF="REF-Jennet-1975" TYPE="REFERENCE">Jennet 1975</LINK>), the Barthel Index (dependency &lt; 60) (<LINK REF="REF-Mahoney-1965" TYPE="REFERENCE">Mahoney 1965</LINK>), Toronto Stroke Scale (dependency &gt; 3) (<LINK REF="REF-Norris-1982" TYPE="REFERENCE">Norris 1982</LINK>) or the disability item in the Mathew Impairment Scale (dependency = 7) (<LINK REF="REF-Mathew-1972" TYPE="REFERENCE">Mathew 1972</LINK>). If more than one scale was available, we selected the one with the smallest number of missing values (see the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for details).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-03-05 10:45:07 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Death from any cause during the scheduled treatment period.</LI>
<LI>Death from any cause during long-term follow-up (at least 3 months).</LI>
<LI>Recurrent stroke during long-term follow-up.</LI>
<LI>Adverse effects of the drug (e.g. impairment of kidney function, impairment of liver function, skin irritation, local infusion-related irritation, nausea, etc) during the scheduled treatment period.</LI>
<LI>Hypotension: substantial fall in blood pressure during the scheduled treatment period.</LI>
<LI>Mean systolic blood pressure during the treatment period.</LI>
</OL>
<P>We recorded these events if they were mentioned as such in the original paper, thus the definitions of the investigators were used.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-03-16 11:04:37 +0000" MODIFIED_BY="[Empty name]">
<P>See the 'Specialized register' section in the '<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A>' module. We searched for trials in all languages and arranged translation of studies published in languages other than English.</P>
<ELECTRONIC_SEARCHES MODIFIED="2012-03-16 11:04:37 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Stroke Group Trials Register (January 2012), MEDLINE (1950 to December 2011) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), EMBASE (1980 to December 2011) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>) and the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>, 2011 issue 4) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).  We also searched the following four Chinese databases: Chinese Biological Medicine Database (CBM-disc) (1978 to December 2011), China National Knowledge Infrastructure (CNKI) (1980 to December 2011), Chinese scientific periodical database of VIP information (1989 to December 2011) and Wanfang Data (<A HREF="http://www.wanfangdata.com/">http://www.wanfangdata.com/</A>) (1982 to December 2011).</P>
<P>The Cochrane Stroke Group Trials Search Co-ordinator developed the search strategies for MEDLINE, EMBASE and CENTRAL and we adapted the MEDLINE strategy for the Chinese databases.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-01-17 06:54:32 +0000" MODIFIED_BY="[Empty name]">
<P>In an effort to identify further published, ongoing and unpublished trials we contacted trialists and researchers in the field.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-03-16 11:05:02 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors (JZ, JY) read the titles, abstracts and keywords of all records identified from the searches of the electronic bibliographic databases and excluded studies that were clearly irrelevant. We obtained the full text of the remaining studies and the same two authors selected trials for inclusion based on our defined criteria and extracted the relevant data. The two review authors resolved any disagreements by discussion and consulted a third author (ML) if necessary.<BR/>
</P>
<STUDY_SELECTION MODIFIED="2012-03-16 11:04:40 +0000" MODIFIED_BY="tingting Yuan">
<P>To identify studies for further evaluation, we scanned the titles, abstracts and keywords of every record found. We eliminated articles on initial screening if we could determine from the title and abstract that the article was not a report of an RCT or the trial did not address the effect of calcium antagonists for acute ischemic stroke. If there was any doubt about these criteria from the information given in the title and abstract, we obtained the full text for clarification. We developed an inclusion/exclusion form to assist with the selection of trials. Two review authors (JZ, JY) independently assessed the selection of studies and they resolved any disagreements through consultation with a third review author (ML). If they could not resolve disagreements in this way, they added the article to those awaiting assessment and we contacted the study authors for clarification.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-03-16 11:04:48 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors (JZ, JY) independently extracted data on methods, patients, interventions, outcomes and results, and recorded the information on a data extraction form. The key information extracted was as follows.</P>
<OL>
<LI>General information: published/unpublished, title, authors, reference/source, contact address, country, language of publication, year of publication, duplicate publications, sponsor, setting.</LI>
<LI>Trial characteristics: design, duration of follow-up, method of randomization, allocation concealment, blinding (patients, people administering treatment, people assessing outcome).</LI>
<LI>Interventions: intervention (dose, route, frequency, duration, time interval from the stroke onset), controlled intervention (dose, route, frequency, duration), comedication(s) (dose, route, frequency, duration).</LI>
<LI>Patients: inclusion/exclusion criteria, diagnostic criteria, total number and number in each groups, age, baseline characteristics, similarity of groups at baseline (including any comorbidity), assessment of compliance, withdrawals (reasons/description), subgroups.</LI>
<LI>Outcomes: outcomes specified above, any other outcomes assessed, other events, length of follow-up, quality of reporting of outcomes.</LI>
</OL>
<P>The same two review authors cross-checked all extracted data and resolved any disagreements by discussion. If they could not reach consensus, the third review author (ML) made the final decision. When patients were excluded or lost to follow-up after randomization or if any of the above data were unavailable from the publications, we sought further information by contacting the study authors. If such information remained unavailable, all the review authors decided whether or not to include the trial in the review.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-03-16 11:04:55 +0000" MODIFIED_BY="tingting Yuan">
<P>Two review authors (JZ, JY) independently evaluated the following methodological qualities of all included studies. They resolved any disagreements by discussion. If they could not reach consensus, they asked another review author (ML) to make the final decision.</P>
<SUBSECTION>
<HEADING LEVEL="4">Sequence generation</HEADING>
<P>Was the allocation sequence adequately generated? We classified allocation sequence as 'low risk', 'high risk' or 'unclear risk' according to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment </HEADING>
<P>Was allocation adequately concealed? We classified allocation concealment as 'low risk', 'high risk' or 'unclear risk' according to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of participants, personnel and outcome assessors</HEADING>
<P>Was knowledge of the allocated interventions adequately prevented during the study? We classified blinding as 'low risk', 'high risk' or 'unclear risk' according to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data </HEADING>
<P>Were incomplete outcome data adequately addressed? We classified studies as 'low risk', 'high risk' or 'unclear risk' according to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). If there were patients excluded or lost to follow-up after randomization or if any of the follow-up data were not available from the publication, we sought further information by contacting the study authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective outcome reporting </HEADING>
<P>Were reports of the study free of suggestion of selective outcome reporting? We classified studies as 'low risk', 'high risk' or 'unclear risk' according to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-03-05 11:07:13 +0000" MODIFIED_BY="tingting Yuan">
<P>These measures are listed under <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-01-04 07:14:23 +0000" MODIFIED_BY="tingting Yuan">
<P>None.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-03-05 11:07:17 +0000" MODIFIED_BY="tingting Yuan">
<P>See <LINK TAG="DATA_EXTRACTION" TYPE="SECTION">Data extraction and management</LINK>.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-01-04 07:14:23 +0000" MODIFIED_BY="tingting Yuan">
<P>We tested heterogeneity among trial results using the I<SUP>2 </SUP>statistic. We considered a value greater than 50% as substantial heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-03-16 11:04:57 +0000" MODIFIED_BY="tingting Yuan">
<P>We examined publication and other biases using a funnel plot. We plotted effect size against sample size, resulting in a graphical display that gave some indication of whether or not some studies had not been published or located.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-03-05 11:08:25 +0000" MODIFIED_BY="[Empty name]">
<P>We performed statistical analysis using RevMan 5.1 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). We reported the results as risk ratio (RR) with 95% confidence interval (CI) for dichotomous data and as mean difference (MD) with 95% CI for continuous data. We used a random-effects model to combine individual results regardless whether there was significant heterogeneity or not.<BR/>
</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-03-05 11:08:44 +0000" MODIFIED_BY="tingting Yuan">
<P>For the subgroup analyses we collected information about route of drug administration, dose and time interval of start of treatment. Heterogeneity might arise from a wide variety of factors, such as the design of the trials, the type of patients included and so on. We also examined the influence of exclusion of the trials on heterogeneity.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-03-16 11:05:02 +0000" MODIFIED_BY="tingting Yuan">
<P>According to the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), we re-analyzed the data of these multicenter studies. We also re-analyzed the data according to the publication status.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-04-03 11:14:51 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-03-16 11:05:47 +0000" MODIFIED_BY="[Empty name]">
<P>Our method of independent data collection by two authors increased accuracy. Much of our data were based on original data sets. The majority of trials were performed with nimodipine. Bayer Germany provided results of various trials. The original data sets were often more complete than the published data. For example, in three trials a significant number of patients were excluded after randomization and outcomes were not presented in the publication (<LINK REF="STD-Martinez_x002d_Vila-1990" TYPE="STUDY">Martinez-Vila 1990</LINK>; <LINK REF="STD-NEST-1993" TYPE="STUDY">NEST 1993</LINK>; <LINK REF="STD-Wimalaratna-1994" TYPE="STUDY">Wimalaratna 1994</LINK>), while data on these patients were available from the original data set.</P>
<P>However, in the trial of <LINK REF="STD-Heiss-1990" TYPE="STUDY">Heiss 1990</LINK>, the number of excluded patients in the published article was not accounted for in the original data set. We did the calculations based on the original data set. Thus, there might be a slight difference from those data in the published article.</P>
<P>In this update, we added four new included studies (<LINK REF="STD-Nag-1998" TYPE="STUDY">Nag 1998</LINK>; <LINK REF="STD-Shibuya-2005" TYPE="STUDY">Shibuya 2005</LINK>; <LINK REF="STD-Squire-1996" TYPE="STUDY">Squire 1996</LINK>; <LINK REF="STD-Sze-1998" TYPE="STUDY">Sze 1998</LINK>). One other study (<LINK REF="STD-Tanahashi-2007" TYPE="STUDY">Tanahashi 2007</LINK>) was unpublished and we could not access any data, hence we included it in the review as an ongoing study.</P>
<SEARCH_RESULTS MODIFIED="2012-03-05 11:16:59 +0000" MODIFIED_BY="[Empty name]">
<P>From a total of 8003<B> </B>articles generated by the electronic searches and handsearches, we identified 53 studies using calcium antagonists in patients with acute ischemic stroke and included 34 in this review. The total number of included patients was 7944: we subsequently excluded 213 patients from <LINK REF="STD-VENUS-1999" TYPE="STUDY">VENUS 1999</LINK>, which were included in the previous version of this review, as they had hemorrhagic stroke.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-03-16 11:05:47 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. Thirty-four trials (including 7731 patients) met the inclusion criteria (<LINK REF="STD-ASCLEPIOS-1990" TYPE="STUDY">ASCLEPIOS 1990</LINK>; <LINK REF="STD-Bogousslavsky-1990" TYPE="STUDY">Bogousslavsky 1990</LINK>; <LINK REF="STD-Bridgers-1991" TYPE="STUDY">Bridgers 1991</LINK>; <LINK REF="STD-Canwin-1993" TYPE="STUDY">Canwin 1993</LINK>; <LINK REF="STD-Capon-1983" TYPE="STUDY">Capon 1983</LINK>; <LINK REF="STD-Chandra-1995" TYPE="STUDY">Chandra 1995</LINK>; <LINK REF="STD-FIST-1990" TYPE="STUDY">FIST 1990</LINK>; <LINK REF="STD-Gelmers-1984" TYPE="STUDY">Gelmers 1984</LINK>; <LINK REF="STD-Gelmers-1988" TYPE="STUDY">Gelmers 1988</LINK>; <LINK REF="STD-German_x002d_Austrian-1994" TYPE="STUDY">German-Austrian 1994</LINK>; <LINK REF="STD-Heiss-1990" TYPE="STUDY">Heiss 1990</LINK>; <LINK REF="STD-INWEST--1990" TYPE="STUDY">INWEST 1990</LINK>; <LINK REF="STD-Kaste-1994" TYPE="STUDY">Kaste 1994</LINK>; <LINK REF="STD-Kornhuber-1993" TYPE="STUDY">Kornhuber 1993</LINK>; <LINK REF="STD-Lamsudin-1995" TYPE="STUDY">Lamsudin 1995</LINK>; <LINK REF="STD-Limburg-1990" TYPE="STUDY">Limburg 1990</LINK>; <LINK REF="STD-Lisk-1993" TYPE="STUDY">Lisk 1993</LINK>; <LINK REF="STD-Lowe--1989" TYPE="STUDY">Lowe 1989</LINK>; <LINK REF="STD-Martinez_x002d_Vila-1990" TYPE="STUDY">Martinez-Vila 1990</LINK>; <LINK REF="STD-Mohr-1992" TYPE="STUDY">Mohr 1992</LINK>; <LINK REF="STD-Nag-1998" TYPE="STUDY">Nag 1998</LINK>; <LINK REF="STD-NEST-1993" TYPE="STUDY">NEST 1993</LINK>; <LINK REF="STD-NIMPAS-1999" TYPE="STUDY">NIMPAS 1999</LINK>; <LINK REF="STD-Oczkowski-1989" TYPE="STUDY">Oczkowski 1989</LINK>; <LINK REF="STD-Paci-1989" TYPE="STUDY">Paci 1989</LINK>; <LINK REF="STD-Sherman-1986" TYPE="STUDY">Sherman 1986</LINK>; <LINK REF="STD-Shibuya-2005" TYPE="STUDY">Shibuya 2005</LINK>; <LINK REF="STD-Squire-1996" TYPE="STUDY">Squire 1996</LINK>; <LINK REF="STD-Sze-1998" TYPE="STUDY">Sze 1998</LINK>; <LINK REF="STD-TRUST-1990" TYPE="STUDY">TRUST 1990</LINK>; <LINK REF="STD-Uzunur-1995" TYPE="STUDY">Uzunur 1995</LINK>; <LINK REF="STD-VENUS-1999" TYPE="STUDY">VENUS 1999</LINK>; <LINK REF="STD-Wimalaratna-1994" TYPE="STUDY">Wimalaratna 1994</LINK>; <LINK REF="STD-Yordanov-1984" TYPE="STUDY">Yordanov 1984</LINK>).</P>
<P>The age of patients in the included studies ranged from 18 to 85 years, with the average age ranging from 52.3 to 74.6 years. Most of the trials included more males than females, which is consistent with the fact that stroke is more common among men worldwide.<BR/>
</P>
<P>In the 34 included trials, nimodipine was used as the treatment in 26 trials, flunarizine in three trials (<LINK REF="STD-FIST-1990" TYPE="STUDY">FIST 1990</LINK>; <LINK REF="STD-Kornhuber-1993" TYPE="STUDY">Kornhuber 1993</LINK>; <LINK REF="STD-Limburg-1990" TYPE="STUDY">Limburg 1990</LINK>), and isradipine (<LINK REF="STD-ASCLEPIOS-1990" TYPE="STUDY">ASCLEPIOS 1990</LINK>), nicardipine (<LINK REF="STD-Lisk-1993" TYPE="STUDY">Lisk 1993</LINK>), PY108-608 (<LINK REF="STD-Oczkowski-1989" TYPE="STUDY">Oczkowski 1989</LINK>), fasudil (<LINK REF="STD-Shibuya-2005" TYPE="STUDY">Shibuya 2005</LINK>), and lifarizine (<LINK REF="STD-Squire-1996" TYPE="STUDY">Squire 1996</LINK>) in one trial respectively. These calcium antagonists were administered intravenously or orally in different dosage and different time intervals from stroke onset, therefore we did subgroup analyses according to these different dosages and time intervals from stroke onset.</P>
<P>Most trials reported that antiplatelet and anticoagulate therapy were added to both treatment and control groups.</P>
<P>Death was reported in 31 trials, but only six of which reported details of the causes of death (<LINK REF="STD-Capon-1983" TYPE="STUDY">Capon 1983</LINK>; <LINK REF="STD-Gelmers-1988" TYPE="STUDY">Gelmers 1988</LINK>; <LINK REF="STD-Kaste-1994" TYPE="STUDY">Kaste 1994</LINK>; <LINK REF="STD-Kornhuber-1993" TYPE="STUDY">Kornhuber 1993</LINK>; <LINK REF="STD-Martinez_x002d_Vila-1990" TYPE="STUDY">Martinez-Vila 1990</LINK>; <LINK REF="STD-Sze-1998" TYPE="STUDY">Sze 1998</LINK>). The main causes of death in these six trials were stroke recurrence, cardiac infarction, cardiac failure and pneumonia.</P>
<P>Only 13 trials reported adverse events.There were 251/2810 (8.93%) in the treatment group and 157/2285 (6.87%) in the control group. We defined severe adverse events as epilepsy, bradycardia, gastrointestinal bleeding and deep venous thrombosis. Epilepsy occurred in three patients (3/2810, 0.11%) in the treatment group and in two patients (2/2285, 0.09%) in the control group, bradycardia occurred in two patients (2/2810, 0.07%) in the treatment group and in two patients (2/2285, 0.09%) in the control group, gastrointestinal bleeding occurred in two patients (2/2810, 0.07%) in the treatment group and in two patients (2/2285, 0.09%) in the control group, and deep venous thrombosis occurred in four patients (4/2810, 0.14%) in the treatment group and in one patient (1/2285, 0.04%) in the control group. The patients who suffered from severe hypotension (reported in six trials with 1667 participants) were 15/827 (1.81%) in the treatment group and 10/840 (1.2%) in the control group, and were too severe to be excluded.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-03-05 11:27:38 +0000" MODIFIED_BY="tingting Yuan">
<P>We excluded 13 studies. For details see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-03-16 11:05:55 +0000" MODIFIED_BY="[Empty name]">
<ALLOCATION MODIFIED="2012-03-05 11:29:04 +0000" MODIFIED_BY="tingting Yuan">
<P>Five trials (<LINK REF="STD-Heiss-1990" TYPE="STUDY">Heiss 1990</LINK>; <LINK REF="STD-Limburg-1990" TYPE="STUDY">Limburg 1990</LINK>; <LINK REF="STD-Lowe--1989" TYPE="STUDY">Lowe 1989</LINK>; <LINK REF="STD-Shibuya-2005" TYPE="STUDY">Shibuya 2005</LINK>; <LINK REF="STD-Wimalaratna-1994" TYPE="STUDY">Wimalaratna 1994</LINK>) allocated participants by random table, one trial (<LINK REF="STD-Bogousslavsky-1990" TYPE="STUDY">Bogousslavsky 1990</LINK>) by random list, and one trial (<LINK REF="STD-Gelmers-1988" TYPE="STUDY">Gelmers 1988</LINK>) used a different method. Five trials (<LINK REF="STD-Gelmers-1988" TYPE="STUDY">Gelmers 1988</LINK>; <LINK REF="STD-Heiss-1990" TYPE="STUDY">Heiss 1990</LINK>; <LINK REF="STD-Mohr-1992" TYPE="STUDY">Mohr 1992</LINK>; <LINK REF="STD-Sze-1998" TYPE="STUDY">Sze 1998</LINK>; <LINK REF="STD-VENUS-1999" TYPE="STUDY">VENUS 1999</LINK>) used numbered boxes as the allocation concealment method. The remaining trials did not report the method of random sequence generation and allocation concealment, hence we graded random sequence generation and allocation concealment for these trials as 'unclear risk'.</P>
</ALLOCATION>
<BLINDING MODIFIED="2012-03-05 11:36:29 +0000" MODIFIED_BY="[Empty name]">
<P>All the trials used placebo as the control except three: one compared the different results between intravenous and oral nimodipine without a placebo group (<LINK REF="STD-Chandra-1995" TYPE="STUDY">Chandra 1995</LINK>), and two were open control (<LINK REF="STD-Gelmers-1984" TYPE="STUDY">Gelmers 1984</LINK>; <LINK REF="STD-Uzunur-1995" TYPE="STUDY">Uzunur 1995</LINK>).</P>
<P>Five trials (<LINK REF="STD-Canwin-1993" TYPE="STUDY">Canwin 1993</LINK>; <LINK REF="STD-Capon-1983" TYPE="STUDY">Capon 1983</LINK>; <LINK REF="STD-Lowe--1989" TYPE="STUDY">Lowe 1989</LINK>; <LINK REF="STD-Uzunur-1995" TYPE="STUDY">Uzunur 1995</LINK>; <LINK REF="STD-Yordanov-1984" TYPE="STUDY">Yordanov 1984</LINK>) did not report the method of blinding. Three trials (<LINK REF="STD-Gelmers-1984" TYPE="STUDY">Gelmers 1984</LINK>; <LINK REF="STD-Martinez_x002d_Vila-1990" TYPE="STUDY">Martinez-Vila 1990</LINK>; <LINK REF="STD-Sze-1998" TYPE="STUDY">Sze 1998</LINK>) reported they were single blind trials - two did not describe which participants were blinded (<LINK REF="STD-Gelmers-1984" TYPE="STUDY">Gelmers 1984</LINK>; <LINK REF="STD-Martinez_x002d_Vila-1990" TYPE="STUDY">Martinez-Vila 1990</LINK>), one reported that the assessors were blinded (<LINK REF="STD-Sze-1998" TYPE="STUDY">Sze 1998</LINK>). The remaining 26 trials reported they were double-blind trials, but only one reported that the assessors were blinded (<LINK REF="STD-Shibuya-2005" TYPE="STUDY">Shibuya 2005</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-03-05 11:39:20 +0000" MODIFIED_BY="tingting Yuan">
<P>Only seven trials (<LINK REF="STD-Gelmers-1984" TYPE="STUDY">Gelmers 1984</LINK>; <LINK REF="STD-Lisk-1993" TYPE="STUDY">Lisk 1993</LINK>; <LINK REF="STD-Lowe--1989" TYPE="STUDY">Lowe 1989</LINK>; <LINK REF="STD-Mohr-1992" TYPE="STUDY">Mohr 1992</LINK>; <LINK REF="STD-Oczkowski-1989" TYPE="STUDY">Oczkowski 1989</LINK>; <LINK REF="STD-Shibuya-2005" TYPE="STUDY">Shibuya 2005</LINK>; <LINK REF="STD-VENUS-1999" TYPE="STUDY">VENUS 1999</LINK>) reported no patient losses at follow-up. One trial (<LINK REF="STD-INWEST--1990" TYPE="STUDY">INWEST 1990</LINK>) reported there were some patients lost but there was no difference after an intention-to-treat (ITT) analysis of the results. We could not obtain any information about incomplete outcome data in six trials (<LINK REF="STD-Capon-1983" TYPE="STUDY">Capon 1983</LINK>; <LINK REF="STD-Chandra-1995" TYPE="STUDY">Chandra 1995</LINK>; <LINK REF="STD-Lowe--1989" TYPE="STUDY">Lowe 1989</LINK>; <LINK REF="STD-Sherman-1986" TYPE="STUDY">Sherman 1986</LINK>; <LINK REF="STD-Uzunur-1995" TYPE="STUDY">Uzunur 1995</LINK>; <LINK REF="STD-Yordanov-1984" TYPE="STUDY">Yordanov 1984</LINK>); we categorized the remaining 20 trials as 'high risk' for incomplete data since they all had data loss and no ITT analysis.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-03-16 11:05:52 +0000" MODIFIED_BY="tingting Yuan">
<P>None of the trial protocols were available but it was clear from the published reports that none included the primary outcome for this review of 'death or dependency at the end of long-term follow-up'. Therefore, there was insufficient information for us to make a judgement on selective reporting.<BR/>
</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2012-03-16 11:05:55 +0000" MODIFIED_BY="tingting Yuan">
<P>None</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-04-03 11:14:51 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Death or dependency at end of follow-up</HEADING>
<P>Data from 22 trials with 6684 participants were available. No difference was found between patients using calcium antagonists or not. If anything, there may be a small but detrimental effect (RR 1.05, 95% CI 0.98 to 1.13). For these 22 trials, there were three drugs involved, nimodipine in 19 trials, flunarizine in two trials and isradipine in one trial. The indirect comparisons of the different drugs did not show clear evidence of differences between different drugs (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>Heterogeneity was present (P = 0.09, I<SUP>2 </SUP>= 64%, df = 1) in the analysis of 'Flunarizine versus control', in which only two trials (<LINK REF="STD-FIST-1990" TYPE="STUDY">FIST 1990</LINK>; <LINK REF="STD-Limburg-1990" TYPE="STUDY">Limburg 1990</LINK>) were included. In <LINK REF="STD-FIST-1990" TYPE="STUDY">FIST 1990</LINK>, there were 331 participants involved while in <LINK REF="STD-Limburg-1990" TYPE="STUDY">Limburg 1990</LINK>, only 26 participants were involved, the latter might be the most substantial cause of the heterogeneity.</P>
<P>A funnel plot showed obvious publication bias existed (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Death at end of treatment period</HEADING>
<P>Data were available from 22 trials with 6323 participants. No difference was found for death at the end of treatment period (RR 1.06, 95% CI 0.93 to 1.20). In patients treated with intravenous flunarizine we also found there was no statistically significant increase in mortality, although it was related to a worse outcome (RR 1.31, 95% CI 0.94 to 1.82) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>A funnel plot showed there was obvious publication bias (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Death at end of follow-up</HEADING>
<P>Data were available from 31 trials with 7483 participants. In this analysis there was no difference found for death (RR 1.07, 95% CI 0.98 to 1.17). In patients treated with intravenous flunarizine, there was a statistically significant increase in mortality, which was related to a worse outcome (RR 1.34, 95% CI 1.01 to 1.77). As for the other calcium antagonists, nimodipine, isradipine, lifarizine, PY106-608 and nicardipine, no difference was found (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>A funnel plot showed there was obvious publication bias (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Recurrence of stroke at end of follow-up</HEADING>
<P>Only a limited number of reports mentioned stroke recurrences (nine trials with 2460 participants). There was no difference in the number of events between treatment groups and control groups, (RR 0.93, 95% CI 0.56 to1.54). However, the confidence intervals were wide (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">All adverse events during treatment period</HEADING>
<P>Adverse events were more frequent in the intervention groups (8.9% versus 6.9%). About half of the excess of adverse events in the treatment groups were caused by thrombophlebitis due to intravenous administration of flunarizine (after correction for differences in the size of the active and control groups). The occurrence of hypotension (defined as episodes leading to cessation of drug treatment) was mentioned in only five trials and was more frequent in the treatment group (1.8% versus 1.2%). Very limited data on mean systolic blood pressure in three trials supported this. The difference was statistically significant, but very small. Bias might play a role here, as studies would be more likely to present blood pressure data if imbalances occurred.</P>
<P>In the largest flunarizine trial there was a clear increase of adverse events in the treated group (33% versus 10%, RR 3.16, 95% CI 1.91 to 5.21). This was mainly due to an excess of superficial thrombophlebitis in the flunarizine group. In the rest of the studies there was no difference in adverse events. The overall result was a RR of 1.18 (95% CI 0.81 to 1.74) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<P>Heterogeneity was strongly present in this analysis, caused by the results of the intravenous flunarizine trial <LINK REF="STD-FIST-1990" TYPE="STUDY">FIST 1990</LINK>, the considerable heterogeneity could be completely reversed by removing it.</P>
<P>A funnel plot showed there was obvious publication bias (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hypotension during treatment period</HEADING>
<P>In six trials with 1667 participants episodes of hypotension (sufficient to stop treatment) were mentioned. Hypotensive episodes were more frequent in the treatment groups (1.8% versus 1.2%, RR 1.43, 95% CI 0.61 to 3.38), but there was no statistically significant difference (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mean systolic blood pressure during or at end of treatment</HEADING>
<P>Data were available in three trials with 630 participants. The mean blood pressure in the treated groups was on average 2 mmHg lower. This was a very small difference. The result was not statistically significant (MD: -1.30, 95% CI -3.92 to 1.32) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
<P>There was considerable heterogeneity, which could be completely reversed by removing <LINK REF="STD-Martinez_x002d_Vila-1990" TYPE="STUDY">Martinez-Vila 1990</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome by route of administration</HEADING>
<P>Data were available for 23 trials: 14 trials with 5131 participants by oral administration, eight trials with 1544 participants by intravenous administration, and one trial with 143 participants compared oral and intravenous administration directly. Intravenous administration was associated with a worse outcome in treated groups compared with placebo controls (RR 1.11, 95% CI 1.01 to 1.22). In the orally treated groups no difference was present (RR 1.03, 95% CI 0.93 to 1.14) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>The only direct comparison between oral and intravenous administration of nimodipine did not support the notion that intravenous administration was associated with poorer outcome (RR 7.10, 95% CI 0.37 to 134.96) (<LINK REF="STD-Chandra-1995" TYPE="STUDY">Chandra 1995</LINK>) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome by dose: indirect comparisons</HEADING>
<P>Data were available for 18 trials: one trial with 529 participants using 60 mg oral nimodipine per day, 14 trials with 4526 participants using 120 mg oral nimodipine per day, two trials with 637 participants using 240 mg oral nimodipine per day, four trials with 552 participants using 2 mg/hour intravenous nimodipine per day, and two trials with 329 participants using 1 mg/hour intravenous nimodipine per day. The indirect comparisons did not show a clear dose-dependent treatment effect. Nimodipine, given orally at 60 mg, 120 mg and 240 mg versus control yielded the following risk ratios: 1.08, 0.99 and 1.07 (i.e. did not show statistically significant difference). Intravenous nimodipine of 2 mg/hour showed a non-significant increase in the odds of the primary outcome (RR 1.34, 95% CI 0.93 to 1.93), the significant difference in the group treated intravenously with 1 mg/hour was not clear (RR 1.09, 95% CI 0.91 to 1.29) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>Heterogeneity existed in the analysis of nimodipine 2 mg/hour versus control in the primary outcome by dose, and it was largely caused by <LINK REF="STD-Bridgers-1991" TYPE="STUDY">Bridgers 1991</LINK>. Removing this trial decreased the heterogeneity but did not eliminate it.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome by dose: direct comparisons</HEADING>
<P>These direct comparisons were possible in very few trials: data were available in six trials, including one trial with 533 participants comparing 60 mg and 120 mg oral nimodipine per day, one trial with 532 participants comparing 60 mg and 240 mg oral nimodipine per day, two trials with 681 participants comparing 120 mg and 240 mg oral nimodipine per day, two trials with 333 participants comparing 1 mg/hour and 2 mg/hour intravenous nimodipine. This direct comparison showed that 120 mg was associated with slightly better results than 60 mg and 240 mg. A dose-dependent relationship seemed to exist for intravenous nimodipine. For both routes, the highest doses were associated with poorer outcome (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome by time start of treatment</HEADING>
<P>Data were available for 32 trials, including 18 trials with 1879 participants whose treatment started within 12 hours after stroke onset and 14 trials with 4071 participants whose treatment started after 12 hours from stroke onset. This comparison showed early treatment (&#8804; 12 hours after stroke onset) with calcium antagonists was associated with an increase in the odds of primary outcome, compared with placebo (RR 1.08, 95% CI 0.96 to 1.21). Treatment after 12 hours gave no effect whatever (RR 1.01, 95% CI 0.90 to 1.13). This analysis might be confounded by route of administration (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome in multicenter placebo-controlled trials</HEADING>
<P>Of the 34 included trials, 10 trials including 4012 participants reported that their data were from multicenter placebo-controlled trials. We did the primary outcome analysis on these 10 trials (RR 1.04, 95% CI 0.95 to 1.14) and found there was no clear difference between it (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>) and the 'Primary outcome at the end of follow-up' (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Analysis 3.6: Publication status</HEADING>
<P>Data were from 22 trials, including 18 trials with 5887 participants from which we could extract the primary outcome from the published papers, and four trials with 788 participants with unpublished data. The published trials did not show an overall effect of active treatment (RR 1.03, 95% CI 0.94 to 1.12) on primary outcome. On the contrary, the unpublished trials were associated with a deleterious effect of calcium antagonist treatment, the overall RR was 1.14 (95% CI 1.00 to 1.30) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-03-29 09:51:20 +0100" MODIFIED_BY="tingting Yuan">
<P>This systematic review of all available data failed to demonstrate a reduction in mortality and dependency after treatment with calcium antagonists in patients with acute ischemic stroke. Due to the large amount of data (34 trials including 7731 patients), confidence intervals were narrow and the overall result was therefore subject to limited statistical uncertainty.</P>
<P>Intravenous administration of calcium antagonists was not associated with a statistically significant increased risk of primary outcome. For nimodipine, data were available to analyze dose dependency, which appeared to be present. A higher dosage (2 mg/hour) led to a significant increase in the risk of primary outcome compared with a dosage of 1 mg/hour, which was also associated with a significant increased risk of primary outcome as compared with placebo. When comparing different oral dosages of nimodipine, 60 mg and 240 mg were associated with a non-significant increase in primary outcome; 120 mg did not show any clear effect.</P>
<P>The quality of the included trials of calcium antagonists for ischemic stroke was generally good. All trials included were placebo-controlled trials except <LINK REF="STD-Chandra-1995" TYPE="STUDY">Chandra 1995</LINK>, <LINK REF="STD-Gelmers-1984" TYPE="STUDY">Gelmers 1984</LINK> and <LINK REF="STD-Uzunur-1995" TYPE="STUDY">Uzunur 1995</LINK>, and all trials used a blinding method except five trials. However, there were still two main drawbacks: (1) only seven trials reported the methods of random sequence generation and only five trials reported the method of allocation concealment, which might lead to selection bias, and (2) we categorized incomplete outcome as 'low risk' in only eight trials, and as most participants were excluded in the treatment period and lost at follow-up, this might lead to reporting bias.</P>
<P>We did two sensitivity analyses: one based on the primary outcome in multicenter placebo-controlled trials and the other on published trials, while drawing the same conclusions.<BR/>
</P>
<P>The findings were intriguing regarding the time interval between stroke onset and the start of treatment. Based on the previous meta-analysis by <LINK REF="REF-Mohr-1994" TYPE="REFERENCE">Mohr 1994</LINK>, we expected to find an improved outcome in the early-treated group (defined as those treated within 12 hours after stroke onset). However, this was not the case. On the contrary, early treatment was associated with a non-significant increase in the risk of primary outcome or death. When patients were treated late (more than 12 hours after stroke onset), no effect of nimodipine was seen on either the primary outcome or death alone. Our results do not confirm the positive effect reported in the meta-analysis by <LINK REF="REF-Mohr-1994" TYPE="REFERENCE">Mohr 1994</LINK>. For the primary outcome and mortality alone we found no effect of nimodipine. Because more studies have become available, our study contains data from a larger number of patients. Direct comparison of the results of the two meta-analyses was hampered by the absence of exact patient numbers in the various outcome categories in the paper of <LINK REF="REF-Mohr-1994" TYPE="REFERENCE">Mohr 1994</LINK>.</P>
<P>There has been some debate about antithrombotic properties of some calcium antagonists (<LINK REF="REF-Heininger-1996" TYPE="REFERENCE">Heininger 1996</LINK>; <LINK REF="REF-Legault-1996" TYPE="REFERENCE">Legault 1996</LINK>). We found no influence of calcium antagonists on stroke recurrence or myocardial infarction. However, the number of trials reporting these data adequately was small. This might be a result of inadequate monitoring and reporting.</P>
<P>A strong argument in favor of the presence of publication bias was found in our sensitivity analysis concerning the relationship of publication status and treatment effect. While the published trials showed no effect on primary outcome, unpublished trials without exception were associated with a statistically significantly worse outcome in the treatment group. It was quite conceivable that more trials had remained unpublished, with perhaps similarly negative results.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-03-16 11:08:05 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-03-05 12:53:08 +0000" MODIFIED_BY="tingting Yuan">
<P>From our review it became clear that no evidence is available to justify the routine use of calcium antagonists in patients with acute ischemic stroke.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-03-16 11:08:05 +0000" MODIFIED_BY="[Empty name]">
<P>There is no need to perform any further studies to justify the effect of calcium antagonists in patients with ischemic stroke.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-03-15 17:30:55 +0000" MODIFIED_BY="[Empty name]">
<P>We are grateful to the following individuals who provided trial information: Prof G Lowe, Glasgow, UK; Beverly Bowyer, Toronto, Canada; Tina Haller, Bayer, Canada; Dr B Infeld from Melbourne, Australia; Prof JP Mohr, New York, USA; Prof JM Orgogozo, Bordeaux, France; Dr H Palomaki from Helsinki, Finland; Dr J Smakman from Janssen Pharmaceutica BV, Tilburg, Netherlands; and Dr G Uzuner, from Eskisehir, Turkey. We also thank Prof K Heininger and Dr J Kuebler of Bayer AG, Wuppertal, Germany who provided tabulated data of trials of nimodipine in acute ischemic stroke.</P>
<P>We thank Hazel Fraser, Managing Editor of the Cochrane Stroke Group for lists of relevant trials from the Cochrane Stroke Group Trials Register and Brenda Thomas, Cochrane Stroke Group Trials Search Co-ordinator, for developing the search strategies. Dr Carl Counsell, Prof Peter Sandercock, Dr Berge and Ashma Krishan have also been of tremendous help.</P>
<P>The protocol and earlier version of the review were written by Dr Horn and Dr Limburg. We express our gratitude to them.</P>
<P>We also thank Dr Chiara Menichetti (Italy) for translation and data extraction, Dr Fangbin Zhang for help with data extraction and data selection and Miss Yan Li also for help of full text writing.<BR/>
<BR/>If anyone is aware of any trials that we have omitted, please contact Professor Ming Liu.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-03-16 11:08:16 +0000" MODIFIED_BY="[Empty name]">
<P>None known.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-03-16 11:15:11 +0000" MODIFIED_BY="tingting Yuan">
<P>Jing Zhang and Jie Yang were involved in all aspects of the development of this review. They assessed all the trials, discussed and resolved any problems, and wrote the review. Canfei Zhang, Xiaoqun Jiang and Hongqing Zhou have helped in the related trials selection and looked for the full text of the related trials. Ming Liu was in charge of the judgement of the selection, did the evaluation for methodological quality of trials and was in charge of the final draft of this review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2008-07-24 14:57:07 +0100" MODIFIED_BY="Hazel Fraser"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-03-16 11:12:41 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-03-16 11:12:20 +0000" MODIFIED_BY="tingting Yuan">
<INCLUDED_STUDIES MODIFIED="2012-03-05 15:58:46 +0000" MODIFIED_BY="tingting Yuan">
<STUDY DATA_SOURCE="UNPUB" ID="STD-ASCLEPIOS-1990" MODIFIED="2012-03-05 14:30:42 +0000" MODIFIED_BY="Hazel Fraser" NAME="ASCLEPIOS 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-03-05 14:30:42 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Azcona A, Lataste X</AU>
<TI>Isradipine in patients with acute ischemic cerebral infarction. An overview of the ASCLEPIOS programme</TI>
<SO>Drugs</SO>
<YR>1990</YR>
<VL>40 Suppl 2</VL>
<PG>52-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Bogousslavsky-1990" MODIFIED="2012-03-05 14:30:57 +0000" MODIFIED_BY="Hazel Fraser" NAME="Bogousslavsky 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-03-05 14:30:57 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bogousslavsky J, Regli F, Zumstein V, Kobberling W</AU>
<TI>Double-blind study of nimodipine in non-severe stroke</TI>
<SO>European Neurology</SO>
<YR>1990</YR>
<VL>30</VL>
<PG>23-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Bridgers-1991" MODIFIED="2012-03-05 14:32:29 +0000" MODIFIED_BY="Hazel Fraser" NAME="Bridgers 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-03-05 14:32:29 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bridgers SL, Koch G, Munera C, Karwon M, Kurtz NM</AU>
<TI>Intravenous nimodipine in acute stroke: interim analysis of randomized trials</TI>
<SO>Stroke</SO>
<YR>1991</YR>
<VL>22</VL>
<PG>153</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Canwin-1993" MODIFIED="2012-03-05 14:33:17 +0000" MODIFIED_BY="[Empty name]" NAME="Canwin 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-03-05 14:33:17 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Norris JW, LeBrun LH, Anderson BA; The Canwin Study Group</AU>
<TI>Intravenous nimodipine in acute ischaemic stroke</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1994</YR>
<VL>4</VL>
<PG>194-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-08-07 02:53:16 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Capon-1983" MODIFIED="2008-07-22 14:47:19 +0100" MODIFIED_BY="Hazel Fraser" NAME="Capon 1983" YEAR="">
<REFERENCE MODIFIED="2008-07-22 14:47:19 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="OTHER">
<TI>Nimodipine for acute ischaemic stroke (unpublished study)</TI>
<SO>Bayer AG, Wuppertal, Germany</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chandra-1995" MODIFIED="2012-03-05 14:34:01 +0000" MODIFIED_BY="Hazel Fraser" NAME="Chandra 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-03-05 14:34:01 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chandra B</AU>
<TI>A new form of management of stroke</TI>
<SO>Journal of Stroke and Cerebrovascular Diseases</SO>
<YR>1995</YR>
<VL>5</VL>
<PG>241-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-FIST-1990" MODIFIED="2012-03-05 14:35:41 +0000" MODIFIED_BY="Hazel Fraser" NAME="FIST 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-03-05 14:35:41 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Franke CL, Palm R, Dalby M, Hantson L, Eriksson B, Lang-Jenssen L, et al</AU>
<TI>Flunarizine in stroke treatment (FIST). A double-blind, placebo-controlled trial in Scandinavia and the Netherlands</TI>
<SO>Acta Neurologic Scandinavica</SO>
<YR>1996</YR>
<VL>93</VL>
<PG>56-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Gelmers-1984" MODIFIED="2012-03-05 14:36:11 +0000" MODIFIED_BY="Hazel Fraser" NAME="Gelmers 1984" YEAR="1984">
<REFERENCE MODIFIED="2012-03-05 14:36:11 +0000" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-03-05 14:36:11 +0000" NOTES_MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gelmers HJ</AU>
<TI>The effects of nimodipine on the clinical course of patients with acute ischemic stroke</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1984</YR>
<VL>69</VL>
<PG>232-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Gelmers-1988" MODIFIED="2012-03-05 14:36:28 +0000" MODIFIED_BY="Hazel Fraser" NAME="Gelmers 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-03-05 14:36:28 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gelmers HJ, Gorter K, De Weerdt CJ, Wiezer HJA</AU>
<TI>A controlled trial of nimodipine in acute ischemic stroke</TI>
<SO>New England Journal of Medicine</SO>
<YR>1988</YR>
<VL>318</VL>
<PG>203-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-German_x002d_Austrian-1994" MODIFIED="2012-03-05 14:38:19 +0000" MODIFIED_BY="Hazel Fraser" NAME="German-Austrian 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-03-05 14:38:19 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kramer G, Tettenborn B, Schmutzhard E, Aichner F, Schwartz A,</AU>
<TI>Nimodipine in acute ischemic stroke. Results of the nimodipine German-Austrian stroke trial</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1994</YR>
<VL>4</VL>
<PG>182-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Heiss-1990" MODIFIED="2012-03-05 15:39:25 +0000" MODIFIED_BY="Hazel Fraser" NAME="Heiss 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-03-05 15:39:25 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heiss WD, Holthoff V, Pawlik G, Neveling M</AU>
<TI>Effect of nimodipine on regional cerebral glucose metabolism in patients with acute ischemic stroke as measured by positron emission tomography</TI>
<SO>Journal of Cerebral Blood Flow and Metabolism</SO>
<YR>1990</YR>
<VL>10</VL>
<PG>127-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-INWEST--1990" MODIFIED="2012-03-05 15:40:14 +0000" MODIFIED_BY="Hazel Fraser" NAME="INWEST  1990" YEAR="1990">
<REFERENCE MODIFIED="2012-03-05 15:40:14 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wahlgren NG, MacMahon DG, De Keyser J, Ryman T; INWEST Study Group</AU>
<TI>Intravenous nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1994</YR>
<VL>4</VL>
<PG>204-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kaste-1994" MODIFIED="2012-03-05 15:41:33 +0000" MODIFIED_BY="Hazel Fraser" NAME="Kaste 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-03-05 15:41:33 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaste M, Fogelholm R, Erila T, Palomaki H, Murros K, Rissanen A, et al</AU>
<TI>A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemishperic stroke</TI>
<SO>Stroke</SO>
<YR>1994</YR>
<VL>25</VL>
<PG>1348-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kornhuber-1993" MODIFIED="2012-03-05 15:42:40 +0000" MODIFIED_BY="Hazel Fraser" NAME="Kornhuber 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-03-05 15:42:40 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kornhuber HH, Hartung J, Herrlinger JD, Hertel G, Hulser P-J, Prange H, et al</AU>
<TI>Flunarizine in ischemic stroke: a randomised, multicentre, placebo-controlled, double blind study</TI>
<SO>Neurology Psychiatry and Brain Research</SO>
<YR>1993</YR>
<VL>1</VL>
<PG>173-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lamsudin-1995" MODIFIED="2012-03-05 15:43:52 +0000" MODIFIED_BY="Deren Wagg" NAME="Lamsudin 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-03-05 15:43:52 +0000" MODIFIED_BY="Deren Wagg" PRIMARY="NO" TYPE="OTHER">
<AU>Lamsudin HR</AU>
<TI>A randomized, double-blind, placebo controlled multicenter trial with nimodipine in acute ischaemic stroke</TI>
<SO>Unpublished</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Limburg-1990" MODIFIED="2012-03-05 15:44:09 +0000" MODIFIED_BY="Hazel Fraser" NAME="Limburg 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-03-05 15:44:09 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Limburg M, Hijdra A</AU>
<TI>Flunarizine in acute ischemic stroke: a pilot study</TI>
<SO>European Neurology</SO>
<YR>1990</YR>
<VL>30</VL>
<PG>121-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lisk-1993" MODIFIED="2012-03-05 15:45:29 +0000" MODIFIED_BY="Hazel Fraser" NAME="Lisk 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-03-05 15:45:29 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lisk D, Grotta J, Lamki L, Tran H, Taylor J, Molony D, et al</AU>
<TI>Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography</TI>
<SO>Archives of Neurology</SO>
<YR>1993</YR>
<VL>50</VL>
<PG>855-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Lowe--1989" NAME="Lowe  1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Lowe G</AU>
<TI>Nimodipine in acute cerebral hemispheric infarction</TI>
<SO>Unpublished (University of Glasgow)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Martinez_x002d_Vila-1990" MODIFIED="2012-03-05 15:46:30 +0000" MODIFIED_BY="Hazel Fraser" NAME="Martinez-Vila 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-03-05 15:46:30 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinez-Vila E, Guillen F, Villanueva JA, Matias-Guiu J, Bigorra J, Gil P, et al</AU>
<TI>Placebo-controlled trial of nimodipine in the treatment of acute ischemic cerebral infarction</TI>
<SO>Stroke</SO>
<YR>1990</YR>
<VL>21</VL>
<PG>1023-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Mohr-1992" MODIFIED="2012-03-05 15:47:04 +0000" MODIFIED_BY="Hazel Fraser" NAME="Mohr 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-03-05 15:47:04 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>American Nimodipine Study Group</AU>
<TI>Clinical trial of nimodipine in acute ischemic stroke</TI>
<SO>Stroke</SO>
<YR>1992</YR>
<VL>23</VL>
<PG>3-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nag-1998" MODIFIED="2012-03-05 15:47:52 +0000" MODIFIED_BY="Deren Wagg" NAME="Nag 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-03-05 15:47:52 +0000" MODIFIED_BY="Deren Wagg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nag D, Garg RK, Varma M</AU>
<TI>A randomized double-blind controlled study of nimodipine in acute cerebral ischemic stroke</TI>
<SO>Indian Journal of Physiology and Pharmacology</SO>
<YR>1998</YR>
<VL>42</VL>
<PG>555-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-NEST-1993" MODIFIED="2012-03-05 15:48:11 +0000" MODIFIED_BY="Hazel Fraser" NAME="NEST 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-03-05 15:48:11 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hennerici M, Kramer G, North PM, Schmitz H, Tettenborn D; Nimodipine European Stroke Trial Group (NEST)</AU>
<TI>Nimodipine in the treatment of acute MCA ischemic stroke</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1994</YR>
<VL>4</VL>
<PG>189-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-NIMPAS-1999" MODIFIED="2012-03-05 15:49:00 +0000" MODIFIED_BY="Hazel Fraser" NAME="NIMPAS 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-03-05 15:49:00 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Infeld B, Davis SM, Donnan GA, Yasaka M, Lichenstein M, Mitchell PJ, et al</AU>
<TI>Nimodipine and perfusion changes after stroke</TI>
<SO>Stroke</SO>
<YR>1999</YR>
<VL>30</VL>
<PG>1417-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oczkowski-1989" MODIFIED="2012-03-05 15:49:38 +0000" MODIFIED_BY="Hazel Fraser" NAME="Oczkowski 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-03-05 15:49:38 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oczkowski WJ, Hachinski VC, Bogousslavsky J, Barnett HJ, Carruthers SG</AU>
<TI>A double-blind, randomized trial of PY 108-068 in acute ischemic cerebral infarction</TI>
<SO>Stroke</SO>
<YR>1989</YR>
<VL>20</VL>
<PG>604-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paci-1989" MODIFIED="2012-03-05 15:50:44 +0000" MODIFIED_BY="Hazel Fraser" NAME="Paci 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-03-05 15:50:44 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paci A, Ottaviano P, Trenta A, Iannone G, De Santis L, Lancia G, et al</AU>
<TI>Nimodipine in acute ischemic stroke: a double-blind controlled study</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1989</YR>
<VL>80</VL>
<PG>282-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sherman-1986" MODIFIED="2012-03-05 15:53:04 +0000" MODIFIED_BY="Hazel Fraser" NAME="Sherman 1986" YEAR="1986">
<REFERENCE MODIFIED="2012-03-05 15:53:04 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Sherman DG, Easton JD, Hart RG, Sherman CP</AU>
<TI>Nimodipine in acute cerebral infarction. A double-blind study of safety and efficacy</TI>
<SO>Acute Brain Ischaemia: Medical and Surgical Therapy</SO>
<YR>1986</YR>
<PG>257-62</PG>
<ED>Battistini N, Fiorani P, Courbier R, Plum F, Fieschi C</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shibuya-2005" MODIFIED="2012-03-05 15:53:52 +0000" MODIFIED_BY="Deren Wagg" NAME="Shibuya 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-03-05 15:53:52 +0000" MODIFIED_BY="Deren Wagg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E</AU>
<TI>Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2005</YR>
<VL>238</VL>
<PG>31-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Squire-1996" MODIFIED="2012-03-05 15:55:37 +0000" MODIFIED_BY="Deren Wang" NAME="Squire 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-03-05 15:55:37 +0000" MODIFIED_BY="Deren Wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Squire IB, Lees KR, Pryse-Phillip W, Kertesz A, Bamford J; Lifarizine Study Group</AU>
<TI>The effects of lifarizine in acute cerebral infarction: a pilot safety study</TI>
<SO>Cardiovascular Diseases</SO>
<YR>1996</YR>
<VL>6</VL>
<PG>156-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sze-1998" MODIFIED="2012-03-05 15:56:51 +0000" MODIFIED_BY="Deren Wagg" NAME="Sze 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-03-05 15:56:51 +0000" MODIFIED_BY="Deren Wagg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sze KH, Sim TC, Wong E, Cheng S, Woo J</AU>
<TI>Effect of nimodipine on memory after cerebral infarction</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1998</YR>
<VL>97</VL>
<PG>386-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-TRUST-1990" MODIFIED="2012-03-05 15:57:02 +0000" MODIFIED_BY="Hazel Fraser" NAME="TRUST 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-03-05 15:57:02 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>TRUST Study Group</AU>
<TI>Randomised, double-blind, placebo-controlled trial of nimodipine in acute stroke</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>336</VL>
<PG>1205-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Uzunur-1995" MODIFIED="2012-03-05 15:57:21 +0000" MODIFIED_BY="Hazel Fraser" NAME="Uzunur 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-03-05 15:57:21 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Uzuner N, Ozdemir G, Gucuyener D</AU>
<TI>The interaction between nimodipine and systemic blood pressure and pulse rate</TI>
<SO>Proceedings of the WHO Pan-European Consensus Meeting on Stroke Management, Helsingborg, Sweden</SO>
<YR>November 1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-VENUS-1999" MODIFIED="2012-03-05 15:58:29 +0000" MODIFIED_BY="Deren Wagg" NAME="VENUS 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-03-05 15:58:29 +0000" MODIFIED_BY="Deren Wagg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horn J, De Haan RJ, Vermeulen M, Limburg M</AU>
<TI>Very Early Nimodipine Use in Stroke (VENUS): a randomized, double-blind, placebo-controlled trial</TI>
<SO>Stroke</SO>
<YR>2001</YR>
<VL>32</VL>
<PG>461-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wimalaratna-1994" MODIFIED="2012-03-05 15:58:46 +0000" MODIFIED_BY="Hazel Fraser" NAME="Wimalaratna 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-03-05 15:58:46 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wimalaratna HSK, Capildeo R</AU>
<TI>Nimodipine in acute ischaemic cerebral hemisphere infarction</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1994</YR>
<VL>4</VL>
<PG>179-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Yordanov-1984" MODIFIED="2008-07-22 14:49:22 +0100" MODIFIED_BY="Hazel Fraser" NAME="Yordanov 1984" YEAR="1984">
<REFERENCE MODIFIED="2008-07-22 14:49:22 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="OTHER">
<TI>Nimodipine for acute ischaemic stroke (unpublished study)</TI>
<SO>Bayer AG, Wuppertal, Germany</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-03-06 16:58:10 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ameriso-1992" MODIFIED="2012-03-06 10:54:09 +0000" MODIFIED_BY="Hazel Fraser" NAME="Ameriso 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-03-06 10:54:09 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ameriso SF, Wenby RB, Meiselman HJ, Fisher M</AU>
<TI>Nimodipine and the evolution of hemorheological variables after acute ischemic stroke</TI>
<SO>Journal of Stroke and Cerebrovascular Diseases</SO>
<YR>1992</YR>
<VL>2</VL>
<PG>22-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Csiba" MODIFIED="2012-03-06 11:21:16 +0000" MODIFIED_BY="Hazel Fraser" NAME="Csiba" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Csiba L</AU>
<TI>Hungarian Nimodipine Trial</TI>
<SO>Unpublished</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalal-1995" MODIFIED="2012-03-06 11:20:14 +0000" MODIFIED_BY="Deren Wagg" NAME="Dalal 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-03-06 11:20:14 +0000" MODIFIED_BY="Deren Wagg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dalal PM, Dalal KP</AU>
<TI>Use of calcium channel blockers in acute ischemic cerebrovascular disease</TI>
<SO>Journal of the Association of Physicians of India</SO>
<YR>1995</YR>
<VL>43</VL>
<NO>6</NO>
<PG>394-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fagan-1988" MODIFIED="2012-03-06 11:20:55 +0000" MODIFIED_BY="Deren Wagg" NAME="Fagan 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-03-06 11:20:55 +0000" MODIFIED_BY="Deren Wagg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fagan SC, Gengo FM, Bates V, Levine SR, Kinkel WR</AU>
<TI>Effect of nimodipine in blood pressure in acute ischemic stroke in humans</TI>
<SO>Stroke</SO>
<YR>1988</YR>
<VL>19</VL>
<PG>401-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mar_x00ed_n-G_x00e1_mez-1988" MODIFIED="2012-03-06 11:24:25 +0000" MODIFIED_BY="Hazel Fraser" NAME="Marín Gámez 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-03-06 11:24:01 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marín Gámez N, Soto Mas JA, Aguilar Martínez JL, Bermúdez García JM, Salim A, Ramos Jiménez A, et al</AU>
<TI>A controlled double blind clinical trial of nicardipine versus placebo in acute focal cerebral ischaemia</TI>
<TO>Ensayo clinico controlado a doble ciego: nicardipina frente a placebo en la isquemia cerebral focal aguda</TO>
<SO>Medicina Clínica</SO>
<YR>1988</YR>
<VL>90</VL>
<PG>690-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matias-Guiu-1992" MODIFIED="2012-03-06 11:27:06 +0000" MODIFIED_BY="Hazel Fraser" NAME="Matias Guiu 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-03-06 11:27:06 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matias-Guiu J, Molto JM, Galiano L, Insa R, Falip R, Martin R</AU>
<TI>Pilot double-blind placebo controlled trial of nicardipine versus placebo for cognitive impairment in minor stroke patients</TI>
<SO>Journal of Neurology</SO>
<YR>1992</YR>
<VL>239 Suppl 2</VL>
<PG>S39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Molto-1994" MODIFIED="2012-03-06 11:27:37 +0000" MODIFIED_BY="Hazel Fraser" NAME="Molto 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-03-06 11:27:37 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Molto JM, Falip R, Martin R, Insa R, Pastor I, Matias Guiu J</AU>
<TI>Comparative study of nicardipine versus placebo in the prevention of cognitive deterioration in patients with transient ischemic attacks</TI>
<TO>Estudio comparativo de nicardipina frente a placebo en la prevencion del deterioro cognitivo en los pacientes con accidentes isquemicos transitorios</TO>
<SO>Revista de Neurologia</SO>
<YR>1995</YR>
<VL>23</VL>
<PG>54-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Orgogozo" MODIFIED="2008-07-22 14:50:48 +0100" MODIFIED_BY="Hazel Fraser" NAME="Orgogozo" YEAR="??">
<REFERENCE MODIFIED="2008-07-22 14:50:48 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="OTHER">
<TI>Nicardipine Stroke Trial</TI>
<SO>Unpublished work</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petrogiannopoulos-96" MODIFIED="2012-03-06 11:28:06 +0000" MODIFIED_BY="Hazel Fraser" NAME="Petrogiannopoulos 96" YEAR="1996">
<REFERENCE MODIFIED="2012-03-06 11:28:06 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petrogiannopoulos G, Zaharof A, Tzoumani A, Poulikakos J</AU>
<TI>Efficacy of long term treatment with nimodipine on brain function after acute ischemic stroke</TI>
<SO>European Journal of Neurology</SO>
<YR>1996</YR>
<VL>3 Suppl 5</VL>
<PG>35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenbaum-1990" MODIFIED="2012-03-06 11:31:48 +0000" MODIFIED_BY="Hazel Fraser" NAME="Rosenbaum 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-03-06 11:31:48 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenbaum DM, Zabramski JM, Fry J, Yatsu F, Marler J, Spetzler RF, et al</AU>
<TI>Early treatment of ischemic stroke with a calcium antagonist</TI>
<SO>Stroke</SO>
<YR>1991</YR>
<VL>22</VL>
<PG>437-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosselli-1992" MODIFIED="2012-03-06 11:32:56 +0000" MODIFIED_BY="[Empty name]" NAME="Rosselli 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-03-06 11:32:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosselli A, Landini G, Castagnoli A, Vannucchi L, Mugnaini C, Calacoci S, et al</AU>
<TI>The nimodipine therapy of acute focal cerebral ischemia (minor stroke). A clinical study with an assessment of regional cerebral blood flow by SPECT</TI>
<SO>Recenti Progressi in Medicina</SO>
<YR>1992</YR>
<VL>83</VL>
<NO>2</NO>
<PG>85-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szczechowski-1994" MODIFIED="2012-03-06 11:34:15 +0000" MODIFIED_BY="Deren Wagg" NAME="Szczechowski 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-03-06 11:34:15 +0000" MODIFIED_BY="Deren Wagg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szczechowski L, Wajgt A</AU>
<TI>Ocena skutecznosci Ieczenia ostrych udarow niedokrwiennych dozylnym wlewem nimodypiny</TI>
<SO>Neurologia i Neurochirurgia Polska</SO>
<YR>1994</YR>
<VL>28</VL>
<PG>299-306</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yao-1991" MODIFIED="2012-03-06 16:58:10 +0000" MODIFIED_BY="Hazel Fraser" NAME="Yao 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-03-06 16:58:10 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yao J</AU>
<TI>Preliminary study of nimodipine in acute cerebral infarction</TI>
<SO>Chinese Journal of Nervous &amp; Mental Diseases</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>1</NO>
<PG>47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="Deren Wagg">
<STUDY DATA_SOURCE="PUB" ID="STD-Davalos-1989" MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="Hazel Fraser" NAME="Davalos 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davalos A, Cendra E, Gonzalez B, Genis D, Teruel J, Ruibal A</AU>
<TI>Double-blind randomized clinical trial of nicardipine versus placebo in acute ischemic stroke: clinical, radiological and biochemical evaluation of the ischemic area. Preliminay results</TI>
<SO>Neurology India</SO>
<YR>1989</YR>
<VL>37 Suppl</VL>
<PG>283</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davalos-Errando-1992" MODIFIED="2012-03-06 11:35:57 +0000" MODIFIED_BY="Hazel Fraser" NAME="Davalos Errando 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-03-06 11:35:57 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davalos Errando E, De Cendra E, Geris D, Teruel J, Ruibal A, Musoles S</AU>
<TI>Double blind controlled trial of nicardipine versus placebo in the treatment of the acute phase of cerebral infarction</TI>
<TO>Ensayo clinico controlado a doble ciego de nicardipino frente a placebo en el tratamiento de la fase aguda del infarto cerebral</TO>
<SO>Neurologia</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>157</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia-Tigeria" MODIFIED="2012-03-06 11:36:09 +0000" MODIFIED_BY="Hazel Fraser" NAME="Garcia Tigeria" YEAR="1993">
<REFERENCE MODIFIED="2012-03-06 11:36:09 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Garcia Tigera J, Alvarez LG, Hernandez MO</AU>
<TI>Treatment with calcium channels blockers (nifedipine) of patients with acute brain infarction</TI>
<SO>Unpublished</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hakim-1989" MODIFIED="2012-03-06 11:37:27 +0000" MODIFIED_BY="Deren Wagg" NAME="Hakim 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-03-06 11:37:27 +0000" MODIFIED_BY="Deren Wagg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hakim AM, Evans AC, Berger L, Kuwabara H, Worsley K, Marchal G, et al</AU>
<TI>The effect of nimodipine on the evolution of human cerebral infarction studied by PET</TI>
<SO>Journal of Cerebral Blood Flow and Metabolism</SO>
<YR>1989</YR>
<VL>9</VL>
<PG>523-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2012-03-16 11:12:20 +0000" MODIFIED_BY="tingting Yuan">
<STUDY DATA_SOURCE="UNPUB" ID="STD-AIIMS-trial" MODIFIED="2008-07-22 14:54:39 +0100" MODIFIED_BY="Hazel Fraser" NAME="AIIMS trial" YEAR="1995">
<REFERENCE MODIFIED="2008-07-22 14:54:39 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="OTHER">
<AU>Behari M, Prasad K</AU>
<TI>Nimodipine in acute stroke, AIIMS trial of nimodipine in acute stroke</TI>
<SO>Unpublished</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Tanahashi-2007" MODIFIED="2012-03-16 11:12:20 +0000" MODIFIED_BY="tingting Yuan" NAME="Tanahashi 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-03-16 11:12:20 +0000" MODIFIED_BY="tingting Yuan" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Tanahashi N</AU>
<TI>Phase Ill clinical trial for AT-877 (i.v.) in patients with acute ischemic stroke. Placebo-controlled, double-blind add-on therapy to antiplatelet drugs</TI>
<SO>Unpublished</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-03-16 11:12:41 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-03-16 11:12:41 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-AHA-2007" MODIFIED="2012-03-16 11:12:41 +0000" MODIFIED_BY="tingting Yuan" NAME="AHA 2007" TYPE="OTHER">
<AU>Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, et al</AU>
<TI>Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee</TI>
<SO>Circulation</SO>
<YR>2007</YR>
<VL>115</VL>
<NO>5</NO>
<PG>e69-171</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bamford-1989" NAME="Bamford 1989" TYPE="JOURNAL_ARTICLE">
<AU>Bamford JM, Sandercock PAG, Warlow CP, Slattery J</AU>
<TI>Interobserver agreement for the assessment of handicap in stroke patients</TI>
<SO>Stroke</SO>
<YR>1989</YR>
<VL>20</VL>
<PG>828</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Counsell-1994" MODIFIED="2012-03-06 11:38:24 +0000" MODIFIED_BY="Hazel Fraser" NAME="Counsell 1994" TYPE="JOURNAL_ARTICLE">
<AU>Counsell CE, Clarke MJ, Slattery J, Sandercock PAG</AU>
<TI>The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis?</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<PG>1677-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Di-Mascio-1994" MODIFIED="2012-03-06 11:38:37 +0000" MODIFIED_BY="Hazel Fraser" NAME="Di Mascio 1994" TYPE="JOURNAL_ARTICLE">
<AU>Di Mascio R, Marchioli R, Tognomi G</AU>
<TI>From pharmacological promises to controlled clinical trials to meta-analysis and back: the case of nimodipine in cerebrovascular disorders</TI>
<SO>Clinical Trials and Meta-analysis</SO>
<YR>1994</YR>
<VL>29</VL>
<PG>57-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gelmers-1990" MODIFIED="2012-03-06 11:38:50 +0000" MODIFIED_BY="Hazel Fraser" NAME="Gelmers 1990" TYPE="JOURNAL_ARTICLE">
<AU>Gelmers HJ, Hennerici M</AU>
<TI>Effect of nimodipine on acute ischemic stroke pooled results from five randomized trials</TI>
<SO>Stroke</SO>
<YR>1990</YR>
<VL>21 Suppl IV</VL>
<PG>IV81-IV84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Germano-1987" MODIFIED="2012-03-06 11:42:02 +0000" MODIFIED_BY="Hazel Fraser" NAME="Germano 1987" TYPE="JOURNAL_ARTICLE">
<AU>Germano IM, Bartkowski HM, Cassel ME, Pitts LH</AU>
<TI>The therapeutic value of nimodipine in experimental focal cerebral ischemia. Neurological outcome and histopathological findings</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1987</YR>
<VL>67</VL>
<PG>81-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harders-1996" MODIFIED="2012-03-06 11:42:30 +0000" MODIFIED_BY="Hazel Fraser" NAME="Harders 1996" TYPE="JOURNAL_ARTICLE">
<AU>Harders A, Kakarieka A, Braakman R; the German tSAH Study Group</AU>
<TI>Traumatic subarachnoid hemorrhage and its treatment with nimodipine</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1996</YR>
<VL>85</VL>
<PG>82-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heininger-1996" MODIFIED="2012-03-06 11:42:37 +0000" MODIFIED_BY="Hazel Fraser" NAME="Heininger 1996" TYPE="JOURNAL_ARTICLE">
<AU>Heininger K, Kuebler J</AU>
<TI>Use of Nimodipine is safe</TI>
<SO>Stroke</SO>
<YR>1996</YR>
<VL>27</VL>
<PG>1911-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-03-06 11:43:33 +0000" MODIFIED_BY="tingting Yuan" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration</TI>
<SO>Available from www.cochrane-handbook.org.</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jennet-1975" MODIFIED="2012-03-06 11:43:53 +0000" MODIFIED_BY="Hazel Fraser" NAME="Jennet 1975" TYPE="JOURNAL_ARTICLE">
<AU>Jennet B, Bond M</AU>
<TI>Assessment of outcome after severe brain damage</TI>
<SO>Lancet</SO>
<YR>1975</YR>
<VL>1</VL>
<NO>7950</NO>
<PG>480-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Legault-1996" MODIFIED="2012-03-06 11:44:41 +0000" MODIFIED_BY="Hazel Fraser" NAME="Legault 1996" TYPE="JOURNAL_ARTICLE">
<AU>Legault C, Furberg CD, Wagenknecht LE, Rogers AT, Stump DA, Coker L, et al</AU>
<TI>Nimodipine neuroprotection in cardiac valve replacement. Report of an early terminated trial</TI>
<SO>Stroke</SO>
<YR>1996</YR>
<VL>27</VL>
<PG>593-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liu-2007" MODIFIED="2012-01-27 15:21:34 +0000" MODIFIED_BY="tingting Yuan" NAME="Liu 2007" TYPE="JOURNAL_ARTICLE">
<AU>Liu M, Wu B, Wang WZ, Lee LM, Zhang SH, Kong LZ</AU>
<TI>Stroke in China: epidemiology, prevention, and management strategies</TI>
<SO>Lancet Neurology</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>5</NO>
<PG>456-64</PG>
<IDENTIFIERS MODIFIED="2011-12-28 11:20:06 +0000" MODIFIED_BY="tingting Yuan"/>
</REFERENCE>
<REFERENCE ID="REF-Mahoney-1965" MODIFIED="2012-03-06 11:48:23 +0000" MODIFIED_BY="Hazel Fraser" NAME="Mahoney 1965" TYPE="JOURNAL_ARTICLE">
<AU>Mahoney FI, Barthel DW</AU>
<TI>Functional evaluation: the Barthel Index</TI>
<SO>Maryland State Medical Journal</SO>
<YR>1965</YR>
<VL>14</VL>
<PG>61-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mathew-1972" MODIFIED="2012-03-06 12:07:56 +0000" MODIFIED_BY="Hazel Fraser" NAME="Mathew 1972" TYPE="JOURNAL_ARTICLE">
<AU>Mathew NT, Meyer JS, Rivera VH</AU>
<TI>Double blind evaluation of glycerol treatment in acute cerebral infarction</TI>
<SO>Lancet</SO>
<YR>1972</YR>
<VL>ii</VL>
<PG>1327-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mees-2008" MODIFIED="2012-03-06 12:10:07 +0000" MODIFIED_BY="tingting Yuan" NAME="Mees 2008" TYPE="COCHRANE_REVIEW">
<AU>Dorhout Mees SM, Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, et al</AU>
<TI>Calcium antagonists for aneurysmal subarachnoid haemorrhage</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-03-06 12:09:30 +0000" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2012-03-06 12:09:30 +0000" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="10.1002/14651858.CD000277.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mohr-1994" MODIFIED="2012-03-06 12:12:17 +0000" MODIFIED_BY="Hazel Fraser" NAME="Mohr 1994" TYPE="JOURNAL_ARTICLE">
<AU>Mohr JP, Orgogozo JM, Harrison MJG, Hennerici M, Wahlgren NG, Gelmers JH, et al</AU>
<TI>Meta-analysis of oral nimodipine trials in acute ischemic stroke</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1994</YR>
<VL>3</VL>
<PG>197-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Norris-1982" MODIFIED="2012-03-06 12:12:28 +0000" MODIFIED_BY="Hazel Fraser" NAME="Norris 1982" TYPE="JOURNAL_ARTICLE">
<AU>Norris JW</AU>
<TI>Comment on 'Study Design of Stroke Treatments'</TI>
<SO>Stroke</SO>
<YR>1982</YR>
<VL>4</VL>
<PG>527-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pickard-1989" MODIFIED="2012-03-06 12:14:26 +0000" MODIFIED_BY="Hazel Fraser" NAME="Pickard 1989" TYPE="JOURNAL_ARTICLE">
<AU>Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale GM, Foy PM, et al</AU>
<TI>Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial</TI>
<SO>BMJ</SO>
<YR>1989</YR>
<VL>298</VL>
<PG>636-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2012-01-04 07:58:39 +0000" MODIFIED_BY="tingting Yuan" NAME="RevMan 2011" TYPE="OTHER">
<TI>Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre</TI>
<SO>The Cochrane Collaboration</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Siesjo-1978" MODIFIED="2012-03-06 12:14:50 +0000" MODIFIED_BY="Hazel Fraser" NAME="Siesjo 1978" TYPE="BOOK">
<AU>Siesjo BK</AU>
<SO>Brain Energy Metabolism</SO>
<YR>1978</YR>
<PB>John Wiley &amp; Sons</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Siesjo-1989" MODIFIED="2012-03-06 12:15:46 +0000" MODIFIED_BY="Hazel Fraser" NAME="Siesjo 1989" TYPE="JOURNAL_ARTICLE">
<AU>Siesjo BK, Bengtsson R</AU>
<TI>Review. Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia, and spreading depression: a unifying hypothesis</TI>
<SO>Journal of Cerebral Blood Flow and Metabolism</SO>
<YR>1989</YR>
<VL>9</VL>
<PG>127-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steen-1983" MODIFIED="2012-03-06 12:16:03 +0000" MODIFIED_BY="Hazel Fraser" NAME="Steen 1983" TYPE="JOURNAL_ARTICLE">
<AU>Steen PA, Newberg LA, Milde JH, Michenfelder JD</AU>
<TI>Nimodipine improves cerebral blood flow and neurologic recovery after complete cerebral ischemia in the dog</TI>
<SO>Journal of Cerebral Blood Flow and Metabolism</SO>
<YR>1983</YR>
<VL>3</VL>
<PG>38-43</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-04-03 11:17:23 +0100" MODIFIED_BY="tingting Yuan">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-04-03 11:17:23 +0100" MODIFIED_BY="tingting Yuan" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-03-16 11:08:22 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-ASCLEPIOS-1990">
<CHAR_METHODS MODIFIED="2012-03-16 11:08:20 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: unpublished</P>
<P>Multicenter placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: unclear<BR/>Losses to follow-up: 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-15 13:47:29 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: age: 45 to 85 years, start within 12 hours, probable MCA infarction, CT scan within 72 hours<BR/>Exclusion: massive hemispherical infarction, Orgogozo score &gt; 65, clinical resolution within 24 hours</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:08:22 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment: intravenous isradipine, 28 days, 80 microgram/hour for 72 hours, followed orally with 2.5 mg bid<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-05 12:59:18 +0000" MODIFIED_BY="Hazel Fraser">
<P>Barthel Index<BR/>Deaths<BR/>Last follow-up: 3 months<BR/>Dependency measurement used in review: Barthel Index<BR/>Missing: 4 patients in isradipine group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 12:59:23 +0000" MODIFIED_BY="Hazel Fraser">
<P>Data available from principal investigator (JM Orgogozo)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:08:36 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Bogousslavsky-1990">
<CHAR_METHODS MODIFIED="2012-03-16 11:08:25 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Unicenter placebo-controlled trial</P>
<P>Random sequence generation: random list<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: 8<BR/>Losses to follow-up: 1</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:08:32 +0000" MODIFIED_BY="tingting Yuan">
<P>Inclusion criteria: age 40 to 85 years, start within 48 hours, acute ischemic stroke of mild-to-moderate severity (Mathew Scale score 50 to 75), diagnosis on CT scan and clinical evaluation<BR/>Exclusion criteria: rapid improvement &lt; 24 hours, loss of consciousness, brainstem infarction, pregnancy, cerebral neoplasm, other cause of brain infarction than atherothrombosis, other severe diseases, medication (concomitant use of calcium channel antagonists, piracetam, pentoxyphylline, naftidrofuryl dehydrogenoxalate, dihydroergetoxine, alpha-methyldopa)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:08:34 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: oral nimodipine, 30 mg qid for 2 weeks<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-16 11:08:36 +0000" MODIFIED_BY="[Empty name]">
<P>Mathew Scale score<BR/>Death<BR/>Last follow-up: 4 months<BR/>Dependency measurement used in review: functional item Mathew Scale scale<BR/>Missing: 1 patient in placebo group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 13:01:27 +0000" MODIFIED_BY="Hazel Fraser">
<P>Data available from publication and database of Bayer AG, Wuppertal, Germany</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:08:44 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Bridgers-1991">
<CHAR_METHODS MODIFIED="2012-03-16 11:08:41 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published as abstract</P>
<P>Multicenter placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear</P>
<P>Double-blind<BR/>Exclusions during trial: unclear<BR/>Losses to follow-up: 1</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-05 13:02:13 +0000" MODIFIED_BY="Hazel Fraser">
<P>Inclusion criteria: acute stroke, moderate to severe, &lt; 24 hours after stroke onset<BR/>Exclusion criteria: unknown</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:08:44 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: intravenous nimodipine, 2 active groups: 1 mg/hour or 2 mg/hour for 5 days, followed by oral nimodipine 120 mg/day days 5 to 21<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-05 13:03:03 +0000" MODIFIED_BY="Hazel Fraser">
<P>Barthel Index, Glasgow Outcome Scale and Mathew Scale<BR/>Deaths<BR/>Last follow-up: 21 days (?not completely clear)<BR/>Dependency measurement used in review: Glasgow Outcome Scale<BR/>Missing: 1 missing in placebo group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 13:03:14 +0000" MODIFIED_BY="Hazel Fraser">
<P>Data available from published abstract and Bayer AG, Wuppertal<BR/>Trial was stopped after inclusion of 204 of planned 720 patients because of deleterious effect in high dosage group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:08:55 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Canwin-1993">
<CHAR_METHODS MODIFIED="2012-03-16 11:08:45 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Blinding: unclear<BR/>Exclusions during trial: 25<BR/>Losses to follow-up: 16</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:08:49 +0000" MODIFIED_BY="Hazel Fraser">
<P>Inclusion criteria: age 45 to 85 years, start within 48 hours, hemiplegia, CT-confirmed hemispheric cerebral infarction, Toronto Stroke Scale scores &gt; 20<BR/>Exclusion: coma, no motor weakness, brainstem strokes or previous strokes, CT scan not compatible with ischemic stroke, use of calcium antagonists, concurrent terminal illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:08:55 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: intravenous nimodipine; days 1 to 10 at 2 mg/hour, days 11 to 6 months at 180 mg/day orally<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-05 13:05:23 +0000" MODIFIED_BY="Hazel Fraser">
<P>Toronto Stroke Scale<BR/>Functional disability using 3 categories: (1) minor or no disability, (2) moderate disability, (3) severely disabled or bedridden</P>
<P>Death<BR/>Last follow-up: 1 year<BR/>Dependency measurement used in review: Toronto Stroke Scale<BR/>Missing: 5 in active treatment group, 11 in control group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 13:05:26 +0000" MODIFIED_BY="Hazel Fraser">
<P>Data available from publication, principal investigator, Bayer Canada and Bayer AG, Wuppertal, Germany</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:08:56 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Capon-1983">
<CHAR_METHODS MODIFIED="2012-03-16 11:08:56 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: unpublished</P>
<P>Placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Blinding: unclear<BR/>Exclusions during trial: unclear<BR/>Losses to follow-up: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-05 13:06:13 +0000" MODIFIED_BY="Hazel Fraser">
<P>Stroke patients, criteria unknown</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-15 16:08:16 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: nimodipine oral, 30 mg qid for 56 days<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-05 13:06:27 +0000" MODIFIED_BY="Hazel Fraser">
<P>Death<BR/>Last follow-up: at end of treatment<BR/>No dependency measurement available</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Very limited data available from Bayer AG, Wuppertal, Germany. No published data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-28 15:21:24 +0100" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Chandra-1995">
<CHAR_METHODS MODIFIED="2012-03-16 11:08:58 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Blinded comparison of oral versus intravenous administration of nimodipine</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: unclear<BR/>Losses to follow-up: 0</P>
<P>Placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:08:59 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: sudden focal neurologic deficit, admission within 6 hours<BR/>Exclusion: transient signs, large (&gt; 60 mL on CT) cerebral hemorrhage; no informed consent; recent myocardial infarction; congestive heart failure; abnormal renal, pulmonary or hepatic function<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:09:03 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: oral versus intravenous treatment: arm 1: oral nimodipine 30 mg qid and intravenous placebo; arm 2: nimodipine 2.5 mg/hour intravenous and oral placebo Treatment period 10 days, followed by oral nimodipine for all</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-28 15:21:24 +0100" MODIFIED_BY="Hazel Fraser">
<P>Unmodified Mathew Scale, Barthel Index<BR/>Death<BR/>Last follow-up: day 14<BR/>Dependency: data reported in unusable way<BR/>Missing: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 13:08:27 +0000" MODIFIED_BY="Hazel Fraser">
<P>Data from original publication, only average scores on functional items available, hence not used in meta-analysis<BR/>This trial is only used for direct comparison of route of administration</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:09:23 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-FIST-1990">
<CHAR_METHODS MODIFIED="2012-03-16 11:09:12 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Multicenter placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: 32<BR/>Losses to follow-up: 5</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:09:12 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: clinical diagnosis of ischemic stroke in MCA territory, disabling motor deficit, total Glasgow Coma Score &gt; 3, &lt; 24 hours of stroke onset<BR/>Exclusion criteria: brain tumor, intracranial hemorrhage or lacunar infarction on CT scan, previous disabling stroke, other severe disorder, poor physical or mental condition</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:09:20 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: intravenous flunarizine: days 1 to 7 at 25 mg bid followed by oral flunarizine: days 8 to 14 at 21 mg/day; days 15 to 28 at 7 mg/day<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-16 11:09:21 +0000" MODIFIED_BY="Hazel Fraser">
<P>Modified Rankin scale, Orgogozo scale, Modified Barthel Index<BR/>Death<BR/>Last follow-up: 24 weeks<BR/>Dependency measurement used in review: Modified Rankin scale<BR/>Missing: 4 in active treatment, 1 in placebo group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-16 11:09:23 +0000" MODIFIED_BY="Hazel Fraser">
<P>Other 'stroke therapies' were not allowed<BR/>Data were available from publication and from Janssen Pharmaceutica BV, Tilburg, Netherlands</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:09:35 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Gelmers-1984">
<CHAR_METHODS MODIFIED="2012-03-16 11:09:29 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Single-blind<BR/>Exclusions during trial: 0<BR/>Losses to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-05 13:11:53 +0000" MODIFIED_BY="Hazel Fraser">
<P>Inclusion criteria: acute ischemic stroke, age &gt; 40 years, CT scan compatible with diagnosis<BR/>Exclusion criteria: not described</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:09:31 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: oral nimodipine, 30 mg qid, 28 days<BR/>Placebo: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-16 11:09:35 +0000" MODIFIED_BY="Hazel Fraser">
<P>Mathew Stroke Scale<BR/>Death<BR/>Last follow-up: 28 days<BR/>Dependency measurement used in review: functional item in Mathew Scale<BR/>Missing: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 13:12:27 +0000" MODIFIED_BY="Hazel Fraser">
<P>All patients standard treatment with 10% depolymerized dextran for 12 hours/day for 5 days<BR/>Data available from publication and Bayer AG, Wuppertal, Germany</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:09:44 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Gelmers-1988">
<CHAR_METHODS MODIFIED="2012-03-16 11:09:37 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Multicenter placebo-controlled trial</P>
<P>Random sequence generation: computer-generated lists<BR/>Concealment: numbered box<BR/>Double-blind<BR/>Exclusions during trial: 22<BR/>Losses to follow-up: 38</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-05 13:13:21 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: age &gt; 45 years, clinical diagnosis of complete acute ischemic stroke &lt; 24 hours after stroke onset<BR/>Exclusion criteria: other causes than atherothrombosis (subarachnoid and intracerebral hemorrhage), complicated migraine, severe systemic diseases</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:09:39 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: oral nimodipine, 30 mg qid, 28 days<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-16 11:09:43 +0000" MODIFIED_BY="Hazel Fraser">
<P>Mathew Scale<BR/>Death<BR/>Last follow-up: 6 months<BR/>Dependency measurement used in review: functional-item Mathew Scale (at end of treatment)<BR/>Missing: 18 patients in active treatment and 20 patients in placebo group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-16 11:09:44 +0000" MODIFIED_BY="Hazel Fraser">
<P>All patients received a standard regimen of 10% depolymerized low-molecular-weight dextran for 12 hours per day during 5 days<BR/>Data available from publication and Bayer AG, Wuppertal, Germany</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:09:54 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-German_x002d_Austrian-1994">
<CHAR_METHODS MODIFIED="2012-03-16 11:09:46 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Multicenter placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: 126<BR/>Losses to follow-up: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:09:51 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: age 40 to 80 years, start within 48 hours, infarcts in anterior circulation (CT-confirmed), no clinical or CT-scan (within 1 week) evidence of non-ischemic disorder, Mathew sum score &lt; 66<BR/>Exclusion criteria: TIA, progressive stroke, vertebrobasilar ischemia, coma, intracerebral bleeding or tumor, SAH, pregnancy, cardiac surgery within last 3 months and severe systemic illnesses, use of other 'stroke treatment'</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:09:52 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: oral nimodipine, 30 mg qid, 21 days<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-16 11:09:54 +0000" MODIFIED_BY="[Empty name]">
<P>Modified Mathew Scale, Barthel Index<BR/>Death<BR/>Last follow-up: 6 months<BR/>Dependency measurement used in review: functional item in Mathew Scale<BR/>Missing: 89 patients in active treatment, 83 in placebo group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 13:16:31 +0000" MODIFIED_BY="Hazel Fraser">
<P>Data available from publication, abstracts and Bayer AG, Wuppertal, Germany</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:09:59 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Heiss-1990">
<CHAR_METHODS MODIFIED="2012-03-16 11:09:57 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Multicenter placebo-controlled trial</P>
<P>Random sequence generation: random number<BR/>Concealment: packed box<BR/>Double-blind<BR/>Exclusions during trial: 4<BR/>Losses to follow-up: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:09:57 +0000" MODIFIED_BY="Hazel Fraser">
<P>Inclusion criteria: age &gt; 45 years, acute completed ischemic stroke; admission &lt; 48 hours, Mathew Scale Score &lt; 66<BR/>Exclusion criteria: other causes than atherothrombosis, overt systemic disease, coma, previous cerebral infarction</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:09:58 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: intravenous nimodipine, 1 mg/hour in first 2 hours, 2 mg/hour next 5 days, followed by 30 mg oral qid days 6 to 21<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-16 11:09:59 +0000" MODIFIED_BY="[Empty name]">
<P>Mathew Scale Score, Barthel Index<BR/>Death<BR/>Last follow-up: 6 months<BR/>Dependency measurement used in review: Barthel Index<BR/>Missing: in publication 27 patients were said to be randomized, in original data set 24: numbers reported in publication used</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-16 11:09:59 +0000" MODIFIED_BY="Hazel Fraser">
<P>All patients were treated with low-molecular-weight dextran (500 mL/day for 15 days) and glycerol (10% for 5 days)<BR/>Data available from publication and Bayer AG, Wuppertal, Germany</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:10:03 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-INWEST--1990">
<CHAR_METHODS MODIFIED="2012-03-16 11:10:00 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Multicenter placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: 67<BR/>Losses to follow-up: 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:10:01 +0000" MODIFIED_BY="Hazel Fraser">
<P>Inclusion criteria: age &gt; 40 years, start &lt; 24 hours, clinical diagnosis of ischemic stroke carotid territory, functionally independent before stroke, conscious, Mathew Scale Score &lt; 66 or Orgogozo score 5 to 50<BR/>Exclusion criteria: cardiac disease, any disorder interfering with assessment, life-threatening concurrent illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:10:02 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: intravenous nimodipine 1 mg/hour or 2 mg/hour for 5 days, followed by oral nimodipine 120 mg/day days 5 to 21<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-16 11:10:03 +0000" MODIFIED_BY="Hazel Fraser">
<P>Barthel Index, Orgogozo and Mathew Scales<BR/>Death<BR/>Last follow-up: 24 weeks<BR/>Dependency measurement used in review: Barthel Index<BR/>Missing: 4 patients in nimodipine group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 13:20:02 +0000" MODIFIED_BY="Hazel Fraser">
<P>Trial was terminated early after including 295 patients (planned 600) because of safety concerns<BR/>Data available from author's manuscript, abstract and Bayer AG, Wuppertal, Germany</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:10:06 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Kaste-1994">
<CHAR_METHODS MODIFIED="2012-03-16 11:10:05 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Multicenter placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: sealed envelope<BR/>Double-blind<BR/>Exclusions during trial: 4<BR/>Losses to follow-up: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:10:05 +0000" MODIFIED_BY="Hazel Fraser">
<P>Inclusion criteria: age 16 to 69 years, start within 48 hours, acute ischemic hemispheric stroke, CT scan compatible with clinical diagnosis</P>
<P>Exclusion criteria: unconsciousness, inability to swallow, rapidly improving, dependence before stroke, brainstem infarction, complicated migraine, pregnancy, overt renal, hepatic or cardiac failure, severe systemic infection, serious psychiatric disturbance, terminal malignancy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:10:06 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: oral nimodipine, 30 mg qid, 21 days<BR/>Placebo: identical regime</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-05 13:22:30 +0000" MODIFIED_BY="Hazel Fraser">
<P>Neurological examination<BR/>Rankin scale<BR/>Death<BR/>Last follow-up: 12 months<BR/>Dependency measurement used in review: Rankin scale<BR/>Missing: 2 living patients in placebo, 1 living patient in active treatment group<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 13:22:32 +0000" MODIFIED_BY="Hazel Fraser">
<P>Data available from authors and publication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:10:13 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Kornhuber-1993">
<CHAR_METHODS MODIFIED="2012-03-16 11:10:08 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Multicenter placebo-controlled trial</P>
<P>Random sequence generation: special sequence generation<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: 4<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:10:09 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: age 50 to 85 years, start within 36 hours, clinical diagnosis of anterior or MCA stroke<BR/>Exclusion criteria: transient signs, coma, previous cerebral infarction, severe cardiac insufficiency, acute myocardial infarction, acute pulmonary embolism, connective tissue disease, cytostatic therapy, use of calcium antagonists or oral anticoagulation, dialysis, dementia, intracranial hemorrhage, brain tumor, brainstem infarction, complicated migraine, flunarizine treatment within previous 4 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:10:12 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: intravenous flunarizine, 25 mg bid, 7 days, followed by oral 10 mg/day and 20 mg/day, days 8 to 28<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-16 11:10:12 +0000" MODIFIED_BY="Hazel Fraser">
<P>Modified Mathew Scale<BR/>Death<BR/>Last follow-up: 28 days<BR/>Data on dependency: not available from all patients randomized, since data from 1 center were excluded from analysis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-16 11:10:13 +0000" MODIFIED_BY="Hazel Fraser">
<P>All patients received aspirin, subcutaneous aspirin and hydroxyethyl starch for 7 days<BR/>Data available from publication and abstract<BR/>Mortality data were available from all centers</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:10:17 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Lamsudin-1995">
<CHAR_METHODS MODIFIED="2012-03-16 11:10:15 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Multicenter placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: 15</P>
<P>Losses to follow-up: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:10:16 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: acute ischemic stroke within the preceding 24 hours, either sex, all ages, diagnosis by CT</P>
<P>Exclusion criteria: coma, intracranial hemorrhage, tumor, infection, trauma, serious organic brain disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:10:17 +0000" MODIFIED_BY="Deren Wagg">
<P>Treatment: oral nimodipine, 30 mg qid, 28 days<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-16 11:10:17 +0000" MODIFIED_BY="[Empty name]">
<P>Canadian Scale score, Barthel Index score<BR/>Death during study period</P>
<P>Missing: 15 patients</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 13:26:41 +0000" MODIFIED_BY="Deren Wagg">
<P>Data provided by Professor Thomas</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:10:23 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Limburg-1990">
<CHAR_METHODS MODIFIED="2012-03-16 11:10:22 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Unicenter placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: 0</P>
<P>Losses to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-05 13:27:49 +0000" MODIFIED_BY="Hazel Fraser">
<P>Inclusion criteria: start within 24 hours, supratentorial ischemic stroke with hemiparesis, CT scan exclusion of other relevant pathology<BR/>Exclusion criteria: lacunar syndromes, serious underlying diseases, previous disabling strokes, use of calcium antagonists</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:10:23 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: intravenous flunarizine; bolus of 0.1 mg/kg body weight, followed after 3 hours by continuous intravenous infusion 0.3 mg/kg/24 hour during 72 hours, subsequently oral administration of 10 mg/24 hours for 11 days<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-05 13:28:59 +0000" MODIFIED_BY="Hazel Fraser">
<P>Motricity Index, Rankin scale, Barthel Index<BR/>Death<BR/>Last follow-up: 6 months<BR/>Dependency measurement used in review: Rankin scale<BR/>Missing: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 13:29:00 +0000" MODIFIED_BY="Hazel Fraser">
<P>Data available from authors and publication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:10:27 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Lisk-1993">
<CHAR_METHODS MODIFIED="2012-03-16 11:10:24 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: 0</P>
<P>Losses to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:10:26 +0000" MODIFIED_BY="Hazel Fraser">
<P>Inclusion criteria: age 40 to 90 years, start within 72 hours, clinical diagnosis of ischemic stroke in MCA territory, systolic BP &gt; 170 mmHg, diastolic BP &gt; 119 mmHg or MABP &gt; 139 mmHg, history of hypertension<BR/>Exclusion criteria: coma, previous serious stroke, unstable cardiac disease, history of angioedema or collagen vascular disease, liver dysfunction, brainstem strokes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:10:27 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: oral nicardipine, 20 mg tid for 3 days<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-05 13:35:35 +0000" MODIFIED_BY="Hazel Fraser">
<P>National Institutes of Health Stroke Scale<BR/>Deaths<BR/>Last follow-up: 3 days<BR/>Data on dependency: not available<BR/>Missing: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-15 13:52:17 +0000" MODIFIED_BY="Hazel Fraser">
<P>Data from publication<BR/>Trial compared treatment with nicardipine or captopril versus placebo, in this analysis the captopril group was excluded<BR/>Trial designed to find differences in cerebral blood flow as measured with SPECT in hypertensive patients with a stroke</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:10:29 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Lowe--1989">
<CHAR_METHODS MODIFIED="2012-03-16 11:10:28 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: unpublished</P>
<P>Placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear</P>
<P>Exclusions during trial: unclear</P>
<P>Losses to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:10:28 +0000" MODIFIED_BY="Hazel Fraser">
<P>Inclusion criteria: age 45 to 85 years, start within 48 hours, clinical diagnosis of acute cerebral hemispheric infarction, Barthel Index &lt; 66<BR/>Exclusion criteria: other cause for neurological deficits, CT scan within 7 days of ictus, not expected to survive, women capable of child bearing, severe liver or renal failure, recent myocardial infarction, decompensated heart failure, disability due to other causes not separable from present illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:10:29 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: oral nimodipine, 40 mg tid for 16 weeks<BR/>Placebo: identical regimen<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-05 13:38:19 +0000" MODIFIED_BY="Hazel Fraser">
<P>Neurological score (MRC 10-item), Barthel Index<BR/>Deaths<BR/>Last follow-up: 24 weeks<BR/>Dependency measurement used in review: Barthel Index<BR/>Missing: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 13:40:57 +0000" MODIFIED_BY="Hazel Fraser">
<P>Data available from investigators and Bayer AG, Wuppertal, Germany<BR/>For analysis on time interval after stroke onset 12 patients with missing data in nimodipine group, and 8 in placebo group<BR/>For all other analyses data from the investigators were used, without missing data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:10:32 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Martinez_x002d_Vila-1990">
<CHAR_METHODS MODIFIED="2012-03-16 11:10:30 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Multicenter placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: 41</P>
<P>Losses to follow-up: 81</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:10:30 +0000" MODIFIED_BY="Hazel Fraser">
<P>Inclusion criteria: age &gt; 44 years, start within 48 hours, clinical diagnosis of ICA territory ischemic stroke, CT scan within 3 days<BR/>Exclusion criteria: complete recovery within 24 hours, acute myocardial infarction, renal or liver failure, severe systemic infections, poorly controlled diabetes mellitus, systolic arterial BP &lt; 100 mmHg, terminal malignancy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:10:31 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: oral nimodipine, 30 mg qid for 28 days<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-16 11:10:32 +0000" MODIFIED_BY="Hazel Fraser">
<P>Mathew Scale, Toronto Stroke Scale<BR/>Deaths<BR/>Last follow-up: 28 days<BR/>Dependency measurement used in review: Toronto Stroke Scale<BR/>Missing: 40 in active treatment group, 41 in placebo group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 13:42:47 +0000" MODIFIED_BY="Hazel Fraser">
<P>Data available from publication and Bayer AG, Wuppertal, Germany</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:10:39 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Mohr-1992">
<CHAR_METHODS MODIFIED="2012-03-16 11:10:34 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Multicenter placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: numbered box<BR/>Double-blind<BR/>Exclusions during trial: 102</P>
<P>Losses to follow-up: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:10:35 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: age 20 to 90 years, start within 48 hours, clinical diagnosis of acute ischemic stroke, CT scan without evidence of cerebral hemorrhage<BR/>Exclusion criteria: coma, intracranial hemorrhage, tumor, infection, trauma, serious other organic brain disease, need for mechanical ventilation, calcium antagonist therapy, pregnancy, hypotension, bradycardia, heart block, hepatic or renal dysfunction, congestive heart failure, pneumonia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:10:38 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: oral nimodipine 20 mg, 40 mg or 80 mg tid for 2 weeks<BR/>Placebo: identical regimen<BR/>(4 groups: 60 mg/day, 120 mg/day and 240 mg/day and placebo)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-16 11:10:39 +0000" MODIFIED_BY="Hazel Fraser">
<P>Motor strength from Stroke Data Bank, Toronto Stroke Scale, Barthel Index, Mathew Scale<BR/>Dependency measurement used in review: Barthel Index at 21 days<BR/>Death<BR/>Last follow-up: 6 months (only deaths)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 13:46:29 +0000" MODIFIED_BY="Hazel Fraser">
<P>Data available from publication and Bayer AG, Wuppertal, Germany</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-28 15:00:30 +0100" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Nag-1998">
<CHAR_METHODS MODIFIED="2012-03-16 11:10:41 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: 18</P>
<P>Losses to follow-up: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:10:43 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: acute ischemic stroke within preceding 48 hours, acute onset of hemiplegia of either side with or without aphasia, diagnosis was confirmed by CT that showed a hypodense lesion in the territory of either MCA </P>
<P>Exclusion criteria: only transient neurological deficiency (persisting &lt; 24 hours), coma (Glasgow Coma Scale score &lt; 10), intracranial hemorrhage, tumor, infection, trauma, need for assisted ventilation, pregnancy, severe hypertension (diastolic BP &gt; 120 mmHg), hepatic or renal dysfunction</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-28 15:00:30 +0100" MODIFIED_BY="Deren Wagg">
<P>Treatment: oral nimodipine 120 mg/day for 28 days</P>
<P>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-16 11:10:45 +0000" MODIFIED_BY="[Empty name]">
<P>Mathew Scale<BR/>Mortality at the end of follow-up<BR/>Adverse effects<BR/>BP</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-16 11:10:48 +0000" MODIFIED_BY="[Empty name]">
<P>Other routine management (antihypertensive drugs, hyperlipidemic drugs, platelet antiaggregants, hemorrheological drugs, edema-reducing measures, etc.) were given in both the groups<BR/>Data provided by Professor Thomas</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:10:52 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-NEST-1993">
<CHAR_METHODS MODIFIED="2012-03-16 11:10:49 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Multicenter placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: unclear</P>
<P>Losses to follow-up: 49</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:10:50 +0000" MODIFIED_BY="Hazel Fraser">
<P>Inclusion criteria: age 39 to 81 years, start within 48 hours, clinical diagnosis of ischemic stroke in MCA territory, Barthel Index &#8804; 60, N-score &#8804; 50, CT scan within 7 days<BR/>Exclusion criteria: stupor and coma, stroke progression before randomization, disorders interfering with assessment, serious infection, cardiac disease, life-threatening concomitant illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:10:51 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: oral nimodipine, 30 mg qid for 21 days<BR/>Placebo: identical regimen<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-05 13:51:52 +0000" MODIFIED_BY="Hazel Fraser">
<P>Neurological score<BR/>Barthel Index<BR/>Death<BR/>Last follow-up: 3 months<BR/>Dependency measurement used in review: Barthel Index<BR/>Missing: 27 patients in active treatment group, 22 in placebo group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-16 11:10:52 +0000" MODIFIED_BY="[Empty name]">
<P>Standard hospital regimens (hemodilution and heparin) were allowed<BR/>Data available from publication and Bayer AG, Wuppertal, Germany<BR/>In paper, 195 patients were excluded from the analysis; however, data set from Bayer included 879 patients</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:10:55 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-NIMPAS-1999">
<CHAR_METHODS MODIFIED="2012-03-16 11:10:52 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: 4</P>
<P>Losses to follow-up: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:10:55 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: start within 12 hours, cortical infarction in MCA territory (confirmed by CT or clinical findings), patient able to have acute SPECT and CT<BR/>Exclusion criteria: concurrent use of dihydropyridine calcium antagonists, contraindications to calcium antagonist use, other severe disease, previous stroke, cerebral hemorrhage or non-cerebrovascular pathology on CT scan</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:10:55 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: oral nimodipine 30 mg qid for 14 days<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-05 13:53:28 +0000" MODIFIED_BY="Hazel Fraser">
<P>Canadian Neurological Scale, Barthel Index<BR/>Death<BR/>Last follow-up: 3 months<BR/>Dependency measurement used in review: Barthel Index<BR/>Missing: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 13:53:36 +0000" MODIFIED_BY="Hazel Fraser">
<P>Data available from investigators<BR/>Trial designed to measure the effect of nimodipine on perfusion changes after acute stroke with SPECT</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-28 15:21:58 +0100" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Oczkowski-1989">
<CHAR_METHODS MODIFIED="2012-03-16 11:10:57 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: 0</P>
<P>Losses to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:10:57 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: age 45 to 80 years, start within &lt; 48 hours, acute ischemic cerebral infarction in MCA territory, chief symptom hemiparesis<BR/>Exclusion criteria: previous stroke, brain hemorrhage, brainstem infarction, coma, recurrent seizures, organ failure, lacunar infarction, systolic BP &gt;165 or &lt; 110 mmHg</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:10:58 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: oral PY108-608 100 mg day 1, 112.5 mg day 2, 125 mg day 3, 150 mg days 4 to 21, divided in 4 daily doses<BR/>Placebo: identical regime</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-28 15:21:58 +0100" MODIFIED_BY="[Empty name]">
<P>Toronto Stroke Scale, Barthel Index<BR/>Deaths<BR/>Last follow-up: 12 weeks<BR/>Data on dependency presented in an unusable way<BR/>Missing: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 13:55:32 +0000" MODIFIED_BY="Hazel Fraser">
<P>Only data from publication, no additional data from authors available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:11:00 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Paci-1989">
<CHAR_METHODS MODIFIED="2012-03-16 11:10:59 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: unclear</P>
<P>Losses to follow-up: 1</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:10:59 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: start within &lt; 12 hours, sudden and persistent focal event in carotid artery distribution<BR/>Exclusion criteria: TIA, progressing stroke, cerebral hemorrhage (confirmed by CT scan), severe systemic disorders, recent myocardial infarction, congestive heart failure, evidence of abnormal hepatic, pulmonary or renal functions, previous complete stroke</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:11:00 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: oral nimodipine 40 mg tid for 28 days<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-16 11:11:00 +0000" MODIFIED_BY="Hazel Fraser">
<P>Mathew Neurological score, Global assessment of outcome: good/fair/poor<BR/>Death<BR/>Dependency measurement used in review: functional item from Mathew score<BR/>Last follow-up: 28 days<BR/>Missing: 1 patient in active treatment and 1 patient in control group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 13:56:11 +0000" MODIFIED_BY="Hazel Fraser">
<P>Data available from publication and Bayer AG, Wuppertal, Germany</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:11:02 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Sherman-1986">
<CHAR_METHODS MODIFIED="2012-03-16 11:11:02 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: unclear</P>
<P>Losses to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-05 13:58:08 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: start within 48 hours, clinical evidence of cerebral hemisphere ischemic event<BR/>Exclusion criteria: TIA, brainstem infarction, progressing stroke, cerebral hemorrhage, severe cardiac, renal or hepatic disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-15 13:55:36 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: oral nimodipine 30 mg qid for 21 days<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-05 13:58:36 +0000" MODIFIED_BY="[Empty name]">
<P>Neurological examination, mobility, functional status<BR/>Death<BR/>Last follow-up: 60 days<BR/>No data available on functional outcome<BR/>Missing: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 13:57:36 +0000" MODIFIED_BY="Hazel Fraser">
<P>Data only from limited publication in book</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:14:22 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Shibuya-2005">
<CHAR_METHODS MODIFIED="2012-03-16 11:11:03 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Multicenter placebo-controlled trial</P>
<P>Random sequence generation: random list<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: 0</P>
<P>Losses to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:14:22 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: age &gt; 20 years, informed consent, acute ischemic stroke due to thrombosis, treatment onset &lt; 48 hours after stroke onset, Japan Coma Scale score of 0 to 3, motor deficit (from moderate to severe) of the arms, legs, or both</P>
<P>Exclusion criteria: history of severe cardiopulmonary, hepato-renal or metabolic diseases, women of child-bearing potential, cerebral hemorrhage on CT scan, systolic BP &lt; 90 mmHg</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:11:07 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment: intravenous fasudil 60 mg bid for 14 days</P>
<P>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-05 13:59:03 +0000" MODIFIED_BY="[Empty name]">
<P>Neurological status was assessed by the Motor System of Japan Stroke Scale (JSS), modified Rankin Scale (mRS), adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 14:00:25 +0000" MODIFIED_BY="[Empty name]">
<P>This article did not provide the result of poor outcome or death at the end of treatment or follow-up, but it did provide adverse events and neurological improvement as the result<BR/>Data were available from publication and from the database of Sichuan University, Chengdu, China</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-28 14:55:04 +0100" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Squire-1996">
<CHAR_METHODS MODIFIED="2012-03-16 11:11:12 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: 30</P>
<P>Losses to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:11:18 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: first-ever ischemic stroke &lt; 6 hours or 6 to 12 hours from onset of symptoms, age 21 to 74 years, stable clinical signs, had written informed consent, pretreatment motor arm or motor leg (NIH scale) of 2 or 3, treatment could be started within 12 hours of onset of symptoms, normal plasma electrolytes prior to start of treatment<BR/>Exclusion criteria: NIH scale level of consciousness 2 or 3; previous stroke; unable to initiate treatment within 12 hours from onset; myocardial infarction within previous 4 months; BP &lt; 120/80 mmHg; history of ventricular arrhythmia, AV block or IVCD; not likely to be available for 3-month assessment; premenopausal female not surgically sterilized; pre-existing life-threatening disease or systematic illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-28 14:55:04 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: lifarizine 250 &#956;g/kg intravenous stat plus 60 mg bid orally for 5 days within 6 hours or 6 to 12 hours since stroke onset</P>
<P>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-16 11:11:19 +0000" MODIFIED_BY="[Empty name]">
<P>Mortality at the end of treatment and follow-up<BR/>Rankin Scale, Barthel Index score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 14:06:55 +0000" MODIFIED_BY="Deren Wang">
<P>Data available Professor Thomas</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:11:21 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Sze-1998">
<CHAR_METHODS MODIFIED="2012-03-16 11:11:21 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: permuted block<BR/>Double-blind<BR/>Exclusions during trial: 14</P>
<P>Losses to follow-up: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:11:21 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: based on brain CT scan within 14 days, clinical assessment according to WHO definition on stroke</P>
<P>Exclusion criteria: cerebral hemorrhage, patient refused, acute cardiopulmonary instability, sepsis, clinical depression, Glasgow Coma Scale score &lt; 15 and patients who did not complete the full course of treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-15 14:03:34 +0000" MODIFIED_BY="Deren Wang">
<P>Treatment: oral nimodipine 30 mg tid between days 7 to 14 after the onset of the stroke for 12 weeks<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-05 14:07:19 +0000" MODIFIED_BY="[Empty name]">
<P>Death, Mini-Mental State Examination and Ful Object-Memory Evaluation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 14:07:20 +0000" MODIFIED_BY="[Empty name]">
<P>Data were available from publication and from the database of Sichuan University, Chengdu, China</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:11:24 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-TRUST-1990">
<CHAR_METHODS MODIFIED="2012-03-16 11:11:23 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Multicenter placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: 26</P>
<P>Losses to follow-up: 12</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 11:11:24 +0000" MODIFIED_BY="Jing Zhang">
<P>Inclusion criteria: age &gt; 40 years, start within 48 hours, clinical evidence of hemiparetic stroke, independent before stroke, conscious, able to swallow<BR/>Exclusion criteria: intracranial hemorrhage or tumor on CT scan between days 7 to 14 (whenever possible)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-15 14:03:46 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: oral nimodipine 40 mg tid for 21 days<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-16 11:11:24 +0000" MODIFIED_BY="Hazel Fraser">
<P>Neurological examination, Orgogozo Stroke scale, Nottingham Activities of Daily Living scale, Barthel Index<BR/>Death<BR/>Last follow-up: 24 weeks<BR/>Dependency measurement used in review: Barthel Index<BR/>Missing: 4 patients in active treatment group, 8 patients in placebo group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 14:10:22 +0000" MODIFIED_BY="[Empty name]">
<P>Data available from publication and Bayer AG, Wuppertal, Germany<BR/>Some minor differences between original data set and publication - we used original data set for analysis on time after stroke onset</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:11:28 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Uzunur-1995">
<CHAR_METHODS MODIFIED="2012-03-05 14:11:54 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published as an abstract</P>
<P>Open controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear</P>
<P>Exclusions during trial: unclear</P>
<P>Losses to follow-up: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-05 14:12:00 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: acute stroke (hemorrhage and ischemic), start within 24 hours<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:11:26 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment: oral nimodipine 180 mg/day. If CT demonstrated intracranial or intracerebral hemorrhage, intravenous nimodipine 2 mg/hour<BR/>Control: no nimodipine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-16 11:11:28 +0000" MODIFIED_BY="Hazel Fraser">
<P>Death<BR/>BP at various time intervals</P>
<P>Last follow-up: discharge from hospital, maximum 40 days<BR/>Data on dependency: not available</P>
<P>Missing: 2 patients in active treatment, 8 patients in control group withdrawn because of "malignant" hypertension</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 14:11:17 +0000" MODIFIED_BY="Hazel Fraser">
<P>Data available from manuscript and abstract, received from principal investigator</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:11:30 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-VENUS-1999">
<CHAR_METHODS MODIFIED="2012-03-16 11:11:29 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Multicenter placebo-controlled trial</P>
<P>Random sequence generation: computer-generated lists<BR/>Concealment: numbered box<BR/>Double-blind<BR/>Exclusions during trial: 0</P>
<P>Losses to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-05 14:13:56 +0000" MODIFIED_BY="Hazel Fraser">
<P>Inclusion criteria: age 18 to 85 years, start within &lt; 6 hours, acute stroke, hemiparesis<BR/>Exclusion criteria: unconsciousness, rapidly improving, symptoms indicative for intracranial hemorrhage (Panzer criteria), dependence before stroke, pregnancy, other severe disease, hypotension, bradycardia, inability to swallow</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:11:30 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: oral nimodipine 30 mg qid for 10 days<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-16 11:11:30 +0000" MODIFIED_BY="[Empty name]">
<P>Neurological examination, Rankin scale<BR/>Death<BR/>Last follow-up: 3 months<BR/>Dependency measurement used in review: Rankin scale<BR/>Missing: 3 living patients in placebo, 3 living patient in active treatment group</P>
<P>261 patients with ischemic stroke were randomized; 133 received nimodipine and 128 received placebo</P>
<P>Missing: none<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 14:15:42 +0000" MODIFIED_BY="Deren Wagg">
<P>All data (assessed in trial) available<BR/>Inclusion by general practitioners<BR/>Data available from publication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:11:34 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Wimalaratna-1994">
<CHAR_METHODS MODIFIED="2012-03-16 11:11:32 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Placebo-controlled trial</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear<BR/>Double-blind<BR/>Exclusions during trial: 0</P>
<P>Losses to follow-up: 45</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-05 14:16:20 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: age 45 to 85 years, start within 24 hours, Barthel Index &lt; 65<BR/>Exclusion criteria: hemorrhage on CT scan</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 11:11:33 +0000" MODIFIED_BY="Hazel Fraser">
<P>Treatment: oral nimodipine 120 mg/day or 240 mg/day for 16 weeks<BR/>Placebo: identical regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-16 11:11:34 +0000" MODIFIED_BY="Hazel Fraser">
<P>MRC-based rating system for motor scoring, Barthel Index<BR/>Death<BR/>Last follow-up: 24 weeks<BR/>Dependency measurement used in review: Barthel Index<BR/>Missing: 32 patients in active treatment group, 13 patients in placebo group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 14:16:04 +0000" MODIFIED_BY="Hazel Fraser">
<P>Data available from publication, manuscript, abstracts and Bayer AG, Wuppertal, Germany</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-16 11:11:34 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Yordanov-1984">
<CHAR_METHODS MODIFIED="2012-03-16 11:11:34 +0000" MODIFIED_BY="tingting Yuan">
<P>Publication status: published</P>
<P>Placebo-controlled trial?</P>
<P>Random sequence generation: unclear<BR/>Concealment: unclear</P>
<P>Exclusions during trial: unclear</P>
<P>Losses to follow-up: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-05 14:17:18 +0000" MODIFIED_BY="Hazel Fraser">
<P>Stroke patients, inclusion within 5 days after onset of symptoms</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-15 14:04:58 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment: nimodipine 0.5 mg/hour intravenously for 7 days, followed by 30 mg qid for 21 days<BR/>Placebo: Identical regimen (?)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-05 14:18:07 +0000" MODIFIED_BY="Hazel Fraser">
<P>Toronto Stroke Scale<BR/>Deaths<BR/>Last follow-up: 6 months<BR/>Dependency measurement used in review: Toronto Stroke Scale</P>
<P>Missing: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-05 14:17:21 +0000" MODIFIED_BY="Hazel Fraser">
<P>Only limited data available from Bayer AG, Wuppertal, Germany</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AV block: atrioventricular block<BR/>bid: twice per day (bis in die)<BR/>BP: blood pressure<BR/>CT: computerized tomography<BR/>ICA: internal carotid artery<BR/>ITT: intention-to-treat<BR/>IVCD: interior vena cava diameter<BR/>MABP: mean arterial blood pressure<BR/>MCA: middle cerebral artery<BR/>MRC: Medical Research Council<BR/>qid: four times per day (quarter in die)<BR/>SPECT: single-photon emission computed tomography<BR/>TIA: transient ischemic attack<BR/>tid: three times per day (ter in die)<BR/>WHO: World Health Organization</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-03-16 11:11:36 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-03-16 11:11:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ameriso-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-16 11:11:35 +0000" MODIFIED_BY="[Empty name]">
<P>Nimodipine trial<BR/>Seems to be part of the another larger trial, but which one is unknown<BR/>In this report the hemorrheological data of few patients are reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-05 14:20:05 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Csiba">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-05 14:20:05 +0000" MODIFIED_BY="Hazel Fraser">
<P>Nimodipine trial performed in Hungary<BR/>Investigators and company are unable to retrieve data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-16 11:11:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dalal-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-16 11:11:35 +0000" MODIFIED_BY="[Empty name]">
<P>Nimodipine trial<BR/>The treatment group is intravenous nimodipine followed by oral nimodipine, while the control group is antithrombotic agents, anticoagulant drugs and other supportive measures</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-05 14:19:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fagan-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-05 14:19:47 +0000" MODIFIED_BY="[Empty name]">
<P>Nimodipine trial<BR/>Outcomes are BP recorded before and 30 and 60 minutes after a dose for the first 8 days that is not related to this systematic review's outcome measures.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-05 14:26:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mar_x00ed_n-G_x00e1_mez-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-05 14:26:17 +0000" MODIFIED_BY="[Empty name]">
<P>Nicardipine trial<BR/>Spanish article: in the study 75 patients were included; unknown how many patients in which treatment group; more than 30% of patients (24/75) were excluded after randomization, no follow-up data are provided</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-05 14:20:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matias-Guiu-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-05 14:20:42 +0000" MODIFIED_BY="[Empty name]">
<P>Nicardipine trial<BR/>Aim of the study was to assess the effect on cognitive impairment after minor stroke</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-05 14:20:52 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Molto-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-05 14:20:52 +0000" MODIFIED_BY="Hazel Fraser">
<P>Nicardipine trial<BR/>Included patients with TIA, Spanish article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-16 11:11:36 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Orgogozo">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-16 11:11:36 +0000" MODIFIED_BY="Hazel Fraser">
<P>Nicardipine trial<BR/>Principal investigator could not supply data from this unpublished trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-05 14:21:25 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Petrogiannopoulos-96">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-05 14:21:25 +0000" MODIFIED_BY="Hazel Fraser">
<P>Nimodipine trial<BR/>Patients were included 1 to 2 months after acute ischemic stroke</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-05 14:22:23 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Rosenbaum-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-05 14:22:23 +0000" MODIFIED_BY="Hazel Fraser">
<P>Nicardipine trial<BR/>Safety study without a control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-05 14:23:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rosselli-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-05 14:23:25 +0000" MODIFIED_BY="[Empty name]">
<P>Nimopidine trial (Italy)<BR/>Outcomes are not included in this review<BR/>Data extraction provided Dr Chiara Menichetti</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-05 14:23:57 +0000" MODIFIED_BY="Deren Wagg" STUDY_ID="STD-Szczechowski-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-05 14:23:57 +0000" MODIFIED_BY="Deren Wagg">
<P>Nimodipine trial</P>
<P>Treatment group given intravenous nimodipine, control group given standard treatment with dextran</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-05 14:24:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yao-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-05 14:24:06 +0000" MODIFIED_BY="[Empty name]">
<P>Nimodipine trial<BR/>Chinese report of "preliminary study", no outcome data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>BP: blood pressure<BR/>TIA: transient ischemic attack<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-06-06 09:25:39 +0100" MODIFIED_BY="Deren Wagg" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Davalos-1989">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Davalos-Errando-1992">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Garcia-Tigeria">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Hakim-1989">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-01-13 07:42:11 +0000" MODIFIED_BY="tingting Yuan" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-AIIMS-trial">
<CHAR_STUDY_NAME/>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-01-13 07:42:11 +0000" MODIFIED_BY="tingting Yuan" STUDY_ID="STD-Tanahashi-2007">
<CHAR_STUDY_NAME/>
<CHAR_METHODS MODIFIED="2012-01-13 07:42:11 +0000" MODIFIED_BY="tingting Yuan"/>
<CHAR_PARTICIPANTS MODIFIED="2012-01-13 07:42:11 +0000" MODIFIED_BY="tingting Yuan"/>
<CHAR_INTERVENTIONS MODIFIED="2012-01-13 07:42:11 +0000" MODIFIED_BY="tingting Yuan"/>
<CHAR_OUTCOMES MODIFIED="2012-01-13 07:42:11 +0000" MODIFIED_BY="tingting Yuan"/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES MODIFIED="2012-01-13 07:42:11 +0000" MODIFIED_BY="tingting Yuan"/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-04-03 11:17:23 +0100" MODIFIED_BY="tingting Yuan">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-04-03 11:15:39 +0100" MODIFIED_BY="tingting Yuan" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 12:59:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ASCLEPIOS-1990">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:01:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bogousslavsky-1990">
<DESCRIPTION>
<P>The patients received nimodipine or placebo according to a random list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-03 11:15:39 +0100" MODIFIED_BY="Jing Zhang" RESULT="UNKNOWN" STUDY_ID="STD-Bridgers-1991">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:05:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Canwin-1993">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Capon-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:08:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chandra-1995">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:11:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-FIST-1990">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:12:33 +0000" MODIFIED_BY="tingting Yuan" RESULT="UNKNOWN" STUDY_ID="STD-Gelmers-1984">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 14:25:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gelmers-1988">
<DESCRIPTION>
<P>Medication was randomized in equal blocks of 10, according to computer-generated lists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:16:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-German_x002d_Austrian-1994">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:19:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heiss-1990">
<DESCRIPTION>
<P>Random number</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:21:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-INWEST--1990">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:22:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaste-1994">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 14:26:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kornhuber-1993">
<DESCRIPTION>
<P>The study was double-blind and randomized in 32 blocks: each block contained 4 sub-blocks of 8 patients randomized at a ratio of 1:1 and given either flunarizine or placebo; each of these sub-block was allocated to 1 of the 4 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:27:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lamsudin-1995">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:29:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Limburg-1990">
<DESCRIPTION>
<P>Random table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:37:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lisk-1993">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:41:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lowe--1989">
<DESCRIPTION>
<P>Random number</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:42:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martinez_x002d_Vila-1990">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:46:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mohr-1992">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:52:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-NEST-1993">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:53:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-NIMPAS-1999">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:48:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nag-1998">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:55:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oczkowski-1989">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:57:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Paci-1989">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:58:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sherman-1986">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 11:11:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shibuya-2005">
<DESCRIPTION>
<P>A random list was prepared by an independent statistical center<BR/>Patients were randomized to fasudil or placebo with the use of separate randomization lists balanced for each participating center by personnel unrelated to the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 14:07:02 +0000" MODIFIED_BY="Deren Wang" RESULT="UNKNOWN" STUDY_ID="STD-Squire-1996">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 14:08:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sze-1998">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 14:10:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-TRUST-1990">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 14:11:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Uzunur-1995">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 14:13:09 +0000" MODIFIED_BY="Deren Wagg" RESULT="YES" STUDY_ID="STD-VENUS-1999">
<DESCRIPTION>
<P>Medication was randomized in equal blocks of 10, according to computer-generated lists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 14:17:03 +0000" MODIFIED_BY="Deren Wang" RESULT="UNKNOWN" STUDY_ID="STD-Wimalaratna-1994">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Yordanov-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-04-03 11:16:55 +0100" MODIFIED_BY="tingting Yuan" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 12:59:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ASCLEPIOS-1990">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:01:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bogousslavsky-1990">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:03:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bridgers-1991">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:05:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Canwin-1993">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Capon-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:08:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chandra-1995">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:11:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-FIST-1990">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:12:35 +0000" MODIFIED_BY="tingting Yuan" RESULT="UNKNOWN" STUDY_ID="STD-Gelmers-1984">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:14:18 +0000" MODIFIED_BY="Deren Wagg" RESULT="YES" STUDY_ID="STD-Gelmers-1988">
<DESCRIPTION>
<P>Numbered boxes contained 1 complete treatment or identical placebo course and were sequentially distributed among participating general practitioners and neurologists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:16:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-German_x002d_Austrian-1994">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:19:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heiss-1990">
<DESCRIPTION>
<P>Nimodipine or placebo was packed in a box identified only by a random number</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:21:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-INWEST--1990">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-03 11:16:55 +0100" MODIFIED_BY="tingting Yuan" RESULT="YES" STUDY_ID="STD-Kaste-1994">
<DESCRIPTION>
<P>Sealed envelope</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:25:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kornhuber-1993">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:27:04 +0000" MODIFIED_BY="Jing Zhang" RESULT="UNKNOWN" STUDY_ID="STD-Lamsudin-1995">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:29:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Limburg-1990">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:37:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lisk-1993">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:41:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lowe--1989">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:42:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martinez_x002d_Vila-1990">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-16 11:10:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mohr-1992">
<DESCRIPTION>
<P>Study centers were provided with numbered boxes containing tablets in blister packs of 4 each<BR/>The appearance of placebo and each drug dose was identical</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:52:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-NEST-1993">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:53:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-NIMPAS-1999">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:48:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nag-1998">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:55:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oczkowski-1989">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:57:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Paci-1989">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:58:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sherman-1986">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 14:00:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shibuya-2005">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 14:07:03 +0000" MODIFIED_BY="Deren Wang" RESULT="UNKNOWN" STUDY_ID="STD-Squire-1996">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 14:08:38 +0000" MODIFIED_BY="Deren Wang" RESULT="YES" STUDY_ID="STD-Sze-1998">
<DESCRIPTION>
<P>Patients were separately randomized to the groups according to random permuted blocks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 14:10:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-TRUST-1990">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 14:11:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Uzunur-1995">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 14:13:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VENUS-1999">
<DESCRIPTION>
<P>Numbered boxes contained 1 complete treatment or identical placebo and were distributed among participating general practitioners and neurologists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 14:17:05 +0000" MODIFIED_BY="Deren Wang" RESULT="UNKNOWN" STUDY_ID="STD-Wimalaratna-1994">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Yordanov-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-07-09 10:03:01 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-03-28 15:16:39 +0100" MODIFIED_BY="tingting Yuan" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-05 12:59:40 +0000" MODIFIED_BY="Jing Zhang" RESULT="NO" STUDY_ID="STD-ASCLEPIOS-1990">
<DESCRIPTION>
<P>Missing 4 patients in isradipine group without ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-16 11:08:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bogousslavsky-1990">
<DESCRIPTION>
<P>60 patients recruited but only 52 patients had been analyzed, there was no ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-05 13:03:20 +0000" MODIFIED_BY="Jing Zhang" RESULT="NO" STUDY_ID="STD-Bridgers-1991">
<DESCRIPTION>
<P>1 missing in the placebo group and there was no ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-05 13:05:41 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Canwin-1993">
<DESCRIPTION>
<P>189 patients randomized into the study but 164 were suitable for statistical evaluation, and they did do the ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Capon-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-05 13:08:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chandra-1995">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-16 11:13:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-FIST-1990">
<DESCRIPTION>
<P>331 patients recruited, but only 290 analyzed, ITT analysis performed but results not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-05 13:12:30 +0000" MODIFIED_BY="Deren Wang" RESULT="YES" STUDY_ID="STD-Gelmers-1984">
<DESCRIPTION>
<P>60 patients recruited and no data loss</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-05 13:14:36 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gelmers-1988">
<DESCRIPTION>
<P>They excluded 22 patients that had been recruited into either group and gave the reason for the exclusion but did not do ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-16 11:09:56 +0000" MODIFIED_BY="Jing Zhang" RESULT="NO" STUDY_ID="STD-German_x002d_Austrian-1994">
<DESCRIPTION>
<P>482 patients included and ITT analysis performed but only 356 patients were eligible for analysis and ITT analysis was not performed for the last 356 patients but reported that there was no significant difference for these 356 patients in both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-05 13:19:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heiss-1990">
<DESCRIPTION>
<P>27 patients were randomly assigned, but 4 of them could not be evaluated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-16 11:10:04 +0000" MODIFIED_BY="Jing Zhang" RESULT="YES" STUDY_ID="STD-INWEST--1990">
<DESCRIPTION>
<P>295 patients were recruited and entered into the treatment and control groups but only 228 patients were valid for the primary analysis<BR/>ITT analysis performed and there were no statistically significant differences between these groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-05 13:23:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaste-1994">
<DESCRIPTION>
<P>Data for 1 patient was lost</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-16 11:10:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kornhuber-1993">
<DESCRIPTION>
<P>443 patients recruited but 11 patients had been withdraw - reason given but ITT analysis not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-16 11:10:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lamsudin-1995">
<DESCRIPTION>
<P>15 patients excluded but did not analyze whether they were related to the outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-05 13:29:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Limburg-1990">
<DESCRIPTION>
<P>Reported all the patients recruited</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-05 13:37:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lisk-1993">
<DESCRIPTION>
<P>They reported all the patients recruited</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-05 13:41:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lowe--1989">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-28 15:16:39 +0100" MODIFIED_BY="Jing Zhang" RESULT="NO" STUDY_ID="STD-Martinez_x002d_Vila-1990">
<DESCRIPTION>
<P>164 patients in total were recruited (81 to the treatment group and 83 to the placebo group) but 41 patients were subsequently excluded (23 from the treatment group and 18 from the placebo group). There were no significant differences in severity of the remaining 123 patients (58 in the treatment group and 65 in the placebo group)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-16 11:10:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mohr-1992">
<DESCRIPTION>
<P>All patients randomized were analyzed, the analysis followed the ITT principle</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-05 13:52:09 +0000" MODIFIED_BY="Jing Zhang" RESULT="NO" STUDY_ID="STD-NEST-1993">
<DESCRIPTION>
<P>27 patients in active treatment group and 22 in placebo group missed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-16 11:10:56 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-NIMPAS-1999">
<DESCRIPTION>
<P>50 patient included and 4 had been excluded. There was no ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-05 13:49:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nag-1998">
<DESCRIPTION>
<P>80 patients recruited but reports of only 62 patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-05 13:55:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oczkowski-1989">
<DESCRIPTION>
<P>Reported all patients included</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-16 11:11:01 +0000" MODIFIED_BY="Jing Zhang" RESULT="NO" STUDY_ID="STD-Paci-1989">
<DESCRIPTION>
<P>1 patient in active treatment and 1 patient in control group missed. No ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-05 13:58:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sherman-1986">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-05 14:00:55 +0000" MODIFIED_BY="Deren Wang" RESULT="YES" STUDY_ID="STD-Shibuya-2005">
<DESCRIPTION>
<P>Reported all the patients included</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-16 11:11:20 +0000" MODIFIED_BY="Deren Wagg" RESULT="NO" STUDY_ID="STD-Squire-1996">
<DESCRIPTION>
<P>147 patients involved but only 117 patients evaluated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-05 14:08:52 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sze-1998">
<DESCRIPTION>
<P>14 patients excluded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-16 11:11:25 +0000" MODIFIED_BY="Jing Zhang" RESULT="NO" STUDY_ID="STD-TRUST-1990">
<DESCRIPTION>
<P>Many patients were withdrawn and 12 patients were lost to follow-up; the article did not provide the results of these patients and there was no ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-05 14:11:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Uzunur-1995">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-16 11:11:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VENUS-1999">
<DESCRIPTION>
<P>261 patients with ischemia recruited and all of them reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-05 14:16:59 +0000" MODIFIED_BY="Jing Zhang" RESULT="NO" STUDY_ID="STD-Wimalaratna-1994">
<DESCRIPTION>
<P>32 patients in active treatment group and 13 in placebo group were missed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Yordanov-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-03-05 13:12:38 +0000" MODIFIED_BY="tingting Yuan" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-06 02:57:28 +0100" MODIFIED_BY="Deren Wagg" RESULT="UNKNOWN" STUDY_ID="STD-ASCLEPIOS-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-06 02:58:46 +0100" MODIFIED_BY="Deren Wagg" RESULT="UNKNOWN" STUDY_ID="STD-Bogousslavsky-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bridgers-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Canwin-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Capon-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-03 08:15:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chandra-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-03 08:16:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-FIST-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-05 13:12:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gelmers-1984">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gelmers-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-22 03:05:40 +0100" MODIFIED_BY="Deren Wang" RESULT="UNKNOWN" STUDY_ID="STD-German_x002d_Austrian-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Heiss-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-06 03:46:08 +0100" MODIFIED_BY="Deren Wagg" RESULT="UNKNOWN" STUDY_ID="STD-INWEST--1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kaste-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-22 08:38:37 +0100" MODIFIED_BY="Deren Wang" RESULT="UNKNOWN" STUDY_ID="STD-Kornhuber-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lamsudin-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Limburg-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lisk-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lowe--1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-31 10:48:41 +0100" MODIFIED_BY="Deren Wang" RESULT="UNKNOWN" STUDY_ID="STD-Martinez_x002d_Vila-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mohr-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-NEST-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-NIMPAS-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nag-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Oczkowski-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Paci-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sherman-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-24 03:39:49 +0100" MODIFIED_BY="Deren Wagg" RESULT="UNKNOWN" STUDY_ID="STD-Shibuya-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-01 03:55:53 +0100" MODIFIED_BY="Deren Wang" RESULT="UNKNOWN" STUDY_ID="STD-Squire-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-02 03:06:08 +0100" MODIFIED_BY="Deren Wang" RESULT="UNKNOWN" STUDY_ID="STD-Sze-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-TRUST-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-03 08:34:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Uzunur-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-VENUS-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wimalaratna-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Yordanov-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-04-03 11:17:23 +0100" MODIFIED_BY="tingting Yuan" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 12:59:45 +0000" MODIFIED_BY="Deren Wagg" RESULT="YES" STUDY_ID="STD-ASCLEPIOS-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:01:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bogousslavsky-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-04-03 11:15:52 +0100" MODIFIED_BY="Jing Zhang" RESULT="YES" STUDY_ID="STD-Bridgers-1991">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:05:49 +0000" MODIFIED_BY="Jing Zhang" RESULT="UNKNOWN" STUDY_ID="STD-Canwin-1993">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" RESULT="UNKNOWN" STUDY_ID="STD-Capon-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:08:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chandra-1995">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:11:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-FIST-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:12:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gelmers-1984">
<DESCRIPTION>
<P>Single-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:14:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gelmers-1988">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:17:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-German_x002d_Austrian-1994">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:19:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heiss-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:21:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-INWEST--1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:23:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaste-1994">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:25:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kornhuber-1993">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:27:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lamsudin-1995">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:29:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Limburg-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:37:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lisk-1993">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:41:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lowe--1989">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:43:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinez_x002d_Vila-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:46:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mohr-1992">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:52:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NEST-1993">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:53:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NIMPAS-1999">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:48:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nag-1998">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:55:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oczkowski-1989">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 13:57:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Paci-1989">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-04-03 11:17:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sherman-1986">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 14:00:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shibuya-2005">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 14:07:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Squire-1996">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 14:08:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sze-1998">
<DESCRIPTION>
<P>Single-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 14:10:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TRUST-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 14:11:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Uzunur-1995">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 14:13:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VENUS-1999">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-05 14:17:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wimalaratna-1994">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" RESULT="UNKNOWN" STUDY_ID="STD-Yordanov-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-04-03 11:15:54 +0100" MODIFIED_BY="tingting Yuan" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 12:59:48 +0000" MODIFIED_BY="Deren Wagg" RESULT="YES" STUDY_ID="STD-ASCLEPIOS-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:01:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bogousslavsky-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-04-03 11:15:54 +0100" MODIFIED_BY="Jing Zhang" RESULT="YES" STUDY_ID="STD-Bridgers-1991">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:05:51 +0000" MODIFIED_BY="Jing Zhang" RESULT="UNKNOWN" STUDY_ID="STD-Canwin-1993">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Capon-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:08:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chandra-1995">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:11:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-FIST-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-08-04 08:50:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gelmers-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:14:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gelmers-1988">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:17:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-German_x002d_Austrian-1994">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:19:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heiss-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:21:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-INWEST--1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:23:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaste-1994">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:25:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kornhuber-1993">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:27:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lamsudin-1995">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:29:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Limburg-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:37:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lisk-1993">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:41:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lowe--1989">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:43:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinez_x002d_Vila-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:47:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mohr-1992">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:52:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NEST-1993">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:53:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NIMPAS-1999">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:48:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nag-1998">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:55:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oczkowski-1989">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:57:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Paci-1989">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:58:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sherman-1986">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 13:59:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shibuya-2005">
<DESCRIPTION>
<P>"All assessments were blinded"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 14:07:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Squire-1996">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-16 11:11:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sze-1998">
<DESCRIPTION>
<P>They described that the assessors were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 14:10:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TRUST-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 14:11:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Uzunur-1995">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-16 11:11:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VENUS-1999">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-05 14:17:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wimalaratna-1994">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Yordanov-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-03-19 10:31:55 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Calcium antagonists versus control in acute ischemic stroke</NAME>
<DICH_OUTCOME CHI2="29.493407670483577" CI_END="1.1346732827612755" CI_START="0.9787529708022877" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0538334054263903" ESTIMABLE="YES" EVENTS_1="1738" EVENTS_2="1224" I2="28.797647818036342" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.05487082900047015" LOG_CI_START="-0.009326906720889264" LOG_EFFECT_SIZE="0.022771961139790423" METHOD="MH" MODIFIED="2012-03-06 12:17:24 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10265067639563763" P_Q="0.8249097818883614" P_Z="0.16438893622333858" Q="0.3849626530711102" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.007210311690438904" TOTALS="YES" TOTAL_1="3733" TOTAL_2="2951" WEIGHT="99.99999999999997" Z="1.3904609933613359">
<NAME>Primary outcome at end of follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favors treatment group</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favors control group</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="26.570708519431548" CI_END="1.1449438589575665" CI_START="0.9728897278594216" DF="18" EFFECT_SIZE="1.0554165620055158" ESTIMABLE="YES" EVENTS_1="1595" EVENTS_2="1089" I2="32.2562287458901" ID="CMP-001.01.01" LOG_CI_END="0.058784192053467306" LOG_CI_START="-0.01193638202983535" LOG_EFFECT_SIZE="0.02342390501181597" MODIFIED="2012-03-06 12:17:12 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08740705285518502" P_Z="0.194167271724967" STUDIES="19" TAU2="0.008281428108703998" TOTAL_1="3435" TOTAL_2="2658" WEIGHT="87.44061680981848" Z="1.2983494773775046">
<NAME>Nimodipine versus control</NAME>
<DICH_DATA CI_END="3.7086562974712898" CI_START="0.11983975024794946" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.569216586623787" LOG_CI_START="-0.9213991047351496" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="4279" O_E="0.0" SE="0.8755950357709131" STUDY_ID="STD-Bogousslavsky-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.7666666666666666" WEIGHT="0.18375649479525352"/>
<DICH_DATA CI_END="1.401303642403668" CI_START="0.9365586636491369" EFFECT_SIZE="1.1456016177957533" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="43" LOG_CI_END="0.14653225086904367" LOG_CI_START="-0.028465014336607967" LOG_EFFECT_SIZE="0.05903361826621785" ORDER="4285" O_E="0.0" SE="0.10279425983223325" STUDY_ID="STD-Bridgers-1991" TOTAL_1="138" TOTAL_2="66" VAR="0.010566659854456682" WEIGHT="7.999389580306562"/>
<DICH_DATA CI_END="1.2507592153141303" CI_START="0.6469643540996552" EFFECT_SIZE="0.8995535714285714" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="42" LOG_CI_END="0.09717371135183471" LOG_CI_START="-0.18911964706590384" LOG_EFFECT_SIZE="-0.04597296785703457" ORDER="4281" O_E="0.0" SE="0.16817013590955968" STUDY_ID="STD-Canwin-1993" TOTAL_1="96" TOTAL_2="93" VAR="0.028281194611839772" WEIGHT="4.006731067836193"/>
<DICH_DATA CI_END="0.728799715585044" CI_START="0.043552861743284196" EFFECT_SIZE="0.1781609195402299" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.13739180551896332" LOG_CI_START="-1.3609833033776908" LOG_EFFECT_SIZE="-0.7491875544483271" MODIFIED="2011-07-02 11:39:03 +0100" MODIFIED_BY="[Empty name]" ORDER="4287" O_E="0.0" SE="0.718743702717815" STUDY_ID="STD-Gelmers-1984" TOTAL_1="29" TOTAL_2="31" VAR="0.5165925101965148" WEIGHT="0.27148559534934014"/>
<DICH_DATA CI_END="1.092074862157147" CI_START="0.4562598347969956" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="34" LOG_CI_END="0.0382524104450592" LOG_CI_START="-0.3407877611063574" LOG_EFFECT_SIZE="-0.15126767533064908" MODIFIED="2011-07-02 11:39:02 +0100" MODIFIED_BY="[Empty name]" ORDER="4288" O_E="0.0" SE="0.22265007304841153" STUDY_ID="STD-Gelmers-1988" TOTAL_1="93" TOTAL_2="93" VAR="0.04957305502846299" WEIGHT="2.504341133022449"/>
<DICH_DATA CI_END="1.3138485918166842" CI_START="0.7136624182533545" EFFECT_SIZE="0.968320382546324" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="63" LOG_CI_END="0.11854531992145151" LOG_CI_START="-0.14650717276097858" LOG_EFFECT_SIZE="-0.013980926419763548" ORDER="4289" O_E="0.0" SE="0.15569314623265834" STUDY_ID="STD-German_x002d_Austrian-1994" TOTAL_1="239" TOTAL_2="243" VAR="0.024240355783823934" WEIGHT="4.521523146114948"/>
<DICH_DATA CI_END="3.405859213276469" CI_START="0.39557056492806414" EFFECT_SIZE="1.1607142857142858" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5322266917296774" LOG_CI_START="-0.40277603245636695" LOG_EFFECT_SIZE="0.0647253296366552" ORDER="4284" O_E="0.0" SE="0.549225228525012" STUDY_ID="STD-Heiss-1990" TOTAL_1="14" TOTAL_2="13" VAR="0.30164835164835163" WEIGHT="0.4604206966655743"/>
<DICH_DATA CI_END="1.549988410037078" CI_START="1.0292433953115954" EFFECT_SIZE="1.2630579297245963" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="54" LOG_CI_END="0.19032845076657462" LOG_CI_START="0.012518088796623928" LOG_EFFECT_SIZE="0.10142326978159924" ORDER="1" O_E="0.0" SE="0.10444668679663607" STUDY_ID="STD-INWEST--1990" TOTAL_1="195" TOTAL_2="100" VAR="0.010909110382794593" WEIGHT="7.848204008433194"/>
<DICH_DATA CI_END="2.1123931866731938" CI_START="0.9321383331068318" EFFECT_SIZE="1.403225806451613" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="31" LOG_CI_END="0.3247747580424526" LOG_CI_START="-0.030519631801723287" LOG_EFFECT_SIZE="0.14712756312036468" ORDER="1" O_E="0.0" SE="0.20870168333006317" STUDY_ID="STD-Kaste-1994" TOTAL_1="176" TOTAL_2="174" VAR="0.043556392624801966" WEIGHT="2.80114541339159"/>
<DICH_DATA CI_END="2.1571053063633716" CI_START="1.0130498460326902" EFFECT_SIZE="1.4782608695652173" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="23" LOG_CI_END="0.33387134716845807" LOG_CI_START="0.005630814880866398" LOG_EFFECT_SIZE="0.16975108102466221" ORDER="4276" O_E="0.0" SE="0.19281011348257088" STUDY_ID="STD-Lowe--1989" TOTAL_1="56" TOTAL_2="56" VAR="0.03717573986116186" WEIGHT="3.2038200284682774"/>
<DICH_DATA CI_END="1.4422893385463413" CI_START="0.4873415074756402" EFFECT_SIZE="0.8383838383838383" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.15905239320522538" LOG_CI_START="-0.31216659764817745" LOG_EFFECT_SIZE="-0.07655710222147603" ORDER="4291" O_E="0.0" SE="0.27679636779891276" STUDY_ID="STD-Martinez_x002d_Vila-1990" TOTAL_1="81" TOTAL_2="83" VAR="0.076616229226671" WEIGHT="1.6964188118684311"/>
<DICH_DATA CI_END="1.1359784548030891" CI_START="0.9002883040792722" EFFECT_SIZE="1.011290322580645" ESTIMABLE="YES" EVENTS_1="475" EVENTS_2="155" LOG_CI_END="0.055370094536212784" LOG_CI_START="-0.045618391871287696" LOG_EFFECT_SIZE="0.0048758513324625415" ORDER="4277" O_E="0.0" SE="0.05932113681683583" STUDY_ID="STD-Mohr-1992" TOTAL_1="800" TOTAL_2="264" VAR="0.003518997273241756" WEIGHT="13.253875102955464"/>
<DICH_DATA CI_END="1.0911833709352186" CI_START="0.8209456033333303" EFFECT_SIZE="0.9464682724738903" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="211" LOG_CI_END="0.03789773894170851" LOG_CI_START="-0.08568561870861255" LOG_EFFECT_SIZE="-0.023893939883451995" ORDER="4282" O_E="0.0" SE="0.07259347603128512" STUDY_ID="STD-NEST-1993" TOTAL_1="437" TOTAL_2="443" VAR="0.005269812762304767" WEIGHT="11.39451144771086"/>
<DICH_DATA CI_END="2.112849075188671" CI_START="0.5726864328404293" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.3248684756828304" LOG_CI_START="-0.2420831053663803" LOG_EFFECT_SIZE="0.04139268515822508" ORDER="4286" O_E="0.0" SE="0.33303016516389455" STUDY_ID="STD-NIMPAS-1999" TOTAL_1="25" TOTAL_2="25" VAR="0.1109090909090909" WEIGHT="1.2039082302826518"/>
<DICH_DATA CI_END="2.1189352691236043" CI_START="0.10123727637314173" EFFECT_SIZE="0.4631578947368421" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3261176897491048" LOG_CI_START="-0.9946595473544253" LOG_EFFECT_SIZE="-0.33427092880266035" ORDER="4278" O_E="0.0" SE="0.77583108702738" STUDY_ID="STD-Paci-1989" TOTAL_1="19" TOTAL_2="22" VAR="0.6019138755980862" WEIGHT="0.23345801055554782"/>
<DICH_DATA CI_END="1.2176136484476676" CI_START="0.9434511318941734" EFFECT_SIZE="1.071801742318861" ESTIMABLE="YES" EVENTS_1="275" EVENTS_2="257" LOG_CI_END="0.0855095075377719" LOG_CI_START="-0.02528059014488096" LOG_EFFECT_SIZE="0.03011445869644548" ORDER="4274" O_E="0.0" SE="0.0650786517986186" STUDY_ID="STD-TRUST-1990" TOTAL_1="607" TOTAL_2="608" VAR="0.004235230919925845" WEIGHT="12.424480497487938"/>
<DICH_DATA CI_END="2.0964042004014067" CI_START="0.9503957371917446" EFFECT_SIZE="1.4115288220551379" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="30" LOG_CI_END="0.3214750211933707" LOG_CI_START="-0.022095520298755573" LOG_EFFECT_SIZE="0.14968975044730756" MODIFIED="2011-06-06 03:33:47 +0100" MODIFIED_BY="Deren Wagg" ORDER="4292" O_E="0.0" SE="0.20181503677408394" STUDY_ID="STD-VENUS-1999" TOTAL_1="133" TOTAL_2="128" VAR="0.04072930906812486" WEIGHT="2.966333873641272"/>
<DICH_DATA CI_END="1.3654657792336078" CI_START="0.677868258077594" EFFECT_SIZE="0.9620841487279843" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="28" LOG_CI_END="0.13528082049461665" LOG_CI_START="-0.16885470192843588" LOG_EFFECT_SIZE="-0.01678694071690962" ORDER="4290" O_E="0.0" SE="0.17865071136641736" STUDY_ID="STD-Wimalaratna-1994" TOTAL_1="146" TOTAL_2="69" VAR="0.03191607667172696" WEIGHT="3.634501595939589"/>
<DICH_DATA CI_END="1.3720978980720941" CI_START="0.8686175200592556" EFFECT_SIZE="1.0917088776326314" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="62" LOG_CI_END="0.13738509903523813" LOG_CI_START="-0.06117141514380901" LOG_EFFECT_SIZE="0.038106841945714544" ORDER="4280" O_E="0.0" SE="0.11663307929936899" STUDY_ID="STD-Yordanov-1984" TOTAL_1="121" TOTAL_2="117" VAR="0.013603275186852896" WEIGHT="6.832312074993355"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.812433840590213" CI_END="1.9437471598869334" CI_START="0.3416396201042099" DF="1" EFFECT_SIZE="0.8148994056215827" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="91" I2="64.44360803914444" ID="CMP-001.01.02" LOG_CI_END="0.28863977180045153" LOG_CI_START="-0.46643176973112277" LOG_EFFECT_SIZE="-0.08889599896533565" MODIFIED="2012-03-06 12:17:19 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.09353647121485631" P_Z="0.6444395464377503" STUDIES="2" TAU2="0.2848127473644501" TOTAL_1="178" TOTAL_2="179" WEIGHT="8.390241117248129" Z="0.4615005248068458">
<NAME>Flunarizine versus control</NAME>
<DICH_DATA CI_END="1.3642571070596832" CI_START="0.9092120853803934" EFFECT_SIZE="1.1137320365800552" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="83" LOG_CI_END="0.13489622490617373" LOG_CI_START="-0.04133480020274899" LOG_EFFECT_SIZE="0.04678071235171239" MODIFIED="2011-07-02 05:15:02 +0100" MODIFIED_BY="[Empty name]" ORDER="4294" O_E="0.0" SE="0.10351897650662473" STUDY_ID="STD-FIST-1990" TOTAL_1="166" TOTAL_2="165" VAR="0.01071617849697912" WEIGHT="7.93266944387433"/>
<DICH_DATA CI_END="1.2881524554389447" CI_START="0.1485897489787242" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.1099672656927676" LOG_CI_START="-0.8280111509761034" LOG_EFFECT_SIZE="-0.3590219426416679" MODIFIED="2011-07-02 05:16:07 +0100" MODIFIED_BY="[Empty name]" ORDER="4293" O_E="0.0" SE="0.5509731650193398" STUDY_ID="STD-Limburg-1990" TOTAL_1="12" TOTAL_2="14" VAR="0.3035714285714286" WEIGHT="0.4575716733737987"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.399499026749544" CI_START="0.7358087918133415" DF="0" EFFECT_SIZE="1.0147727272727274" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="44" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.1459726007818528" LOG_CI_START="-0.13323502730509712" LOG_EFFECT_SIZE="0.006368786738377846" MODIFIED="2012-03-06 12:17:24 +0000" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="1.0" P_Z="0.9287525720161502" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="114" WEIGHT="4.16914207293337" Z="0.08941440975638108">
<NAME>Isradipine versus control</NAME>
<DICH_DATA CI_END="1.399499026749544" CI_START="0.7358087918133415" EFFECT_SIZE="1.0147727272727274" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="44" LOG_CI_END="0.1459726007818528" LOG_CI_START="-0.13323502730509712" LOG_EFFECT_SIZE="0.006368786738377846" ORDER="4295" O_E="0.0" SE="0.16400794283832365" STUDY_ID="STD-ASCLEPIOS-1990" TOTAL_1="120" TOTAL_2="114" VAR="0.02689860531405884" WEIGHT="4.16914207293337"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.375252492154805" CI_END="1.2027118319008896" CI_START="0.9303324888822305" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0577910436284008" ESTIMABLE="YES" EVENTS_1="486" EVENTS_2="362" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.0801615834437777" LOG_CI_START="-0.031361812434493194" LOG_EFFECT_SIZE="0.024399885504642237" METHOD="MH" MODIFIED="2012-03-06 12:17:48 +0000" MODIFIED_BY="Jing Zhang" NO="2" P_CHI2="0.5707802840598981" P_Q="0.4052310599175106" P_Z="0.39109689393344216" Q="1.8065959295134226" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3465" TOTAL_2="2858" WEIGHT="100.00000000000001" Z="0.8576298531690876">
<NAME>Death at end of treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favors treatment group</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favors control group</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.310064398226926" CI_END="1.187285102231413" CI_START="0.8824396151133678" DF="10" EFFECT_SIZE="1.0235757952603821" ESTIMABLE="YES" EVENTS_1="395" EVENTS_2="285" I2="3.0073953590459546" ID="CMP-001.02.01" LOG_CI_END="0.07455501841412936" LOG_CI_START="-0.05431500347023592" LOG_EFFECT_SIZE="0.010120007471946732" MODIFIED="2012-03-06 12:17:33 +0000" MODIFIED_BY="Deren Wagg" NO="1" P_CHI2="0.4137245026957741" P_Z="0.7582138099509024" STUDIES="16" TAU2="0.0019986689829340327" TOTAL_1="2889" TOTAL_2="2274" WEIGHT="79.262708601789" Z="0.30782721812664265">
<NAME>Nimodipine versus control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4327" O_E="0.0" SE="0.0" STUDY_ID="STD-Bogousslavsky-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.304923745043358" CI_START="0.5401849543228979" EFFECT_SIZE="0.8395833333333333" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="0.11558513383944177" LOG_CI_START="-0.26745751630839726" LOG_EFFECT_SIZE="-0.07593619123447776" ORDER="4335" O_E="0.0" SE="0.22500114878853866" STUDY_ID="STD-Canwin-1993" TOTAL_1="96" TOTAL_2="93" VAR="0.05062551695616212" WEIGHT="8.476912560292398"/>
<DICH_DATA CI_END="1.3013296787770838" CI_START="0.3530586795089037" EFFECT_SIZE="0.6778242677824268" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="0.11438733463679383" LOG_CI_START="-0.4521531074478073" LOG_EFFECT_SIZE="-0.16888288640550675" ORDER="4326" O_E="0.0" SE="0.3327886601009122" STUDY_ID="STD-German_x002d_Austrian-1994" TOTAL_1="239" TOTAL_2="243" VAR="0.11074829229176045" WEIGHT="3.8749859855754596"/>
<DICH_DATA CI_END="23.52490498352025" CI_START="0.32987185653114665" EFFECT_SIZE="2.7857142857142856" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.371527877998713" LOG_CI_START="-0.48165473530219094" LOG_EFFECT_SIZE="0.44493657134826115" ORDER="4324" O_E="0.0" SE="1.0885686404548336" STUDY_ID="STD-Heiss-1990" TOTAL_1="14" TOTAL_2="13" VAR="1.184981684981685" WEIGHT="0.36215587632784324"/>
<DICH_DATA CI_END="2.1363999420392092" CI_START="0.8039311801309788" EFFECT_SIZE="1.3105413105413106" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="18" LOG_CI_END="0.32968255751463765" LOG_CI_START="-0.09478112708313756" LOG_EFFECT_SIZE="0.11745071521575003" ORDER="4331" O_E="0.0" SE="0.2493320694618585" STUDY_ID="STD-INWEST--1990" TOTAL_1="195" TOTAL_2="100" VAR="0.062166480862133035" WEIGHT="6.903206914811708"/>
<DICH_DATA CI_END="7.293961008369778" CI_START="1.2060136769915717" EFFECT_SIZE="2.965909090909091" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" LOG_CI_END="0.8629634373579232" LOG_CI_START="0.08135223301830136" LOG_EFFECT_SIZE="0.47215783518811233" ORDER="4334" O_E="0.0" SE="0.4591222904669544" STUDY_ID="STD-Kaste-1994" TOTAL_1="176" TOTAL_2="174" VAR="0.21079327760362243" WEIGHT="2.035871757561265"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-04-24 09:43:58 +0100" MODIFIED_BY="Deren Wagg" ORDER="265" O_E="0.0" SE="0.0" STUDY_ID="STD-Lamsudin-1995" TOTAL_1="72" TOTAL_2="78" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.2942419902171656" CI_START="0.5932726874126617" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.36063922414643057" LOG_CI_START="-0.22674564488520407" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="4336" O_E="0.0" SE="0.3450327796711771" STUDY_ID="STD-Lowe--1989" TOTAL_1="56" TOTAL_2="56" VAR="0.11904761904761907" WEIGHT="3.6048438766786854"/>
<DICH_DATA CI_END="1.7823191996773877" CI_START="0.432819762375228" EFFECT_SIZE="0.8783068783068783" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.25098548547206184" LOG_CI_START="-0.3636929177384399" LOG_EFFECT_SIZE="-0.05635371613318907" ORDER="4328" O_E="0.0" SE="0.3610651367530168" STUDY_ID="STD-Martinez_x002d_Vila-1990" TOTAL_1="81" TOTAL_2="83" VAR="0.13036803297847474" WEIGHT="3.2918198637532847"/>
<DICH_DATA CI_END="1.3438852411103268" CI_START="0.6932939911820277" EFFECT_SIZE="0.96525" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="40" LOG_CI_END="0.12836218443176445" LOG_CI_START="-0.15908256383959093" LOG_EFFECT_SIZE="-0.015360189703913245" ORDER="4333" O_E="0.0" SE="0.1688464680090459" STUDY_ID="STD-Mohr-1992" TOTAL_1="800" TOTAL_2="264" VAR="0.028509129759129764" WEIGHT="15.053005271743032"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-04-24 08:40:26 +0100" MODIFIED_BY="Deren Wagg" ORDER="261" O_E="0.0" SE="0.0" STUDY_ID="STD-Nag-1998" TOTAL_1="31" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.3146377176029902" CI_START="0.6884484825168934" EFFECT_SIZE="0.9513465939095229" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="65" LOG_CI_END="0.11880608824547784" LOG_CI_START="-0.16212855300435947" LOG_EFFECT_SIZE="-0.021661232379440842" ORDER="4330" O_E="0.0" SE="0.1650223989190567" STUDY_ID="STD-NEST-1993" TOTAL_1="437" TOTAL_2="443" VAR="0.027232392145000284" WEIGHT="15.758736076947086"/>
<DICH_DATA CI_END="4.487151628279848" CI_START="0.222858526486512" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6519707453103448" LOG_CI_START="-0.6519707453103449" LOG_EFFECT_SIZE="0.0" ORDER="4337" O_E="0.0" SE="0.7659416862050704" STUDY_ID="STD-NIMPAS-1999" TOTAL_1="25" TOTAL_2="25" VAR="0.5866666666666666" WEIGHT="0.7315024100403179"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4329" O_E="0.0" SE="0.0" STUDY_ID="STD-Paci-1989" TOTAL_1="19" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4332" O_E="0.0" SE="0.0" STUDY_ID="STD-Sherman-1986" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.450431977629846" CI_START="0.8068260675776174" EFFECT_SIZE="1.0817792421746293" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="75" LOG_CI_END="0.1614973660702807" LOG_CI_START="-0.09322007870142654" LOG_EFFECT_SIZE="0.034138643684427046" ORDER="4325" O_E="0.0" SE="0.14962228793058752" STUDY_ID="STD-TRUST-1990" TOTAL_1="607" TOTAL_2="608" VAR="0.022386829045583638" WEIGHT="19.16966800805792"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2467366100368689" CI_END="1.8219626090388645" CI_START="0.9359007162189901" DF="2" EFFECT_SIZE="1.305823920260191" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="52" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.26053945998345523" LOG_CI_START="-0.028770220370049854" LOG_EFFECT_SIZE="0.11588461980670273" MODIFIED="2012-03-06 12:17:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5361358504159718" P_Z="0.11638040533272566" STUDIES="3" TAU2="0.0" TOTAL_1="393" TOTAL_2="397" WEIGHT="14.859563063664787" Z="1.570149197259673">
<NAME>Flunarizine versus control</NAME>
<DICH_DATA CI_END="2.1876899428843144" CI_START="0.9216581377378067" EFFECT_SIZE="1.4199655765920827" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="28" LOG_CI_END="0.3399857702956519" LOG_CI_START="-0.035430137976463175" LOG_EFFECT_SIZE="0.15227781615959438" MODIFIED="2011-07-02 05:15:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4340" O_E="0.0" SE="0.22052116285775725" STUDY_ID="STD-FIST-1990" TOTAL_1="166" TOTAL_2="165" VAR="0.04862958326813749" WEIGHT="8.82483566002853"/>
<DICH_DATA CI_END="2.2122163941103956" CI_START="0.7261535869348191" EFFECT_SIZE="1.2674418604651163" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="20" LOG_CI_END="0.34482760643533417" LOG_CI_START="-0.13897151304122232" LOG_EFFECT_SIZE="0.10292804669705592" ORDER="4341" O_E="0.0" SE="0.28418599762479424" STUDY_ID="STD-Kornhuber-1993" TOTAL_1="215" TOTAL_2="218" VAR="0.08076168124599957" WEIGHT="5.313758628300519"/>
<DICH_DATA CI_END="2.6462632283676255" CI_START="0.1285880308995873" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4226330420214051" LOG_CI_START="-0.890799454088141" LOG_EFFECT_SIZE="-0.23408320603336796" ORDER="4339" O_E="0.0" SE="0.7715167498104596" STUDY_ID="STD-Limburg-1990" TOTAL_1="12" TOTAL_2="14" VAR="0.5952380952380952" WEIGHT="0.7209687753357372"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.00391490284309" CI_END="1.6622199999985732" CI_START="0.5763481499831515" DF="2" EFFECT_SIZE="0.9787836440522348" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.22068850348076066" LOG_CI_START="-0.23931509654138455" LOG_EFFECT_SIZE="-0.009313296530311915" MODIFIED="2012-03-06 12:17:48 +0000" MODIFIED_BY="Deren Wagg" NO="3" P_CHI2="0.6053446307099188" P_Z="0.9367435761676192" STUDIES="3" TAU2="0.0" TOTAL_1="183" TOTAL_2="187" WEIGHT="5.877728334546228" Z="0.0793634040075966">
<NAME>Any other agent versus control</NAME>
<DICH_DATA CI_END="2.0838249335563277" CI_START="0.6107355733828486" EFFECT_SIZE="1.128125" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.3188612301821418" LOG_CI_START="-0.2141467830106379" LOG_EFFECT_SIZE="0.05235722358575196" ORDER="4343" O_E="0.0" SE="0.3130915453816562" STUDY_ID="STD-ASCLEPIOS-1990" TOTAL_1="120" TOTAL_2="114" VAR="0.09802631578947368" WEIGHT="4.3778864593732845"/>
<DICH_DATA CI_END="15.283894463332386" CI_START="0.08077574103880536" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1842340301842182" LOG_CI_START="-1.092719049062868" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="4342" O_E="0.0" SE="1.3374935098492586" STUDY_ID="STD-Oczkowski-1989" TOTAL_1="9" TOTAL_2="10" VAR="1.7888888888888888" WEIGHT="0.23989644254738374"/>
<DICH_DATA CI_END="1.831016421086712" CI_START="0.18584092084538612" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.2626922391981283" LOG_CI_START="-0.7308586512648643" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2011-06-06 09:55:18 +0100" MODIFIED_BY="Deren Wagg" ORDER="267" O_E="0.0" SE="0.5836167112141886" STUDY_ID="STD-Squire-1996" TOTAL_1="54" TOTAL_2="63" VAR="0.34060846560846564" WEIGHT="1.2599454326255601"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.071616159766872" CI_END="1.1718939532541977" CI_START="0.98280747965311" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0731943638588852" ESTIMABLE="YES" EVENTS_1="894" EVENTS_2="686" I2="0.0" I2_Q="3.5762253183796995" ID="CMP-001.03" LOG_CI_END="0.06888831338831308" LOG_CI_START="-0.007531546982645213" LOG_EFFECT_SIZE="0.030678383202833906" METHOD="MH" MODIFIED="2012-03-06 12:18:11 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6886096816648475" P_Q="0.37478655862857635" P_Z="0.11557159838266111" Q="3.1112658780530413" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="31" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4121" TOTAL_2="3362" WEIGHT="100.00000000000003" Z="1.5736361173547397">
<NAME>Death at end of follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favors treatment group</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favors control group</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="16.616296319420382" CI_END="1.1580714593772956" CI_START="0.9575805188599019" DF="19" EFFECT_SIZE="1.0530653678415953" ESTIMABLE="YES" EVENTS_1="773" EVENTS_2="583" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.06373535857597962" LOG_CI_START="-0.01882469785405434" LOG_EFFECT_SIZE="0.02245533036096262" MODIFIED="2012-03-06 12:17:57 +0000" MODIFIED_BY="Deren Wagg" NO="1" P_CHI2="0.6158452270208779" P_Z="0.28634560057849046" STUDIES="24" TAU2="0.0" TOTAL_1="3540" TOTAL_2="2772" WEIGHT="85.67863077224297" Z="1.066172691045422">
<NAME>Nimodipine versus control</NAME>
<DICH_DATA CI_END="2.1767384778714605" CI_START="0.7802208301181125" EFFECT_SIZE="1.303202479338843" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="22" LOG_CI_END="0.337806254286899" LOG_CI_START="-0.10778245919649945" LOG_EFFECT_SIZE="0.11501189754519978" ORDER="1" O_E="0.0" SE="0.26174101599985305" STUDY_ID="STD-Kaste-1994" TOTAL_1="176" TOTAL_2="174" VAR="0.06850835945663533" WEIGHT="2.941332461273965"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-04-24 08:39:49 +0100" MODIFIED_BY="Deren Wagg" ORDER="260" O_E="0.0" SE="0.0" STUDY_ID="STD-Nag-1998" TOTAL_1="31" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-04-24 09:43:25 +0100" MODIFIED_BY="Deren Wagg" ORDER="264" O_E="0.0" SE="0.0" STUDY_ID="STD-Lamsudin-1995" TOTAL_1="72" TOTAL_2="78" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.069583951807983" CI_START="0.04493253457556609" EFFECT_SIZE="0.4772727272727273" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7049723193238526" LOG_CI_START="-1.3474390828283886" LOG_EFFECT_SIZE="-0.3212333817522681" MODIFIED="2011-06-06 04:21:15 +0100" MODIFIED_BY="Deren Wagg" ORDER="271" O_E="0.0" SE="1.2055966172245192" STUDY_ID="STD-Sze-1998" TOTAL_1="44" TOTAL_2="42" VAR="1.4534632034632036" WEIGHT="0.13863843340395104"/>
<DICH_DATA CI_END="3.405859213276469" CI_START="0.39557056492806414" EFFECT_SIZE="1.1607142857142858" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5322266917296774" LOG_CI_START="-0.40277603245636695" LOG_EFFECT_SIZE="0.0647253296366552" ORDER="4296" O_E="0.0" SE="0.549225228525012" STUDY_ID="STD-Heiss-1990" TOTAL_1="14" TOTAL_2="13" VAR="0.30164835164835163" WEIGHT="0.668015788706624"/>
<DICH_DATA CI_END="1.393520757629854" CI_START="0.9576923587369608" EFFECT_SIZE="1.1552333882482153" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="150" LOG_CI_END="0.1441134422685267" LOG_CI_START="-0.01877397772734367" LOG_EFFECT_SIZE="0.06266973227059154" ORDER="4297" O_E="0.0" SE="0.09568087681130717" STUDY_ID="STD-TRUST-1990" TOTAL_1="607" TOTAL_2="608" VAR="0.009154830187380537" WEIGHT="22.01087922047884"/>
<DICH_DATA CI_END="1.5918715772698346" CI_START="0.7699736256484637" EFFECT_SIZE="1.107112970711297" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="45" LOG_CI_END="0.20190802851928238" LOG_CI_START="-0.11352415071259347" LOG_EFFECT_SIZE="0.044191938903344455" ORDER="4298" O_E="0.0" SE="0.18528642349527324" STUDY_ID="STD-German_x002d_Austrian-1994" TOTAL_1="239" TOTAL_2="243" VAR="0.03433105873166974" WEIGHT="5.869491620208654"/>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="4299" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Bogousslavsky-1990" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="0.07743820298790778"/>
<DICH_DATA CI_END="1.3938596327575241" CI_START="0.4237304097382113" EFFECT_SIZE="0.7685185185185185" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="20" LOG_CI_END="0.14421904077186265" LOG_CI_START="-0.3729103669936143" LOG_EFFECT_SIZE="-0.11434566311087581" ORDER="4300" O_E="0.0" SE="0.30376437395329403" STUDY_ID="STD-Martinez_x002d_Vila-1990" TOTAL_1="81" TOTAL_2="83" VAR="0.09227279488323666" WEIGHT="2.183805766297804"/>
<DICH_DATA CI_END="1.024547539508993" CI_START="0.34275225624367245" EFFECT_SIZE="0.5925925925925926" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="27" LOG_CI_END="0.010532114681991682" LOG_CI_START="-0.4650196776881167" LOG_EFFECT_SIZE="-0.22724378150306254" ORDER="4301" O_E="0.0" SE="0.279341476857539" STUDY_ID="STD-Gelmers-1988" TOTAL_1="93" TOTAL_2="93" VAR="0.078031660692951" WEIGHT="2.5823602849020197"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4302" O_E="0.0" SE="0.0" STUDY_ID="STD-Paci-1989" TOTAL_1="19" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.3019197778247134" CI_START="0.6828220962447229" EFFECT_SIZE="0.9428571428571428" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="42" LOG_CI_END="0.11458422453829856" LOG_CI_START="-0.16569243348307489" LOG_EFFECT_SIZE="-0.025554104472388168" ORDER="4303" O_E="0.0" SE="0.16463589631358755" STUDY_ID="STD-Mohr-1992" TOTAL_1="800" TOTAL_2="264" VAR="0.02710497835497835" WEIGHT="7.434274947554654"/>
<DICH_DATA CI_END="1.3104818368122877" CI_START="0.8149251502103065" EFFECT_SIZE="1.0334140543422718" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="103" LOG_CI_END="0.11743100603282015" LOG_CI_START="-0.08888227879799303" LOG_EFFECT_SIZE="0.01427436361741357" ORDER="4304" O_E="0.0" SE="0.12118944477685038" STUDY_ID="STD-NEST-1993" TOTAL_1="437" TOTAL_2="443" VAR="0.01468688152532127" WEIGHT="13.720125759237295"/>
<DICH_DATA CI_END="1.782266660532993" CI_START="0.9334399820836791" EFFECT_SIZE="1.2898212898212897" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="33" LOG_CI_END="0.2509726831654877" LOG_CI_START="-0.02991360089415089" LOG_EFFECT_SIZE="0.11052954113566839" ORDER="4305" O_E="0.0" SE="0.164993993666162" STUDY_ID="STD-INWEST--1990" TOTAL_1="195" TOTAL_2="100" VAR="0.027223017945909506" WEIGHT="7.402039771593535"/>
<DICH_DATA CI_END="2.4247594208562386" CI_START="0.6443938258618025" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.3846686553598624" LOG_CI_START="-0.19084862934374955" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="4307" O_E="0.0" SE="0.33806170189140666" STUDY_ID="STD-Lowe--1989" TOTAL_1="56" TOTAL_2="56" VAR="0.1142857142857143" WEIGHT="1.7631762884612336"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4308" O_E="0.0" SE="0.0" STUDY_ID="STD-Sherman-1986" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2819331182874545" CI_START="0.5653614335825451" EFFECT_SIZE="0.8513257575757576" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="33" LOG_CI_END="0.10786536752570283" LOG_CI_START="-0.24767382045483216" LOG_EFFECT_SIZE="-0.06990422646456469" ORDER="4309" O_E="0.0" SE="0.20884547896713082" STUDY_ID="STD-Canwin-1993" TOTAL_1="96" TOTAL_2="93" VAR="0.043616434085010286" WEIGHT="4.619952679893161"/>
<DICH_DATA CI_END="1.1955346582682078" CI_START="0.5189527269750911" EFFECT_SIZE="0.7876712328767124" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="24" LOG_CI_END="0.07756217072904782" LOG_CI_START="-0.2848722015906986" LOG_EFFECT_SIZE="-0.10365501543082539" ORDER="4310" O_E="0.0" SE="0.21289574437969658" STUDY_ID="STD-Wimalaratna-1994" TOTAL_1="146" TOTAL_2="69" VAR="0.04532459797498511" WEIGHT="4.445838916202608"/>
<DICH_DATA CI_END="5.224499169520386" CI_START="0.047851476646507" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7180446644790353" LOG_CI_START="-1.3201046558069978" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="4311" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Capon-1983" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="0.1405854847942512"/>
<DICH_DATA CI_END="2.637173230903484" CI_START="0.8245784786577098" EFFECT_SIZE="1.4746376811594204" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="12" LOG_CI_END="0.42113865871055994" LOG_CI_START="-0.08376800439055526" LOG_EFFECT_SIZE="0.16868532716000237" ORDER="4312" O_E="0.0" SE="0.2965846732338861" STUDY_ID="STD-Bridgers-1991" TOTAL_1="138" TOTAL_2="66" VAR="0.087962468397251" WEIGHT="2.2908163584996"/>
<DICH_DATA CI_END="1.6935405985278387" CI_START="0.8247184721111215" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="36" LOG_CI_END="0.22879561226218037" LOG_CI_START="-0.08369427796495685" LOG_EFFECT_SIZE="0.07255066714861175" ORDER="4313" O_E="0.0" SE="0.1835581083693243" STUDY_ID="STD-Yordanov-1984" TOTAL_1="121" TOTAL_2="117" VAR="0.0336935791481246" WEIGHT="5.9805418905650045"/>
<DICH_DATA CI_END="4.487151628279848" CI_START="0.222858526486512" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6519707453103448" LOG_CI_START="-0.6519707453103449" LOG_EFFECT_SIZE="0.0" ORDER="4314" O_E="0.0" SE="0.7659416862050704" STUDY_ID="STD-NIMPAS-1999" TOTAL_1="25" TOTAL_2="25" VAR="0.5866666666666666" WEIGHT="0.343475900349591"/>
<DICH_DATA CI_END="2.0341796468102213" CI_START="0.08987896649879219" EFFECT_SIZE="0.42758620689655175" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3083893046207237" LOG_CI_START="-1.0463419300941657" LOG_EFFECT_SIZE="-0.368976312736721" ORDER="4315" O_E="0.0" SE="0.7957758332992912" STUDY_ID="STD-Gelmers-1984" TOTAL_1="29" TOTAL_2="31" VAR="0.6332591768631813" WEIGHT="0.3182044080854481"/>
<DICH_DATA CI_END="2.3711569500113296" CI_START="0.30984616077291294" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.374960301455169" LOG_CI_START="-0.5088538807163955" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="4316" O_E="0.0" SE="0.519156825558337" STUDY_ID="STD-Uzunur-1995" TOTAL_1="50" TOTAL_2="50" VAR="0.2695238095238095" WEIGHT="0.7476365887468128"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2979712540408272" CI_END="1.7656885372209905" CI_START="1.0097728312102718" DF="2" EFFECT_SIZE="1.3352693785394627" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="66" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.24691409760175784" LOG_CI_START="0.004223681457316587" LOG_EFFECT_SIZE="0.1255688895295372" MODIFIED="2012-03-06 12:18:03 +0000" MODIFIED_BY="Deren Wang" NO="2" P_CHI2="0.5225756260002453" P_Z="0.04254139527477487" STUDIES="3" TAU2="0.0" TOTAL_1="393" TOTAL_2="397" WEIGHT="9.91533123457858" Z="2.0281847546060896">
<NAME>Flunarizine versus control</NAME>
<DICH_DATA CI_END="2.0000163863470743" CI_START="1.0229501451272374" EFFECT_SIZE="1.430355568615927" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="41" LOG_CI_END="0.30103355389946107" LOG_CI_START="0.009854468293058765" LOG_EFFECT_SIZE="0.15544401109625985" ORDER="4318" O_E="0.0" SE="0.1710400362449204" STUDY_ID="STD-FIST-1990" TOTAL_1="166" TOTAL_2="165" VAR="0.02925469399866368" WEIGHT="6.887983909441378"/>
<DICH_DATA CI_END="2.3379040026017486" CI_START="0.20958944398687923" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.36882667449208634" LOG_CI_START="-0.6786305944635728" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="4319" O_E="0.0" SE="0.615281584781658" STUDY_ID="STD-Limburg-1990" TOTAL_1="12" TOTAL_2="14" VAR="0.37857142857142856" WEIGHT="0.532279634252448"/>
<DICH_DATA CI_END="2.2122163941103956" CI_START="0.7261535869348191" EFFECT_SIZE="1.2674418604651163" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="20" LOG_CI_END="0.34482760643533417" LOG_CI_START="-0.13897151304122232" LOG_EFFECT_SIZE="0.10292804669705592" ORDER="4320" O_E="0.0" SE="0.28418599762479424" STUDY_ID="STD-Kornhuber-1993" TOTAL_1="215" TOTAL_2="218" VAR="0.08076168124599957" WEIGHT="2.495067690884754"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8477054254618508" CI_START="0.5966860219206317" DF="0" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.2666327340411146" LOG_CI_START="-0.2242541359012384" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2012-03-06 12:18:07 +0000" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="1.0" P_Z="0.8656353759195758" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="114" WEIGHT="2.423536963190121" Z="0.16920502697333833">
<NAME>Isradipine versus control</NAME>
<DICH_DATA CI_END="1.8477054254618508" CI_START="0.5966860219206317" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" LOG_CI_END="0.2666327340411146" LOG_CI_START="-0.2242541359012384" LOG_EFFECT_SIZE="0.021189299069938092" ORDER="4321" O_E="0.0" SE="0.28834937733333377" STUDY_ID="STD-ASCLEPIOS-1990" TOTAL_1="120" TOTAL_2="114" VAR="0.0831453634085213" WEIGHT="2.423536963190121"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.047369225743510594" CI_END="1.5647494312842831" CI_START="0.44843053892911555" DF="1" EFFECT_SIZE="0.8376642709103916" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.19444480237894143" LOG_CI_START="-0.34830481883180453" LOG_EFFECT_SIZE="-0.0769300082264316" MODIFIED="2012-03-06 12:18:11 +0000" MODIFIED_BY="Deren Wagg" NO="4" P_CHI2="0.8277059361377067" P_Z="0.5784737498158397" STUDIES="3" TAU2="0.0" TOTAL_1="68" TOTAL_2="79" WEIGHT="1.9825010299883596" Z="0.5556154792621371">
<NAME>Any other agent versus control</NAME>
<DICH_DATA CI_END="1.5671422035700462" CI_START="0.4327627004725797" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.19510840643904395" LOG_CI_START="-0.3637501778391158" LOG_EFFECT_SIZE="-0.08432088570003593" MODIFIED="2011-06-06 09:55:48 +0100" MODIFIED_BY="Deren Wagg" ORDER="266" O_E="0.0" SE="0.3282762987995991" STUDY_ID="STD-Squire-1996" TOTAL_1="54" TOTAL_2="63" VAR="0.10776532835356364" WEIGHT="1.869858001799177"/>
<DICH_DATA CI_END="15.283894463332386" CI_START="0.08077574103880536" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1842340301842182" LOG_CI_START="-1.092719049062868" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="4322" O_E="0.0" SE="1.3374935098492586" STUDY_ID="STD-Oczkowski-1989" TOTAL_1="9" TOTAL_2="10" VAR="1.7888888888888888" WEIGHT="0.11264302818918263"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4323" O_E="0.0" SE="0.0" STUDY_ID="STD-Lisk-1993" TOTAL_1="5" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.9360520337486693" CI_END="1.5447747130674019" CI_START="0.5601796881237883" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9302426656456968" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.1888651517182732" LOG_CI_START="-0.2516726425593675" LOG_EFFECT_SIZE="-0.03140374542054716" METHOD="MH" MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5586592827825285" P_Q="0.7747701183541572" P_Z="0.7799132067306775" Q="0.08187668864281125" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1496" TOTAL_2="964" WEIGHT="100.0" Z="0.27943214318245846">
<NAME>Recurrence of stroke at end of follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favors treatment group</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favors control group</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.7505670621388036" CI_END="2.1007129696593667" CI_START="0.4538922152937555" DF="3" EFFECT_SIZE="0.9764718447016348" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="18" I2="20.012095496588298" ID="CMP-001.04.01" LOG_CI_END="0.32236671675205625" LOG_CI_START="-0.3430472657787582" LOG_EFFECT_SIZE="-0.01034027451335101" MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="0.28968887512396413" P_Z="0.9514275753598606" STUDIES="6" TAU2="0.1315398775083181" TOTAL_1="1106" TOTAL_2="571" WEIGHT="66.05986230203776" Z="0.060914156204966305">
<NAME>Nimodipine versus control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4348" O_E="0.0" SE="0.0" STUDY_ID="STD-Bogousslavsky-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.1824463626199204" CI_START="0.2284933213734146" EFFECT_SIZE="0.7061688311688312" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.338943578973511" LOG_CI_START="-0.6411264893930873" LOG_EFFECT_SIZE="-0.1510914552097881" ORDER="4345" O_E="0.0" SE="0.575698009583621" STUDY_ID="STD-Kaste-1994" TOTAL_1="176" TOTAL_2="174" VAR="0.3314281982385431" WEIGHT="20.204685474030825"/>
<DICH_DATA CI_END="34.67675164114823" CI_START="0.4614042331754636" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5400384079968334" LOG_CI_START="-0.33591842534090866" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="4346" O_E="0.0" SE="1.1019463300386796" STUDY_ID="STD-Lowe--1989" TOTAL_1="56" TOTAL_2="56" VAR="1.2142857142857144" WEIGHT="5.514684413934294"/>
<DICH_DATA CI_END="2.595645114531947" CI_START="0.4931839892433578" EFFECT_SIZE="1.1314285714285715" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="7" LOG_CI_END="0.41424531396183023" LOG_CI_START="-0.30699103081135687" LOG_EFFECT_SIZE="0.05362714157523668" ORDER="4344" O_E="0.0" SE="0.42365779909725576" STUDY_ID="STD-Mohr-1992" TOTAL_1="800" TOTAL_2="264" VAR="0.17948593073593072" WEIGHT="37.308787798452045"/>
<DICH_DATA CI_END="2.6300131119236196" CI_START="0.00775971920930058" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41995791366918006" LOG_CI_START="-2.110153993697694" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="4349" O_E="0.0" SE="1.4862002586432317" STUDY_ID="STD-NIMPAS-1999" TOTAL_1="25" TOTAL_2="25" VAR="2.208791208791209" WEIGHT="3.0317046156205945"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4347" O_E="0.0" SE="0.0" STUDY_ID="STD-Paci-1989" TOTAL_1="19" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07652843530305861" CI_END="1.9689005528324375" CI_START="0.3451768929663056" DF="1" EFFECT_SIZE="0.8243900626440994" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.2942237809188088" LOG_CI_START="-0.461958284779285" LOG_EFFECT_SIZE="-0.08386725193023813" MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="0.7820582959974449" P_Z="0.6637406063765052" STUDIES="2" TAU2="0.0" TOTAL_1="381" TOTAL_2="383" WEIGHT="33.940137697962236" Z="0.4347545405321517">
<NAME>Flunarizine versus control</NAME>
<DICH_DATA CI_END="4.853455120568607" CI_START="0.2035638678884972" EFFECT_SIZE="0.9939759036144579" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6860510180995206" LOG_CI_START="-0.6912993057518182" LOG_EFFECT_SIZE="-0.0026241438261488006" ORDER="4350" O_E="0.0" SE="0.8090623982243387" STUDY_ID="STD-FIST-1990" TOTAL_1="166" TOTAL_2="165" VAR="0.6545819642205184" WEIGHT="10.230044316312062"/>
<DICH_DATA CI_END="2.1549725601908976" CI_START="0.26835942311307664" EFFECT_SIZE="0.7604651162790698" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3334417445507884" LOG_CI_START="-0.5712831503893893" LOG_EFFECT_SIZE="-0.11892070291930046" ORDER="4351" O_E="0.0" SE="0.531439881748318" STUDY_ID="STD-Kornhuber-1993" TOTAL_1="215" TOTAL_2="218" VAR="0.28242834791266624" WEIGHT="23.71009338165017"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Any other agent versus control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4352" O_E="0.0" SE="0.0" STUDY_ID="STD-Oczkowski-1989" TOTAL_1="9" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="28.134192199870803" CI_END="1.7368501797891736" CI_START="0.8063899575523563" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1834604103031896" ESTIMABLE="YES" EVENTS_1="251" EVENTS_2="157" I2="60.90166754441056" I2_Q="89.571744757572" ID="CMP-001.05" LOG_CI_END="0.23976235794217624" LOG_CI_START="-0.09345488938906797" LOG_EFFECT_SIZE="0.0731537342765541" METHOD="MH" MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="Deren Wang" NO="5" P_CHI2="0.0030875770317552176" P_Q="6.845591017501373E-5" P_Z="0.38947392736011877" Q="19.178663673889353" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.21550604296116332" TOTALS="YES" TOTAL_1="2810" TOTAL_2="2285" WEIGHT="100.0" Z="0.8605718081221025">
<NAME>Adverse events (all) during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favors treatment group</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favors control group</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.894654518177482" CI_END="1.1601414048263694" CI_START="0.7407432620562256" DF="9" EFFECT_SIZE="0.9270204575183749" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="131" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.0645109268071496" LOG_CI_START="-0.1303322902564289" LOG_EFFECT_SIZE="-0.032910681724639644" MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.44705499834010964" P_Z="0.5079011943617087" STUDIES="11" TAU2="0.0" TOTAL_1="2563" TOTAL_2="2041" WEIGHT="76.59413454364797" Z="0.6621092780038249">
<NAME>Nimodipine versus control</NAME>
<DICH_DATA CI_END="3.0683219164168825" CI_START="0.18332496241361632" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4869009221574032" LOG_CI_START="-0.736778395374003" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="4355" O_E="0.0" SE="0.7187952884282608" STUDY_ID="STD-Bogousslavsky-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.5166666666666666" WEIGHT="5.232588850822608"/>
<DICH_DATA CI_END="2.8859065736471434" CI_START="0.22176740087298893" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.46028226743444384" LOG_CI_START="-0.6541022934505566" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="4357" O_E="0.0" SE="0.6545950073563913" STUDY_ID="STD-Gelmers-1988" TOTAL_1="93" TOTAL_2="93" VAR="0.428494623655914" WEIGHT="5.948998123558104"/>
<DICH_DATA CI_END="2.4478433731606417" CI_START="0.6226943009216075" EFFECT_SIZE="1.234608487746563" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.388783625749575" LOG_CI_START="-0.20572510904915417" LOG_EFFECT_SIZE="0.0915292583502104" ORDER="4354" O_E="0.0" SE="0.3492173736864727" STUDY_ID="STD-German_x002d_Austrian-1994" TOTAL_1="239" TOTAL_2="243" VAR="0.12195277408447751" WEIGHT="11.352966832563162"/>
<DICH_DATA CI_END="195.20316382536996" CI_START="0.6059378513662087" EFFECT_SIZE="10.875706214689265" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.290486852371476" LOG_CI_START="-0.2175719174060504" LOG_EFFECT_SIZE="1.0364574674827127" ORDER="4361" O_E="0.0" SE="1.4732461364584575" STUDY_ID="STD-Kaste-1994" TOTAL_1="176" TOTAL_2="174" VAR="2.1704541785897717" WEIGHT="1.605709400630665"/>
<DICH_DATA CI_END="3.198610512457931" CI_START="0.17585760998695463" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5049613602502472" LOG_CI_START="-0.7548388334668471" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="4362" O_E="0.0" SE="0.7400128699009548" STUDY_ID="STD-Lowe--1989" TOTAL_1="56" TOTAL_2="56" VAR="0.5476190476190474" WEIGHT="5.020354859990644"/>
<DICH_DATA CI_END="14.787120783829943" CI_START="0.6390650046781314" EFFECT_SIZE="3.074074074074074" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1698836202833682" LOG_CI_START="-0.19445496384919508" LOG_EFFECT_SIZE="0.4877143282170866" ORDER="4356" O_E="0.0" SE="0.8014192379043796" STUDY_ID="STD-Martinez_x002d_Vila-1990" TOTAL_1="81" TOTAL_2="83" VAR="0.6422727948832366" WEIGHT="4.46637126989851"/>
<DICH_DATA CI_END="1.4121876341419937" CI_START="0.6654129153283008" EFFECT_SIZE="0.969375" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="32" LOG_CI_END="0.14989240426440478" LOG_CI_START="-0.17690877394904453" LOG_EFFECT_SIZE="-0.013508184842319844" ORDER="4359" O_E="0.0" SE="0.19196462977450204" STUDY_ID="STD-Mohr-1992" TOTAL_1="800" TOTAL_2="264" VAR="0.03685041908446164" WEIGHT="15.181536173947883"/>
<DICH_DATA CI_END="1.287564955988561" CI_START="0.5780956446481028" EFFECT_SIZE="0.8627489166950679" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="47" LOG_CI_END="0.10976914786142815" LOG_CI_START="-0.23800030257164284" LOG_EFFECT_SIZE="-0.06411557735510735" MODIFIED="2011-07-02 05:36:18 +0100" MODIFIED_BY="[Empty name]" ORDER="4360" O_E="0.0" SE="0.20428149667092935" STUDY_ID="STD-NEST-1993" TOTAL_1="437" TOTAL_2="443" VAR="0.04173092988211492" WEIGHT="14.893499619937204"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-07-02 05:36:17 +0100" MODIFIED_BY="[Empty name]" ORDER="4363" O_E="0.0" SE="0.0" STUDY_ID="STD-NIMPAS-1999" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="80.02859269917121" CI_START="0.14872809327963177" EFFECT_SIZE="3.45" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9032451799033536" LOG_CI_START="-0.8276069897568056" LOG_EFFECT_SIZE="0.5378190950732742" MODIFIED="2011-07-02 05:36:06 +0100" MODIFIED_BY="[Empty name]" ORDER="4358" O_E="0.0" SE="1.6041160823946319" STUDY_ID="STD-Paci-1989" TOTAL_1="19" TOTAL_2="22" VAR="2.5731884057971013" WEIGHT="1.3738180455664761"/>
<DICH_DATA CI_END="1.1071893847006908" CI_START="0.2894935524810395" EFFECT_SIZE="0.5661485566936466" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="0.04422191328680299" LOG_CI_START="-0.5383611043133604" LOG_EFFECT_SIZE="-0.24706959551327873" MODIFIED="2011-07-02 05:36:05 +0100" MODIFIED_BY="[Empty name]" ORDER="4353" O_E="0.0" SE="0.34221214837078295" STUDY_ID="STD-TRUST-1990" TOTAL_1="607" TOTAL_2="608" VAR="0.11710915449254676" WEIGHT="11.518291366732699"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.209122039488307" CI_START="1.9137132200743427" DF="0" EFFECT_SIZE="3.1573352232459246" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="17" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.7167645322177779" LOG_CI_START="0.28187685701931364" LOG_EFFECT_SIZE="0.4993206946185457" MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="Deren Wang" NO="2" P_CHI2="1.0" P_Z="6.772843263234445E-6" STUDIES="1" TAU2="0.0" TOTAL_1="166" TOTAL_2="165" WEIGHT="13.645506910604883" Z="4.500705050982454">
<NAME>Flunarizine versus control</NAME>
<DICH_DATA CI_END="5.209122039488307" CI_START="1.9137132200743427" EFFECT_SIZE="3.157335223245925" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="17" LOG_CI_END="0.7167645322177779" LOG_CI_START="0.28187685701931364" LOG_EFFECT_SIZE="0.4993206946185458" MODIFIED="2012-01-03 12:26:50 +0000" MODIFIED_BY="Deren Wang" ORDER="4365" O_E="0.0" SE="0.2554551731402889" STUDY_ID="STD-FIST-1990" TOTAL_1="166" TOTAL_2="165" VAR="0.06525734548413499" WEIGHT="13.645506910604883"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7190729868883405" CI_START="0.5225930514705474" DF="0" EFFECT_SIZE="1.1920438957475994" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="0.4344208653210156" LOG_CI_START="-0.281836369059632" LOG_EFFECT_SIZE="0.07629224813069183" MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6762895267407332" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="79" WEIGHT="9.760358545747158" Z="0.41753172312472037">
<NAME>Any other agent versus control</NAME>
<DICH_DATA CI_END="2.7190729868883405" CI_START="0.5225930514705474" EFFECT_SIZE="1.1920438957475994" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.4344208653210156" LOG_CI_START="-0.281836369059632" LOG_EFFECT_SIZE="0.07629224813069183" MODIFIED="2011-07-02 05:35:58 +0100" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.0" SE="0.42073304500568415" STUDY_ID="STD-Shibuya-2005" TOTAL_1="81" TOTAL_2="79" VAR="0.17701629515975506" WEIGHT="9.760358545747158"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.092944603654731" CI_END="3.3849262997916068" CI_START="0.6074394186104218" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4339238695218586" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" I2="2.270849294459968" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.5295492172036537" LOG_CI_START="-0.21649702879984617" LOG_EFFECT_SIZE="0.15652609420190378" METHOD="MH" MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="Jing Zhang" NO="6" P_CHI2="0.39357354755510365" P_Q="0.3432764080614874" P_Z="0.4108320659994077" Q="0.8981572929558357" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.02260241874221874" TOTALS="YES" TOTAL_1="827" TOTAL_2="840" WEIGHT="100.0" Z="0.8224302686860945">
<NAME>Hypotension during treatment period (reason to stop treatment)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favors treatment group</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favors control group</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.195591634209115" CI_END="3.141073988304054" CI_START="0.5023980296820157" DF="3" EFFECT_SIZE="1.2562123159758416" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" I2="6.12067049228968" ID="CMP-001.06.01" LOG_CI_END="0.49707816636785485" LOG_CI_START="-0.2989520724951957" LOG_EFFECT_SIZE="0.09906304693632956" MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="Deren Wagg" NO="1" P_CHI2="0.3624407280380023" P_Z="0.6256768673832869" STUDIES="5" TAU2="0.05453258038249156" TOTAL_1="818" TOTAL_2="830" WEIGHT="91.39457769589076" Z="0.4878206749314465">
<NAME>Nimodipine versus control</NAME>
<DICH_DATA CI_END="3.0260386806300987" CI_START="0.036718338011454264" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48087447513357967" LOG_CI_START="-1.4351169845729046" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="4367" O_E="0.0" SE="1.1254628677422753" STUDY_ID="STD-Bogousslavsky-1990" TOTAL_1="30" TOTAL_2="30" VAR="1.2666666666666664" WEIGHT="14.895776030475673"/>
<DICH_DATA CI_END="4.987373926515771" CI_START="0.20727399343214117" EFFECT_SIZE="1.0167364016736402" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6978719305072263" LOG_CI_START="-0.6834551852068772" LOG_EFFECT_SIZE="0.00720837265017452" ORDER="4366" O_E="0.0" SE="0.8113983854499638" STUDY_ID="STD-German_x002d_Austrian-1994" TOTAL_1="239" TOTAL_2="243" VAR="0.6583673399108081" WEIGHT="28.20193304509471"/>
<DICH_DATA CI_END="7.10147344224917" CI_START="0.1478555665594286" EFFECT_SIZE="1.0246913580246915" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8513484672329205" LOG_CI_START="-0.8301623202380719" LOG_EFFECT_SIZE="0.0105930734974242" ORDER="4368" O_E="0.0" SE="0.9877277601731005" STUDY_ID="STD-Martinez_x002d_Vila-1990" TOTAL_1="81" TOTAL_2="83" VAR="0.9756061282165699" WEIGHT="19.239129536385178"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-04-24 08:40:55 +0100" MODIFIED_BY="Deren Wagg" ORDER="262" O_E="0.0" SE="0.0" STUDY_ID="STD-Nag-1998" TOTAL_1="31" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.984496584163907" CI_START="0.7411873323595703" EFFECT_SIZE="3.5480549199084668" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2300526790270792" LOG_CI_START="-0.13007201182123238" LOG_EFFECT_SIZE="0.5499903336029234" ORDER="4369" O_E="0.0" SE="0.7989439761301019" STUDY_ID="STD-NEST-1993" TOTAL_1="437" TOTAL_2="443" VAR="0.6383114769945769" WEIGHT="29.057739083935207"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="101.27551608422263" CI_START="0.298690158980217" DF="0" EFFECT_SIZE="5.499999999999999" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="2.005504464958159" LOG_CI_START="-0.5247790859696713" LOG_EFFECT_SIZE="0.7403626894942438" MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="1.0" P_Z="0.25139255463109134" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="8.605422304109236" Z="1.1469735922472648">
<NAME>Any other agent versus control</NAME>
<DICH_DATA CI_END="101.27551608422263" CI_START="0.2986901589802171" EFFECT_SIZE="5.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.005504464958159" LOG_CI_START="-0.524779085969671" LOG_EFFECT_SIZE="0.7403626894942439" ORDER="4371" O_E="0.0" SE="1.4863010829205867" STUDY_ID="STD-Oczkowski-1989" TOTAL_1="9" TOTAL_2="10" VAR="2.209090909090909" WEIGHT="8.605422304109236"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.183794498059779" CI_END="1.3161744845734626" CI_START="-3.923851352929546" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3038384341780416" ESTIMABLE="YES" I2="52.1965048491867" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="Deren Wang" NO="7" P_CHI2="0.12345274347705903" P_Q="1.0" P_Z="0.32937783685559774" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="2.777767690929342" TOTALS="YES" TOTAL_1="313" TOTAL_2="317" UNITS="" WEIGHT="100.0" Z="0.9753678519515859">
<NAME>Mean systolic blood pressure during or at end of treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_SUBGROUP CHI2="4.183794498059779" CI_END="1.3161744845734626" CI_START="-3.923851352929546" DF="2" EFFECT_SIZE="-1.3038384341780416" ESTIMABLE="YES" I2="52.1965048491867" ID="CMP-001.07.01" MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="Deren Wang" NO="1" P_CHI2="0.12345274347705903" P_Z="0.32937783685559774" STUDIES="3" TAU2="2.777767690929342" TOTAL_1="313" TOTAL_2="317" WEIGHT="100.0" Z="0.9753678519515859">
<NAME>Nimodipine versus control</NAME>
<CONT_DATA CI_END="3.321649963091355" CI_START="-17.321649963091353" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="134.0" MEAN_2="141.0" MODIFIED="2011-07-02 05:17:49 +0100" MODIFIED_BY="[Empty name]" ORDER="4372" SD_1="24.0" SD_2="16.0" SE="5.266244708835067" STUDY_ID="STD-Bogousslavsky-1990" TOTAL_1="30" TOTAL_2="30" WEIGHT="5.856697639974497"/>
<CONT_DATA CI_END="-1.2583583735967203" CI_START="-2.74164162640328" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="132.0" MEAN_2="134.0" MODIFIED="2011-07-02 05:17:12 +0100" MODIFIED_BY="[Empty name]" ORDER="4373" SD_1="4.0" SD_2="4.0" SE="0.37839553800644" STUDY_ID="STD-German_x002d_Austrian-1994" TOTAL_1="225" TOTAL_2="222" WEIGHT="61.17675409933606"/>
<CONT_DATA CI_END="4.186195948697263" CI_START="-2.186195948697262" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="139.0" MEAN_2="138.0" MODIFIED="2012-01-03 12:26:25 +0000" MODIFIED_BY="Deren Wang" ORDER="4374" SD_1="9.0" SD_2="9.0" SE="1.6256400494241574" STUDY_ID="STD-Martinez_x002d_Vila-1990" TOTAL_1="58" TOTAL_2="65" WEIGHT="32.966548260689436"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-03-19 10:31:55 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Calcium antagonists versus control: subgroup analysis</NAME>
<DICH_OUTCOME CHI2="30.8596735680152" CI_END="1.1533383209920907" CI_START="1.0021503317337805" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0750899408809969" ESTIMABLE="YES" EVENTS_1="1741" EVENTS_2="1224" I2="28.70955050282156" I2_Q="25.232531980506366" ID="CMP-002.01" LOG_CI_END="0.06195672220143111" LOG_CI_START="9.328745704221371E-4" LOG_EFFECT_SIZE="0.031444798385926655" METHOD="MH" MODIFIED="2012-03-06 12:20:10 +0000" MODIFIED_BY="tingting Yuan" NO="1" P_CHI2="0.09902295785747617" P_Q="0.2625065087615658" P_Z="0.04339499416775181" Q="2.674960183857708" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.007516194883249975" TOTALS="SUB" TOTAL_1="3795" TOTAL_2="3023" WEIGHT="300.0" Z="2.0198881168621043">
<NAME>Primary outcome by route of administration</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favors treatment group</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favors control group</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="20.859630390764266" CI_END="1.1442729269378697" CI_START="0.9267170412530025" DF="13" EFFECT_SIZE="1.0297656147093743" ESTIMABLE="YES" EVENTS_1="1245" EVENTS_2="884" I2="37.67866565001155" ID="CMP-002.01.01" LOG_CI_END="0.058529622819111844" LOG_CI_START="-0.03305285073296475" LOG_EFFECT_SIZE="0.01273838604307352" MODIFIED="2011-06-06 03:42:24 +0100" MODIFIED_BY="Deren Wagg" NO="1" P_CHI2="0.07575180089406874" P_Z="0.5855950153473353" STUDIES="14" TAU2="0.011101929464947521" TOTAL_1="2862" TOTAL_2="2269" WEIGHT="100.00000000000001" Z="0.5452304769076795">
<NAME>Oral administration</NAME>
<DICH_DATA CI_END="3.7086562974712898" CI_START="0.11983975024794946" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.569216586623787" LOG_CI_START="-0.9213991047351496" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="4377" O_E="0.0" SE="0.8755950357709131" STUDY_ID="STD-Bogousslavsky-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.7666666666666666" WEIGHT="0.3720913197100475"/>
<DICH_DATA CI_END="0.728799715585044" CI_START="0.043552861743284196" EFFECT_SIZE="0.1781609195402299" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.13739180551896332" LOG_CI_START="-1.3609833033776908" LOG_EFFECT_SIZE="-0.7491875544483271" ORDER="4383" O_E="0.0" SE="0.718743702717815" STUDY_ID="STD-Gelmers-1984" TOTAL_1="29" TOTAL_2="31" VAR="0.5165925101965148" WEIGHT="0.5484252279582592"/>
<DICH_DATA CI_END="1.092074862157147" CI_START="0.4562598347969956" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="34" LOG_CI_END="0.0382524104450592" LOG_CI_START="-0.3407877611063574" LOG_EFFECT_SIZE="-0.15126767533064908" ORDER="4384" O_E="0.0" SE="0.22265007304841153" STUDY_ID="STD-Gelmers-1988" TOTAL_1="93" TOTAL_2="93" VAR="0.04957305502846299" WEIGHT="4.769691262056657"/>
<DICH_DATA CI_END="1.3638514450460373" CI_START="0.7423542664302464" EFFECT_SIZE="1.0062111801242235" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="63" LOG_CI_END="0.13476706818680004" LOG_CI_START="-0.1293887911652377" LOG_EFFECT_SIZE="0.002689138510781192" ORDER="4385" O_E="0.0" SE="0.15516645937597937" STUDY_ID="STD-German_x002d_Austrian-1994" TOTAL_1="230" TOTAL_2="243" VAR="0.024076630115277456" WEIGHT="8.226628571976125"/>
<DICH_DATA CI_END="2.1123931866731938" CI_START="0.9321383331068318" EFFECT_SIZE="1.403225806451613" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="31" LOG_CI_END="0.3247747580424526" LOG_CI_START="-0.030519631801723287" LOG_EFFECT_SIZE="0.14712756312036468" ORDER="4381" O_E="0.0" SE="0.20870168333006317" STUDY_ID="STD-Kaste-1994" TOTAL_1="176" TOTAL_2="174" VAR="0.043556392624801966" WEIGHT="5.294727907827908"/>
<DICH_DATA CI_END="2.1571053063633716" CI_START="1.0130498460326902" EFFECT_SIZE="1.4782608695652173" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="23" LOG_CI_END="0.33387134716845807" LOG_CI_START="0.005630814880866398" LOG_EFFECT_SIZE="0.16975108102466221" ORDER="4376" O_E="0.0" SE="0.19281011348257088" STUDY_ID="STD-Lowe--1989" TOTAL_1="56" TOTAL_2="56" VAR="0.03717573986116186" WEIGHT="5.994509416119023"/>
<DICH_DATA CI_END="1.4422893385463413" CI_START="0.4873415074756402" EFFECT_SIZE="0.8383838383838383" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.15905239320522538" LOG_CI_START="-0.31216659764817745" LOG_EFFECT_SIZE="-0.07655710222147603" ORDER="4387" O_E="0.0" SE="0.27679636779891276" STUDY_ID="STD-Martinez_x002d_Vila-1990" TOTAL_1="81" TOTAL_2="83" VAR="0.076616229226671" WEIGHT="3.2992136141509723"/>
<DICH_DATA CI_END="1.1359784548030891" CI_START="0.9002883040792722" EFFECT_SIZE="1.011290322580645" ESTIMABLE="YES" EVENTS_1="475" EVENTS_2="155" LOG_CI_END="0.055370094536212784" LOG_CI_START="-0.045618391871287696" LOG_EFFECT_SIZE="0.0048758513324625415" ORDER="4380" O_E="0.0" SE="0.05932113681683583" STUDY_ID="STD-Mohr-1992" TOTAL_1="800" TOTAL_2="264" VAR="0.003518997273241756" WEIGHT="19.793611482077914"/>
<DICH_DATA CI_END="1.0911833709352186" CI_START="0.8209456033333303" EFFECT_SIZE="0.9464682724738903" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="211" LOG_CI_END="0.03789773894170851" LOG_CI_START="-0.08568561870861255" LOG_EFFECT_SIZE="-0.023893939883451995" ORDER="4378" O_E="0.0" SE="0.07259347603128512" STUDY_ID="STD-NEST-1993" TOTAL_1="437" TOTAL_2="443" VAR="0.005269812762304767" WEIGHT="17.67685682724154"/>
<DICH_DATA CI_END="2.112849075188671" CI_START="0.5726864328404293" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.3248684756828304" LOG_CI_START="-0.2420831053663803" LOG_EFFECT_SIZE="0.04139268515822508" ORDER="4382" O_E="0.0" SE="0.33303016516389455" STUDY_ID="STD-NIMPAS-1999" TOTAL_1="25" TOTAL_2="25" VAR="0.1109090909090909" WEIGHT="2.3719246218616346"/>
<DICH_DATA CI_END="2.1189352691236043" CI_START="0.10123727637314173" EFFECT_SIZE="0.4631578947368421" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3261176897491048" LOG_CI_START="-0.9946595473544253" LOG_EFFECT_SIZE="-0.33427092880266035" ORDER="4379" O_E="0.0" SE="0.77583108702738" STUDY_ID="STD-Paci-1989" TOTAL_1="19" TOTAL_2="22" VAR="0.6019138755980862" WEIGHT="0.47209377143854464"/>
<DICH_DATA CI_END="1.2176136484476676" CI_START="0.9434511318941734" EFFECT_SIZE="1.071801742318861" ESTIMABLE="YES" EVENTS_1="275" EVENTS_2="257" LOG_CI_END="0.0855095075377719" LOG_CI_START="-0.02528059014488096" LOG_EFFECT_SIZE="0.03011445869644548" ORDER="4375" O_E="0.0" SE="0.0650786517986186" STUDY_ID="STD-TRUST-1990" TOTAL_1="607" TOTAL_2="608" VAR="0.004235230919925845" WEIGHT="18.869264981350245"/>
<DICH_DATA CI_END="2.0964042004014067" CI_START="0.9503957371917446" EFFECT_SIZE="1.4115288220551379" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="30" LOG_CI_END="0.3214750211933707" LOG_CI_START="-0.022095520298755573" LOG_EFFECT_SIZE="0.14968975044730756" MODIFIED="2011-06-06 03:37:48 +0100" MODIFIED_BY="Deren Wagg" ORDER="4388" O_E="0.0" SE="0.20181503677408394" STUDY_ID="STD-VENUS-1999" TOTAL_1="133" TOTAL_2="128" VAR="0.04072930906812486" WEIGHT="5.583523596083525"/>
<DICH_DATA CI_END="1.3654657792336078" CI_START="0.677868258077594" EFFECT_SIZE="0.9620841487279843" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="28" LOG_CI_END="0.13528082049461665" LOG_CI_START="-0.16885470192843588" LOG_EFFECT_SIZE="-0.01678694071690962" ORDER="4386" O_E="0.0" SE="0.17865071136641736" STUDY_ID="STD-Wimalaratna-1994" TOTAL_1="146" TOTAL_2="69" VAR="0.03191607667172696" WEIGHT="6.7274374001476085"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.462930263787525" CI_END="1.2203893723581536" CI_START="1.0106895990731117" DF="7" EFFECT_SIZE="1.1106011189719505" ESTIMABLE="YES" EVENTS_1="493" EVENTS_2="340" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.0864984169756903" LOG_CI_START="0.004617796433545542" LOG_EFFECT_SIZE="0.04555810670461787" NO="2" P_CHI2="0.486849893816481" P_Z="0.029180830117792968" STUDIES="8" TAU2="0.0" TOTAL_1="862" TOTAL_2="682" WEIGHT="99.99999999999999" Z="2.1810349690479995">
<NAME>Intravenous administration</NAME>
<DICH_DATA CI_END="1.399499026749544" CI_START="0.7358087918133415" EFFECT_SIZE="1.0147727272727274" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="44" LOG_CI_END="0.1459726007818528" LOG_CI_START="-0.13323502730509712" LOG_EFFECT_SIZE="0.006368786738377846" ORDER="4395" O_E="0.0" SE="0.16400794283832365" STUDY_ID="STD-ASCLEPIOS-1990" TOTAL_1="120" TOTAL_2="114" VAR="0.02689860531405884" WEIGHT="8.600182993834512"/>
<DICH_DATA CI_END="1.401303642403668" CI_START="0.9365586636491369" EFFECT_SIZE="1.1456016177957533" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="43" LOG_CI_END="0.14653225086904367" LOG_CI_START="-0.028465014336607967" LOG_EFFECT_SIZE="0.05903361826621785" ORDER="4393" O_E="0.0" SE="0.10279425983223325" STUDY_ID="STD-Bridgers-1991" TOTAL_1="138" TOTAL_2="66" VAR="0.010566659854456682" WEIGHT="21.892720231953582"/>
<DICH_DATA CI_END="1.2507592153141303" CI_START="0.6469643540996552" EFFECT_SIZE="0.8995535714285714" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="42" LOG_CI_END="0.09717371135183471" LOG_CI_START="-0.18911964706590384" LOG_EFFECT_SIZE="-0.04597296785703457" ORDER="4390" O_E="0.0" SE="0.16817013590955968" STUDY_ID="STD-Canwin-1993" TOTAL_1="96" TOTAL_2="93" VAR="0.028281194611839772" WEIGHT="8.179743860006154"/>
<DICH_DATA CI_END="1.3642571070596832" CI_START="0.9092120853803934" EFFECT_SIZE="1.1137320365800552" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="83" LOG_CI_END="0.13489622490617373" LOG_CI_START="-0.04133480020274899" LOG_EFFECT_SIZE="0.04678071235171239" ORDER="4391" O_E="0.0" SE="0.10351897650662473" STUDY_ID="STD-FIST-1990" TOTAL_1="166" TOTAL_2="165" VAR="0.01071617849697912" WEIGHT="21.587259678909604"/>
<DICH_DATA CI_END="3.405859213276469" CI_START="0.39557056492806414" EFFECT_SIZE="1.1607142857142858" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5322266917296774" LOG_CI_START="-0.40277603245636695" LOG_EFFECT_SIZE="0.0647253296366552" ORDER="4394" O_E="0.0" SE="0.549225228525012" STUDY_ID="STD-Heiss-1990" TOTAL_1="14" TOTAL_2="13" VAR="0.30164835164835163" WEIGHT="0.7668960453976331"/>
<DICH_DATA CI_END="1.549988410037078" CI_START="1.0292433953115954" EFFECT_SIZE="1.2630579297245963" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="54" LOG_CI_END="0.19032845076657462" LOG_CI_START="0.012518088796623928" LOG_EFFECT_SIZE="0.10142326978159924" ORDER="4392" O_E="0.0" SE="0.10444668679663607" STUDY_ID="STD-INWEST--1990" TOTAL_1="195" TOTAL_2="100" VAR="0.010909110382794593" WEIGHT="21.205480544470834"/>
<DICH_DATA CI_END="1.2881524554389447" CI_START="0.1485897489787242" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.1099672656927676" LOG_CI_START="-0.8280111509761034" LOG_EFFECT_SIZE="-0.3590219426416679" ORDER="4389" O_E="0.0" SE="0.5509731650193398" STUDY_ID="STD-Limburg-1990" TOTAL_1="12" TOTAL_2="14" VAR="0.3035714285714286" WEIGHT="0.7620378804041639"/>
<DICH_DATA CI_END="1.3720978980720941" CI_START="0.8686175200592556" EFFECT_SIZE="1.0917088776326314" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="62" LOG_CI_END="0.13738509903523813" LOG_CI_START="-0.06117141514380901" LOG_EFFECT_SIZE="0.038106841945714544" ORDER="4396" O_E="0.0" SE="0.11663307929936899" STUDY_ID="STD-Yordanov-1984" TOTAL_1="121" TOTAL_2="117" VAR="0.013603275186852896" WEIGHT="17.005678765023507"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="134.95670892767674" CI_START="0.3732349704718906" DF="0" EFFECT_SIZE="7.097222222222222" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="2.130194478946978" LOG_CI_START="-0.4280176715400894" LOG_EFFECT_SIZE="0.8510884037034443" MODIFIED="2012-03-06 12:20:10 +0000" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="1.0" P_Z="0.19219405556078537" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="72" WEIGHT="100.0" Z="1.3041159378442018">
<NAME>Oral versus intravenous administration (outcome death)</NAME>
<DICH_DATA CI_END="134.95670892767674" CI_START="0.3732349704718906" EFFECT_SIZE="7.097222222222222" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.130194478946978" LOG_CI_START="-0.4280176715400894" LOG_EFFECT_SIZE="0.8510884037034443" ORDER="4397" O_E="0.0" SE="1.5027064805504802" STUDY_ID="STD-Chandra-1995" TOTAL_1="71" TOTAL_2="72" VAR="2.2581267666884104" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="48.83130554852899" CI_END="1.1252449952107437" CI_START="0.9871301003080377" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0539275141078246" ESTIMABLE="YES" EVENTS_1="1532" EVENTS_2="1459" I2="54.946934650075654" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.05124708998892951" LOG_CI_START="-0.005625605058491038" LOG_EFFECT_SIZE="0.022810742465219223" METHOD="MH" MODIFIED="2012-03-19 10:30:22 +0000" MODIFIED_BY="tingting Yuan" NO="2" P_CHI2="8.416540827113073E-4" P_Q="0.5313507940751574" P_Z="0.11589921755592841" Q="3.1603999510342042" RANDOM="YES" SCALE="17.78" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.01951573523186229" TOTALS="SUB" TOTAL_1="3305" TOTAL_2="3304" WEIGHT="500.0" Z="1.5722213851539943">
<NAME>Primary outcome by dose: indirect comparisons</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favors treatment group</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favors control group</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.237568642478342" CI_START="0.9421107867525051" DF="0" EFFECT_SIZE="1.079780888618381" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="155" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.09256929667454296" LOG_CI_START="-0.02589802369735376" LOG_EFFECT_SIZE="0.033335636488594604" MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="Deren Wang" NO="1" P_CHI2="1.0" P_Z="0.27001310848314064" STUDIES="1" TAU2="0.0" TOTAL_1="265" TOTAL_2="264" WEIGHT="100.0" Z="1.1030324095161037">
<NAME>Nimodipine 60 mg versus control oral</NAME>
<DICH_DATA CI_END="1.237568642478342" CI_START="0.9421107867525051" EFFECT_SIZE="1.079780888618381" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="155" LOG_CI_END="0.09256929667454296" LOG_CI_START="-0.02589802369735376" LOG_EFFECT_SIZE="0.033335636488594604" ORDER="4398" O_E="0.0" SE="0.06958829040914566" STUDY_ID="STD-Mohr-1992" TOTAL_1="265" TOTAL_2="264" VAR="0.004842530162067593" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="21.768285428923182" CI_END="1.1072444791066434" CI_START="0.8829427969332024" DF="13" EFFECT_SIZE="0.9887535270588249" ESTIMABLE="YES" EVENTS_1="886" EVENTS_2="897" I2="40.28009214392649" ID="CMP-002.02.02" LOG_CI_END="0.044243523502294116" LOG_CI_START="-0.05406743207474128" LOG_EFFECT_SIZE="-0.0049119542862236095" MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="tingting Yuan" NO="2" P_CHI2="0.05905769594298793" P_Z="0.8447251345861748" STUDIES="14" TAU2="0.013776131348015131" TOTAL_1="2257" TOTAL_2="2269" WEIGHT="99.99999999999997" Z="0.19585311602757507">
<NAME>Nimodipine 120 mg versus control oral</NAME>
<DICH_DATA CI_END="3.7086562974712898" CI_START="0.11983975024794946" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.569216586623787" LOG_CI_START="-0.9213991047351496" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2012-01-04 08:16:21 +0000" MODIFIED_BY="tingting Yuan" ORDER="4402" O_E="0.0" SE="0.8755950357709131" STUDY_ID="STD-Bogousslavsky-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.7666666666666666" WEIGHT="0.4273049872210185"/>
<DICH_DATA CI_END="0.728799715585044" CI_START="0.043552861743284196" EFFECT_SIZE="0.1781609195402299" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.13739180551896332" LOG_CI_START="-1.3609833033776908" LOG_EFFECT_SIZE="-0.7491875544483271" ORDER="4408" O_E="0.0" SE="0.718743702717815" STUDY_ID="STD-Gelmers-1984" TOTAL_1="29" TOTAL_2="31" VAR="0.5165925101965148" WEIGHT="0.6287835925993371"/>
<DICH_DATA CI_END="1.092074862157147" CI_START="0.4562598347969956" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="34" LOG_CI_END="0.0382524104450592" LOG_CI_START="-0.3407877611063574" LOG_EFFECT_SIZE="-0.15126767533064908" ORDER="4410" O_E="0.0" SE="0.22265007304841153" STUDY_ID="STD-Gelmers-1988" TOTAL_1="93" TOTAL_2="93" VAR="0.04957305502846299" WEIGHT="5.264268081527011"/>
<DICH_DATA CI_END="1.3638514450460373" CI_START="0.7423542664302464" EFFECT_SIZE="1.0062111801242235" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="63" LOG_CI_END="0.13476706818680004" LOG_CI_START="-0.1293887911652377" LOG_EFFECT_SIZE="0.002689138510781192" MODIFIED="2012-01-04 08:16:19 +0000" MODIFIED_BY="tingting Yuan" ORDER="4411" O_E="0.0" SE="0.15516645937597937" STUDY_ID="STD-German_x002d_Austrian-1994" TOTAL_1="230" TOTAL_2="243" VAR="0.024076630115277456" WEIGHT="8.81011284092961"/>
<DICH_DATA CI_END="1.048558808054204" CI_START="0.46269883167131476" EFFECT_SIZE="0.6965392561983471" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="44" LOG_CI_END="0.020592792738623075" LOG_CI_START="-0.3347015971055528" LOG_EFFECT_SIZE="-0.15705440218346486" MODIFIED="2012-01-04 08:16:17 +0000" MODIFIED_BY="tingting Yuan" ORDER="4409" O_E="0.0" SE="0.20870168333006317" STUDY_ID="STD-Kaste-1994" TOTAL_1="176" TOTAL_2="174" VAR="0.043556392624801966" WEIGHT="5.816717575359403"/>
<DICH_DATA CI_END="2.1571053063633716" CI_START="1.0130498460326902" EFFECT_SIZE="1.4782608695652173" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="23" LOG_CI_END="0.33387134716845807" LOG_CI_START="0.005630814880866398" LOG_EFFECT_SIZE="0.16975108102466221" ORDER="4404" O_E="0.0" SE="0.19281011348257088" STUDY_ID="STD-Lowe--1989" TOTAL_1="56" TOTAL_2="56" VAR="0.03717573986116186" WEIGHT="6.5451394015208395"/>
<DICH_DATA CI_END="1.4422893385463413" CI_START="0.4873415074756402" EFFECT_SIZE="0.8383838383838383" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.15905239320522538" LOG_CI_START="-0.31216659764817745" LOG_EFFECT_SIZE="-0.07655710222147603" ORDER="4401" O_E="0.0" SE="0.27679636779891276" STUDY_ID="STD-Martinez_x002d_Vila-1990" TOTAL_1="81" TOTAL_2="83" VAR="0.076616229226671" WEIGHT="3.689328364832976"/>
<DICH_DATA CI_END="1.1508431037751423" CI_START="0.8650835515285779" EFFECT_SIZE="0.9977852672123255" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="155" LOG_CI_END="0.06101611962524352" LOG_CI_START="-0.06294194546527451" LOG_EFFECT_SIZE="-9.629129200154858E-4" ORDER="4407" O_E="0.0" SE="0.07281358103648856" STUDY_ID="STD-Mohr-1992" TOTAL_1="268" TOTAL_2="264" VAR="0.005301817583357286" WEIGHT="17.48023862691037"/>
<DICH_DATA CI_END="1.0911833709352186" CI_START="0.8209456033333303" EFFECT_SIZE="0.9464682724738903" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="211" LOG_CI_END="0.03789773894170851" LOG_CI_START="-0.08568561870861255" LOG_EFFECT_SIZE="-0.023893939883451995" ORDER="4405" O_E="0.0" SE="0.07259347603128512" STUDY_ID="STD-NEST-1993" TOTAL_1="437" TOTAL_2="443" VAR="0.005269812762304767" WEIGHT="17.50961243510644"/>
<DICH_DATA CI_END="2.112849075188671" CI_START="0.5726864328404293" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.3248684756828304" LOG_CI_START="-0.2420831053663803" LOG_EFFECT_SIZE="0.04139268515822508" ORDER="4399" O_E="0.0" SE="0.33303016516389455" STUDY_ID="STD-NIMPAS-1999" TOTAL_1="25" TOTAL_2="25" VAR="0.1109090909090909" WEIGHT="2.6746321159434236"/>
<DICH_DATA CI_END="2.1189352691236043" CI_START="0.10123727637314173" EFFECT_SIZE="0.4631578947368421" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3261176897491048" LOG_CI_START="-0.9946595473544253" LOG_EFFECT_SIZE="-0.33427092880266035" MODIFIED="2012-01-04 08:16:23 +0000" MODIFIED_BY="tingting Yuan" ORDER="4400" O_E="0.0" SE="0.77583108702738" STUDY_ID="STD-Paci-1989" TOTAL_1="19" TOTAL_2="22" VAR="0.6019138755980862" WEIGHT="0.5416477384236539"/>
<DICH_DATA CI_END="1.2176136484476676" CI_START="0.9434511318941734" EFFECT_SIZE="1.071801742318861" ESTIMABLE="YES" EVENTS_1="275" EVENTS_2="257" LOG_CI_END="0.0855095075377719" LOG_CI_START="-0.02528059014488096" LOG_EFFECT_SIZE="0.03011445869644548" ORDER="4406" O_E="0.0" SE="0.0650786517986186" STUDY_ID="STD-TRUST-1990" TOTAL_1="607" TOTAL_2="608" VAR="0.004235230919925845" WEIGHT="18.515373510974477"/>
<DICH_DATA CI_END="2.0964042004014067" CI_START="0.9503957371917446" EFFECT_SIZE="1.4115288220551379" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="30" LOG_CI_END="0.3214750211933707" LOG_CI_START="-0.022095520298755573" LOG_EFFECT_SIZE="0.14968975044730756" MODIFIED="2011-06-06 03:38:23 +0100" MODIFIED_BY="Deren Wagg" ORDER="4412" O_E="0.0" SE="0.20181503677408394" STUDY_ID="STD-VENUS-1999" TOTAL_1="133" TOTAL_2="128" VAR="0.04072930906812486" WEIGHT="6.118418588791888"/>
<DICH_DATA CI_END="1.462925999274391" CI_START="0.6551036754487332" EFFECT_SIZE="0.9789628180039139" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="28" LOG_CI_END="0.16522235830602652" LOG_CI_START="-0.18368996395895393" LOG_EFFECT_SIZE="-0.0092338028264637" ORDER="4403" O_E="0.0" SE="0.20495282524229974" STUDY_ID="STD-Wimalaratna-1994" TOTAL_1="73" TOTAL_2="69" VAR="0.04200566057480066" WEIGHT="5.978422139859532"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4028869857053194" CI_END="1.2167417108442646" CI_START="0.9403557208768653" DF="1" EFFECT_SIZE="1.0696588374906781" ESTIMABLE="YES" EVENTS_1="198" EVENTS_2="183" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.08519839625776066" LOG_CI_START="-0.02670782896392684" LOG_EFFECT_SIZE="0.029245283646916944" MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.525602064535712" P_Z="0.3056351391441957" STUDIES="2" TAU2="0.0" TOTAL_1="340" TOTAL_2="333" WEIGHT="100.00000000000001" Z="1.02442384330388">
<NAME>Nimodipine 240 mg versus control oral</NAME>
<DICH_DATA CI_END="1.2421887265587472" CI_START="0.9467431987957741" EFFECT_SIZE="1.0844508880028996" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="155" LOG_CI_END="0.09418758350271758" LOG_CI_START="-0.023767806076241026" LOG_EFFECT_SIZE="0.035209888713238276" ORDER="4414" O_E="0.0" SE="0.06928757972727553" STUDY_ID="STD-Mohr-1992" TOTAL_1="267" TOTAL_2="264" VAR="0.0048007687044635625" WEIGHT="90.00630112738139"/>
<DICH_DATA CI_END="1.4207618298525875" CI_START="0.6288269994407758" EFFECT_SIZE="0.9452054794520548" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="28" LOG_CI_END="0.15252128084790387" LOG_CI_START="-0.2014688196143051" LOG_EFFECT_SIZE="-0.024473769383200585" ORDER="4413" O_E="0.0" SE="0.20793553729075923" STUDY_ID="STD-Wimalaratna-1994" TOTAL_1="73" TOTAL_2="69" VAR="0.043237187668396716" WEIGHT="9.993698872618621"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.503648736407166" CI_END="1.9341541640467825" CI_START="0.9290362021245588" DF="3" EFFECT_SIZE="1.340484702967335" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="127" I2="76.0070035295791" ID="CMP-002.02.04" LOG_CI_END="0.28649108708229143" LOG_CI_START="-0.031967362350174264" LOG_EFFECT_SIZE="0.12726186236605866" MODIFIED="2012-03-06 13:52:53 +0000" MODIFIED_BY="Deren Wang" NO="4" P_CHI2="0.005842762129300794" P_Z="0.1172373583114726" STUDIES="4" TAU2="0.0938430911922708" TOTAL_1="280" TOTAL_2="272" WEIGHT="100.0" Z="1.5664754211262568">
<NAME>Nimodipine 2 mg/hour versus control intravenous</NAME>
<DICH_DATA CI_END="2.7493913152075127" CI_START="1.4851989670234484" EFFECT_SIZE="2.0207407407407407" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="27" LOG_CI_END="0.4392365564825005" LOG_CI_START="0.17178463849636993" LOG_EFFECT_SIZE="0.3055105974894352" MODIFIED="2012-01-03 12:31:04 +0000" MODIFIED_BY="Deren Wang" ORDER="4415" O_E="0.0" SE="0.15710258053339882" STUDY_ID="STD-Bridgers-1991" TOTAL_1="75" TOTAL_2="66" VAR="0.024681220810253063" WEIGHT="29.523871972649005"/>
<DICH_DATA CI_END="1.2507592153141303" CI_START="0.6469643540996552" EFFECT_SIZE="0.8995535714285714" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="42" LOG_CI_END="0.09717371135183471" LOG_CI_START="-0.18911964706590384" LOG_EFFECT_SIZE="-0.04597296785703457" MODIFIED="2011-07-02 05:32:15 +0100" MODIFIED_BY="[Empty name]" ORDER="4416" O_E="0.0" SE="0.16817013590955968" STUDY_ID="STD-Canwin-1993" TOTAL_1="96" TOTAL_2="93" VAR="0.028281194611839772" WEIGHT="28.653568699855096"/>
<DICH_DATA CI_END="3.405859213276469" CI_START="0.39557056492806414" EFFECT_SIZE="1.1607142857142858" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5322266917296774" LOG_CI_START="-0.40277603245636695" LOG_EFFECT_SIZE="0.0647253296366552" MODIFIED="2011-07-02 05:32:13 +0100" MODIFIED_BY="[Empty name]" ORDER="4417" O_E="0.0" SE="0.549225228525012" STUDY_ID="STD-Heiss-1990" TOTAL_1="14" TOTAL_2="13" VAR="0.30164835164835163" WEIGHT="8.847970484709043"/>
<DICH_DATA CI_END="1.6955035794937876" CI_START="1.0981524600919346" EFFECT_SIZE="1.364522417153996" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="54" LOG_CI_END="0.22929871098391283" LOG_CI_START="0.0406626388209682" LOG_EFFECT_SIZE="0.13498067490244053" MODIFIED="2011-07-02 05:32:12 +0100" MODIFIED_BY="[Empty name]" ORDER="4418" O_E="0.0" SE="0.11080576255213047" STUDY_ID="STD-INWEST--1990" TOTAL_1="95" TOTAL_2="100" VAR="0.012277917014759119" WEIGHT="32.97458884278685"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7837346282623313" CI_END="1.2894767454287572" CI_START="0.9139037706798225" DF="1" EFFECT_SIZE="1.0855678973934735" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="97" I2="0.0" ID="CMP-002.02.05" LOG_CI_END="0.11041351442817463" LOG_CI_START="-0.03909953081201781" LOG_EFFECT_SIZE="0.03565699180807843" MODIFIED="2012-03-19 10:30:22 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.37600143062780034" P_Z="0.3498636568643767" STUDIES="2" TAU2="0.0" TOTAL_1="163" TOTAL_2="166" WEIGHT="100.0" Z="0.9348538066173558">
<NAME>Nimodipine 1 mg/hour versus control intravenous</NAME>
<DICH_DATA CI_END="1.286054937231175" CI_START="0.7758505162325892" EFFECT_SIZE="0.9988925802879292" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="43" LOG_CI_END="0.10925952101957523" LOG_CI_START="-0.11022194656270327" LOG_EFFECT_SIZE="-4.81212771564051E-4" ORDER="4419" O_E="0.0" SE="0.12892450050861695" STUDY_ID="STD-Bridgers-1991" TOTAL_1="63" TOTAL_2="66" VAR="0.016621526831396373" WEIGHT="46.40475278491188"/>
<DICH_DATA CI_END="1.4759136374831088" CI_START="0.9222159593512725" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="54" LOG_CI_END="0.16906094565649793" LOG_CI_START="-0.035167366395271425" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="4420" O_E="0.0" SE="0.1199647214456583" STUDY_ID="STD-INWEST--1990" TOTAL_1="100" TOTAL_2="100" VAR="0.014391534391534387" WEIGHT="53.59524721508812"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.727184160267957" CI_END="1.0222097379017774" CI_START="0.8946089122948322" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9562834003377318" ESTIMABLE="YES" EVENTS_1="626" EVENTS_2="657" I2="42.70775191426141" I2_Q="62.68406247566244" ID="CMP-002.03" LOG_CI_END="0.00954001386913322" LOG_CI_START="-0.04836677960267888" LOG_EFFECT_SIZE="-0.019413382866772792" METHOD="MH" MODIFIED="2012-03-06 13:52:53 +0000" MODIFIED_BY="tingting Yuan" NO="3" P_CHI2="0.12045336511826898" P_Q="0.04520330261624561" P_Z="0.18879079304076984" Q="8.039460345980565" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.005485697182740431" TOTALS="SUB" TOTAL_1="1034" TOTAL_2="1045" WEIGHT="400.0" Z="1.3141646758763617">
<NAME>Primary outcome by dose: direct comparisons</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favors treatment group</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favors control group</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2398670608293105" CI_START="0.9445435276608805" DF="0" EFFECT_SIZE="1.0821776228818651" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="157" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.09337512238536168" LOG_CI_START="-0.024778023568141475" LOG_EFFECT_SIZE="0.03429854940861008" MODIFIED="2012-03-06 12:20:10 +0000" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="1.0" P_Z="0.2551573885146422" STUDIES="1" TAU2="0.0" TOTAL_1="265" TOTAL_2="268" WEIGHT="100.0" Z="1.1379116657511261">
<NAME>Nimodipine 60 mg versus 120 mg oral</NAME>
<DICH_DATA CI_END="1.2398670608293105" CI_START="0.9445435276608805" EFFECT_SIZE="1.0821776228818651" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="157" LOG_CI_END="0.09337512238536168" LOG_CI_START="-0.024778023568141475" LOG_EFFECT_SIZE="0.03429854940861008" ORDER="4421" O_E="0.0" SE="0.06940374280059283" STUDY_ID="STD-Mohr-1992" TOTAL_1="265" TOTAL_2="268" VAR="0.004816879514730841" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.855985946651381E-30" CI_END="1.1325187936727494" CI_START="0.8753990639068363" DF="0" EFFECT_SIZE="0.9956936736958935" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="170" I2="100.0" ID="CMP-002.03.02" LOG_CI_END="0.054045417678818285" LOG_CI_START="-0.05779392212810569" LOG_EFFECT_SIZE="-0.0018742522246437017" MODIFIED="2012-03-06 12:20:10 +0000" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="0.0" P_Z="0.9476231570139828" STUDIES="1" TAU2="0.0" TOTAL_1="265" TOTAL_2="267" WEIGHT="100.0" Z="0.06569185520206919">
<NAME>Nimodipine 60 mg versus 240 mg oral</NAME>
<DICH_DATA CI_END="1.1325187936727494" CI_START="0.8753990639068363" EFFECT_SIZE="0.9956936736958935" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="170" LOG_CI_END="0.054045417678818285" LOG_CI_START="-0.05779392212810569" LOG_EFFECT_SIZE="-0.0018742522246437017" ORDER="4422" O_E="0.0" SE="0.06569498181624774" STUDY_ID="STD-Mohr-1992" TOTAL_1="265" TOTAL_2="267" VAR="0.0043158306358371205" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3021537223000909" CI_END="1.0587112224938655" CI_START="0.8188371413473088" DF="1" EFFECT_SIZE="0.9310811301595534" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="198" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="0.024777516689083835" LOG_CI_START="-0.08680246655135264" LOG_EFFECT_SIZE="-0.031012474931134456" MODIFIED="2012-03-06 12:19:32 +0000" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="0.5825354636470687" P_Z="0.2759323810199391" STUDIES="2" TAU2="0.0" TOTAL_1="341" TOTAL_2="340" WEIGHT="100.0" Z="1.0895024747493771">
<NAME>Nimodipine 120 mg versus 240 mg oral</NAME>
<DICH_DATA CI_END="1.053530522526933" CI_START="0.8035395812553194" EFFECT_SIZE="0.9200834064969271" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="170" LOG_CI_END="0.022647122357975755" LOG_CI_START="-0.0949927256244834" LOG_EFFECT_SIZE="-0.03617280163325381" ORDER="4423" O_E="0.0" SE="0.06910222903153568" STUDY_ID="STD-Mohr-1992" TOTAL_1="268" TOTAL_2="267" VAR="0.004775118057126812" WEIGHT="89.96294717481481"/>
<DICH_DATA CI_END="1.5535937551588004" CI_START="0.6904662676910714" EFFECT_SIZE="1.0357142857142858" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="28" LOG_CI_END="0.19133746687293832" LOG_CI_START="-0.16085753375946452" LOG_EFFECT_SIZE="0.015239966556736905" ORDER="4424" O_E="0.0" SE="0.20688108676484365" STUDY_ID="STD-Wimalaratna-1994" TOTAL_1="73" TOTAL_2="73" VAR="0.042799784061002766" WEIGHT="10.037052825185187"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.32650096377043175" CI_END="0.9481440583792756" CI_START="0.7146300745076359" DF="1" EFFECT_SIZE="0.8231477747546634" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="132" I2="0.0" ID="CMP-002.03.04" LOG_CI_END="-0.02312567214920321" LOG_CI_START="-0.14591871089054131" LOG_EFFECT_SIZE="-0.08452219151987227" MODIFIED="2012-03-06 13:52:53 +0000" MODIFIED_BY="Deren Wang" NO="4" P_CHI2="0.5677268895663359" P_Z="0.0069714305364816055" STUDIES="2" TAU2="0.0" TOTAL_1="163" TOTAL_2="170" WEIGHT="100.0" Z="2.6982059076216514">
<NAME>Nimodipine 1 versus 2 mg/hour intravenous</NAME>
<DICH_DATA CI_END="0.969724989569151" CI_START="0.6391122986551123" EFFECT_SIZE="0.7872503840245776" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="62" LOG_CI_END="-0.013351412586042027" LOG_CI_START="-0.19442282509475803" LOG_EFFECT_SIZE="-0.10388711884040003" MODIFIED="2012-01-03 12:30:15 +0000" MODIFIED_BY="Deren Wang" ORDER="4425" O_E="0.0" SE="0.10636224402556733" STUDY_ID="STD-Bridgers-1991" TOTAL_1="63" TOTAL_2="75" VAR="0.011312926954154335" WEIGHT="45.98833802956569"/>
<DICH_DATA CI_END="1.0363517249413579" CI_START="0.7053831073049693" EFFECT_SIZE="0.855" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="70" LOG_CI_END="0.01550717459564648" LOG_CI_START="-0.15157494513930125" LOG_EFFECT_SIZE="-0.06803388527182737" MODIFIED="2012-01-03 12:30:13 +0000" MODIFIED_BY="Deren Wang" ORDER="4426" O_E="0.0" SE="0.09814486420213983" STUDY_ID="STD-INWEST--1990" TOTAL_1="100" TOTAL_2="95" VAR="0.00963241436925647" WEIGHT="54.011661970434304"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="45.42948280210434" CI_END="1.125571992588028" CI_START="0.9581427337071771" CI_STUDY="95" CI_TOTAL="95" DF="31" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0384886258224149" ESTIMABLE="YES" EVENTS_1="1595" EVENTS_2="1109" I2="31.762375250805082" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.051373278087135966" LOG_CI_START="-0.01856978962292203" LOG_EFFECT_SIZE="0.016401744232106948" METHOD="MH" MODIFIED="2012-03-19 10:31:55 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.04562799523945571" P_Q="0.4033350212244864" P_Z="0.35797611702273446" Q="0.6983621068863679" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.013228140723947474" TOTALS="YES" TOTAL_1="3365" TOTAL_2="2585" WEIGHT="100.0" Z="0.919228424804833">
<NAME>Primary outcome by time of start of treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favors treatment group</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favors control group</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="19.511931636853973" CI_END="1.2104604163699932" CI_START="0.9619820998253389" DF="17" EFFECT_SIZE="1.079092791698221" ESTIMABLE="YES" EVENTS_1="496" EVENTS_2="332" I2="12.873823481984005" ID="CMP-002.04.01" LOG_CI_END="0.0829505920155329" LOG_CI_START="-0.016833009063441935" LOG_EFFECT_SIZE="0.03305879147604546" MODIFIED="2012-03-19 10:31:55 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.29995075991312503" P_Z="0.1940499366333197" STUDIES="18" TAU2="0.007561220921402763" TOTAL_1="1055" TOTAL_2="824" WEIGHT="42.72347861705245" Z="1.2986911669821763">
<NAME>Treatment started &#8804; 12 hours</NAME>
<DICH_DATA CI_END="1.4637224949832954" CI_START="0.7822945475497385" EFFECT_SIZE="1.0700757575757576" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="44" LOG_CI_END="0.1654587472679779" LOG_CI_START="-0.10662969669672538" LOG_EFFECT_SIZE="0.029414525285626266" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="233" O_E="0.0" SE="0.15982609884438617" STUDY_ID="STD-ASCLEPIOS-1990" TOTAL_1="120" TOTAL_2="113" VAR="0.0255443818718155" WEIGHT="4.353519554162172"/>
<DICH_DATA CI_END="1.6069521753984992" CI_START="0.9012443494565826" EFFECT_SIZE="1.2034353193773484" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="23" LOG_CI_END="0.20600295189116286" LOG_CI_START="-0.04515744516573935" LOG_EFFECT_SIZE="0.08042275336271172" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="232" O_E="0.0" SE="0.1475328604952409" STUDY_ID="STD-Bridgers-1991" TOTAL_1="81" TOTAL_2="38" VAR="0.021765944925908207" WEIGHT="4.823584675816351"/>
<DICH_DATA CI_END="1.4610516599618846" CI_START="0.2649875459141949" EFFECT_SIZE="0.6222222222222222" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.16466557201898996" LOG_CI_START="-0.5767745368852388" LOG_EFFECT_SIZE="-0.20605448243312446" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="231" O_E="0.0" SE="0.4355255901580751" STUDY_ID="STD-Canwin-1993" TOTAL_1="10" TOTAL_2="14" VAR="0.18968253968253965" WEIGHT="0.8318780211406369"/>
<DICH_DATA CI_END="1.426617163713002" CI_START="0.8163161408340087" EFFECT_SIZE="1.0791527313266445" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="46" LOG_CI_END="0.15430744473794158" LOG_CI_START="-0.08814161620933827" LOG_EFFECT_SIZE="0.03308291426430162" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="230" O_E="0.0" SE="0.14241577854263954" STUDY_ID="STD-FIST-1990" TOTAL_1="78" TOTAL_2="88" VAR="0.02028225397790615" WEIGHT="5.0371515103494655"/>
<DICH_DATA CI_END="1.0504748641445714" CI_START="0.29872912947469876" EFFECT_SIZE="0.5601851851851852" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.021385665029535983" LOG_CI_START="-0.5247224266984976" LOG_EFFECT_SIZE="-0.2516683808344808" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="229" O_E="0.0" SE="0.3207865963596989" STUDY_ID="STD-Gelmers-1988" TOTAL_1="48" TOTAL_2="44" VAR="0.10290404040404039" WEIGHT="1.453489753187531"/>
<DICH_DATA CI_END="4.357139134293644" CI_START="0.6719779066781068" EFFECT_SIZE="1.711111111111111" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.6392014282605641" LOG_CI_START="-0.17264500546628783" LOG_EFFECT_SIZE="0.23327821139713817" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="228" O_E="0.0" SE="0.47688261387581266" STUDY_ID="STD-German_x002d_Austrian-1994" TOTAL_1="36" TOTAL_2="28" VAR="0.2274170274170274" WEIGHT="0.7014349657997869"/>
<DICH_DATA CI_END="37.67191710248514" CI_START="0.2389047516619824" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5760177217653923" LOG_CI_START="-0.6217752123260675" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="227" O_E="0.0" SE="1.2909944487358056" STUDY_ID="STD-Heiss-1990" TOTAL_1="1" TOTAL_2="1" VAR="1.6666666666666665" WEIGHT="0.10048065780204508"/>
<DICH_DATA CI_END="1.8621052572547978" CI_START="1.0031737177872617" EFFECT_SIZE="1.3667534722222223" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="24" LOG_CI_END="0.2700042262441098" LOG_CI_START="0.0013761455266291813" LOG_EFFECT_SIZE="0.1356901858853695" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="0.15779346434389324" STUDY_ID="STD-INWEST--1990" TOTAL_1="96" TOTAL_2="47" VAR="0.02489877738964751" WEIGHT="4.427237858091144"/>
<DICH_DATA CI_END="3.634251995983794" CI_START="0.8756904607673716" EFFECT_SIZE="1.7839506172839505" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" LOG_CI_END="0.5604150376310361" LOG_CI_START="-0.057649381203202274" LOG_EFFECT_SIZE="0.2513828282139169" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="225" O_E="0.0" SE="0.36305409909144726" STUDY_ID="STD-Kaste-1994" TOTAL_1="54" TOTAL_2="51" VAR="0.1318082788671024" WEIGHT="1.1638244777470022"/>
<DICH_DATA CI_END="15.07064099877046" CI_START="0.3046875534403948" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.178131724531528" LOG_CI_START="-0.5161452864486791" LOG_EFFECT_SIZE="0.3309932190414244" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="0.9952267030562386" STUDY_ID="STD-Limburg-1990" TOTAL_1="7" TOTAL_2="5" VAR="0.9904761904761905" WEIGHT="0.16817396322582046"/>
<DICH_DATA CI_END="2.633084494479202" CI_START="0.30762400587536404" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.42046479564130995" LOG_CI_START="-0.5119797767626603" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.5477225575051661" STUDY_ID="STD-Lowe--1989" TOTAL_1="5" TOTAL_2="3" VAR="0.3" WEIGHT="0.538894541514429"/>
<DICH_DATA CI_END="1.3390381354348575" CI_START="0.764826508673212" EFFECT_SIZE="1.0119940029985008" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="23" LOG_CI_END="0.12679294577457853" LOG_CI_START="-0.11643706794562657" LOG_EFFECT_SIZE="0.005177938914475995" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="239" O_E="0.0" SE="0.1428745140672344" STUDY_ID="STD-Mohr-1992" TOTAL_1="116" TOTAL_2="36" VAR="0.02041312676994836" WEIGHT="5.017555753970231"/>
<DICH_DATA CI_END="1.1100746917329245" CI_START="0.5645891360091462" EFFECT_SIZE="0.7916666666666666" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="40" LOG_CI_END="0.0453522014137933" LOG_CI_START="-0.2482674829313474" LOG_EFFECT_SIZE="-0.10145764075877708" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="240" O_E="0.0" SE="0.17247365602521395" STUDY_ID="STD-NEST-1993" TOTAL_1="102" TOTAL_2="85" VAR="0.02974716202270382" WEIGHT="3.927766053911084"/>
<DICH_DATA CI_END="2.112849075188671" CI_START="0.5726864328404293" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.3248684756828304" LOG_CI_START="-0.2420831053663803" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="0.33303016516389455" STUDY_ID="STD-NIMPAS-1999" TOTAL_1="25" TOTAL_2="25" VAR="0.1109090909090909" WEIGHT="1.3597607507780478"/>
<DICH_DATA CI_END="2.1189352691236043" CI_START="0.10123727637314173" EFFECT_SIZE="0.4631578947368421" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3261176897491048" LOG_CI_START="-0.9946595473544253" LOG_EFFECT_SIZE="-0.33427092880266035" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="0.77583108702738" STUDY_ID="STD-Paci-1989" TOTAL_1="19" TOTAL_2="22" VAR="0.6019138755980862" WEIGHT="0.2744031960198304"/>
<DICH_DATA CI_END="1.4940258110862508" CI_START="0.774738416732709" EFFECT_SIZE="1.0758620689655172" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="35" LOG_CI_END="0.17435810050180323" LOG_CI_START="-0.1108449082628298" LOG_EFFECT_SIZE="0.031756596119486676" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="235" O_E="0.0" SE="0.1675296591260077" STUDY_ID="STD-TRUST-1990" TOTAL_1="87" TOTAL_2="78" VAR="0.028066186686876337" WEIGHT="4.087654306741529"/>
<DICH_DATA CI_END="2.0964042004014067" CI_START="0.9503957371917446" EFFECT_SIZE="1.4115288220551379" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="30" LOG_CI_END="0.3214750211933707" LOG_CI_START="-0.022095520298755573" LOG_EFFECT_SIZE="0.14968975044730756" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="236" O_E="0.0" SE="0.20181503677408394" STUDY_ID="STD-VENUS-1999" TOTAL_1="133" TOTAL_2="128" VAR="0.04072930906812486" WEIGHT="3.128334195469133"/>
<DICH_DATA CI_END="1.6493519901004907" CI_START="0.4394447806156961" EFFECT_SIZE="0.8513513513513513" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.21731334881939326" LOG_CI_START="-0.35709568937418235" LOG_EFFECT_SIZE="-0.0698911702773945" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="234" O_E="0.0" SE="0.3374107124055027" STUDY_ID="STD-Wimalaratna-1994" TOTAL_1="37" TOTAL_2="18" VAR="0.11384598884598884" WEIGHT="1.3283343813262154"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="25.29482427954003" CI_END="1.1295626591843624" CI_START="0.8974315187889851" DF="13" EFFECT_SIZE="1.006829247091654" ESTIMABLE="YES" EVENTS_1="1099" EVENTS_2="777" I2="48.606086935677276" ID="CMP-002.04.02" LOG_CI_END="0.05291032714060246" LOG_CI_START="-0.04699868163183561" LOG_EFFECT_SIZE="0.00295582275438338" MODIFIED="2012-03-06 13:53:42 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.021107788230096514" P_Z="0.9076750126645361" STUDIES="14" TAU2="0.017874759174932517" TOTAL_1="2310" TOTAL_2="1761" WEIGHT="57.27652138294755" Z="0.1159716468906385">
<NAME>Treatment started &gt; 12 hours</NAME>
<DICH_DATA CI_END="1.4206122413441449" CI_START="0.8221217922406833" EFFECT_SIZE="1.080701754385965" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="20" LOG_CI_END="0.15247555264584042" LOG_CI_START="-0.08506383966197227" LOG_EFFECT_SIZE="0.03370585649193407" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="253" O_E="0.0" SE="0.1395318148805648" STUDY_ID="STD-Bridgers-1991" TOTAL_1="57" TOTAL_2="28" VAR="0.019469127363864205" WEIGHT="5.162417081192478"/>
<DICH_DATA CI_END="1.4341869458423318" CI_START="0.6861556910487372" EFFECT_SIZE="0.9920058139534884" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="32" LOG_CI_END="0.15660576517835928" LOG_CI_START="-0.16357733022379461" LOG_EFFECT_SIZE="-0.0034857825227176424" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="0.18807713517110888" STUDY_ID="STD-Canwin-1993" TOTAL_1="86" TOTAL_2="78" VAR="0.03537300877417156" WEIGHT="3.4731058221448348"/>
<DICH_DATA CI_END="1.656887541007524" CI_START="0.8921428208003732" EFFECT_SIZE="1.2158043940467753" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="34" LOG_CI_END="0.21929303227128577" LOG_CI_START="-0.049565614995597126" LOG_EFFECT_SIZE="0.08486370863784433" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="251" O_E="0.0" SE="0.157928900276335" STUDY_ID="STD-FIST-1990" TOTAL_1="83" TOTAL_2="73" VAR="0.024941537542492564" WEIGHT="4.4222781786782885"/>
<DICH_DATA CI_END="1.9227586808010364" CI_START="0.4829882848663451" EFFECT_SIZE="0.9636752136752137" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.2839247807683854" LOG_CI_START="-0.31606340316071235" LOG_EFFECT_SIZE="-0.01606931119616349" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="0.35243602922936185" STUDY_ID="STD-Gelmers-1988" TOTAL_1="39" TOTAL_2="41" VAR="0.1242111546989596" WEIGHT="1.2281562908588313"/>
<DICH_DATA CI_END="0.9275892901652532" CI_START="0.42087297434592663" EFFECT_SIZE="0.6248177842565598" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="49" LOG_CI_END="-0.032644274317128935" LOG_CI_START="-0.3758489608503732" LOG_EFFECT_SIZE="-0.2042466175837511" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="249" O_E="0.0" SE="0.20160013176022537" STUDY_ID="STD-German_x002d_Austrian-1994" TOTAL_1="112" TOTAL_2="127" VAR="0.04064261312574023" WEIGHT="3.1333687246299275"/>
<DICH_DATA CI_END="3.0209422655530718" CI_START="0.3310225459793489" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.48014242537546103" LOG_CI_START="-0.480142425375461" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="250" O_E="0.0" SE="0.5640760748177661" STUDY_ID="STD-Heiss-1990" TOTAL_1="11" TOTAL_2="11" VAR="0.3181818181818181" WEIGHT="0.5093297010209796"/>
<DICH_DATA CI_END="1.5805167015203103" CI_START="0.9041262611921067" EFFECT_SIZE="1.1954022988505748" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="29" LOG_CI_END="0.19879908944468194" LOG_CI_START="-0.043770916084358194" LOG_EFFECT_SIZE="0.07751408668016187" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="247" O_E="0.0" SE="0.14248682198865084" STUDY_ID="STD-INWEST--1990" TOTAL_1="99" TOTAL_2="52" VAR="0.02030249444042547" WEIGHT="5.034110879718713"/>
<DICH_DATA CI_END="0.7109295270117677" CI_START="0.22876205648921008" EFFECT_SIZE="0.40327868852459015" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="35" LOG_CI_END="-0.14817344785928988" LOG_CI_START="-0.640616007955486" LOG_EFFECT_SIZE="-0.39439472790738794" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="248" O_E="0.0" SE="0.2892631974304916" STUDY_ID="STD-Kaste-1994" TOTAL_1="122" TOTAL_2="123" VAR="0.08367319738771158" WEIGHT="1.741946381486958"/>
<DICH_DATA CI_END="1.6170378960576337" CI_START="0.0076347493416478686" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.20872019792486965" LOG_CI_START="-2.11720521680352" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="242" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-Limburg-1990" TOTAL_1="5" TOTAL_2="9" VAR="1.8666666666666665" WEIGHT="0.0897906279762255"/>
<DICH_DATA CI_END="2.576095243217688" CI_START="0.9432612409208251" EFFECT_SIZE="1.5588235294117647" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="16" LOG_CI_END="0.4109619156905792" LOG_CI_START="-0.02536801057351135" LOG_EFFECT_SIZE="0.19279695255853393" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="241" O_E="0.0" SE="0.2563023585554957" STUDY_ID="STD-Lowe--1989" TOTAL_1="51" TOTAL_2="53" VAR="0.06569089900110987" WEIGHT="2.138862001779458"/>
<DICH_DATA CI_END="1.1530300156294953" CI_START="0.8896606135877299" EFFECT_SIZE="1.0128205128205128" ESTIMABLE="YES" EVENTS_1="395" EVENTS_2="130" LOG_CI_END="0.06184061297777602" LOG_CI_START="-0.050775635777854" LOG_EFFECT_SIZE="0.0055324885999610066" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="244" O_E="0.0" SE="0.066151341978479" STUDY_ID="STD-Mohr-1992" TOTAL_1="684" TOTAL_2="228" VAR="0.004376000045553677" WEIGHT="9.588479068361364"/>
<DICH_DATA CI_END="1.1651099895777337" CI_START="0.8525271558752139" EFFECT_SIZE="0.996638302342683" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="171" LOG_CI_END="0.06636692588727114" LOG_CI_START="-0.06929177836605603" LOG_EFFECT_SIZE="-0.001462426239392477" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="243" O_E="0.0" SE="0.07968659439982058" STUDY_ID="STD-NEST-1993" TOTAL_1="334" TOTAL_2="358" VAR="0.006349953327041517" WEIGHT="8.621724609414771"/>
<DICH_DATA CI_END="1.2349230299942655" CI_START="0.932840626165392" EFFECT_SIZE="1.0733062808750882" ESTIMABLE="YES" EVENTS_1="230" EVENTS_2="218" LOG_CI_END="0.09163988983011659" LOG_CI_START="-0.03019254820336729" LOG_EFFECT_SIZE="0.03072367081337463" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="246" O_E="0.0" SE="0.07156497718116303" STUDY_ID="STD-TRUST-1990" TOTAL_1="520" TOTAL_2="529" VAR="0.0051215459589403845" WEIGHT="9.198900133933163"/>
<DICH_DATA CI_END="1.5480552580265945" CI_START="0.6783647270873213" EFFECT_SIZE="1.0247663551401869" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="20" LOG_CI_END="0.18978645881955813" LOG_CI_START="-0.16853674216289408" LOG_EFFECT_SIZE="0.010624858328332041" MODIFIED="2012-01-25 07:42:01 +0000" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="0.21048082198554363" STUDY_ID="STD-Wimalaratna-1994" TOTAL_1="107" TOTAL_2="51" VAR="0.04430217642371011" WEIGHT="2.934051881751559"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2012-03-06 12:16:51 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Calcium antagonists versus control: sensitivity analysis</NAME>
<DICH_OUTCOME CHI2="11.316520694870981" CI_END="1.1438322166284671" CI_START="0.9501202772008668" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0424865383947752" ESTIMABLE="YES" EVENTS_1="830" EVENTS_2="773" I2="20.470255455114433" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.0583623245125664" LOG_CI_START="-0.022221413218315444" LOG_EFFECT_SIZE="0.018070455647125495" METHOD="MH" MODIFIED="2012-01-27 15:16:22 +0000" MODIFIED_BY="tingting Yuan" NO="1" P_CHI2="0.25463548914822065" P_Q="1.0" P_Z="0.3793893151472465" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="EFFECT_SIZE" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.004251564817659973" TOTALS="YES" TOTAL_1="2029" TOTAL_2="1983" WEIGHT="100.0" Z="0.8790220769077451">
<NAME>Primary outcome in multicenter placebo controlled trials</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favors treatment group</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favors control group</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.092074862157147" CI_START="0.4562598347969956" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="34" LOG_CI_END="0.0382524104450592" LOG_CI_START="-0.3407877611063574" LOG_EFFECT_SIZE="-0.15126767533064908" MODIFIED="2011-12-28 11:06:17 +0000" MODIFIED_BY="tingting Yuan" ORDER="241" O_E="0.0" SE="0.22265007304841153" STUDY_ID="STD-Gelmers-1988" TOTAL_1="93" TOTAL_2="93" VAR="0.04957305502846299" WEIGHT="4.162833567005276"/>
<DICH_DATA CI_END="1.4422893385463413" CI_START="0.4873415074756402" EFFECT_SIZE="0.8383838383838383" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.15905239320522538" LOG_CI_START="-0.31216659764817745" LOG_EFFECT_SIZE="-0.07655710222147603" MODIFIED="2011-12-28 11:06:17 +0000" MODIFIED_BY="tingting Yuan" ORDER="239" O_E="0.0" SE="0.27679636779891276" STUDY_ID="STD-Martinez_x002d_Vila-1990" TOTAL_1="81" TOTAL_2="83" VAR="0.076616229226671" WEIGHT="2.7707313755079044"/>
<DICH_DATA CI_END="1.0911833709352186" CI_START="0.8209456033333303" EFFECT_SIZE="0.9464682724738903" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="211" LOG_CI_END="0.03789773894170851" LOG_CI_START="-0.08568561870861255" LOG_EFFECT_SIZE="-0.023893939883451995" MODIFIED="2011-12-28 11:06:17 +0000" MODIFIED_BY="tingting Yuan" ORDER="240" O_E="0.0" SE="0.07259347603128512" STUDY_ID="STD-NEST-1993" TOTAL_1="437" TOTAL_2="443" VAR="0.005269812762304767" WEIGHT="23.53261724419176"/>
<DICH_DATA CI_END="1.3138485918166842" CI_START="0.7136624182533545" EFFECT_SIZE="0.968320382546324" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="63" LOG_CI_END="0.11854531992145151" LOG_CI_START="-0.14650717276097858" LOG_EFFECT_SIZE="-0.013980926419763548" MODIFIED="2011-12-28 11:06:17 +0000" MODIFIED_BY="tingting Yuan" ORDER="237" O_E="0.0" SE="0.15569314623265834" STUDY_ID="STD-German_x002d_Austrian-1994" TOTAL_1="239" TOTAL_2="243" VAR="0.024240355783823934" WEIGHT="7.8640867128862295"/>
<DICH_DATA CI_END="1.399499026749544" CI_START="0.7358087918133415" EFFECT_SIZE="1.0147727272727274" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="44" LOG_CI_END="0.1459726007818528" LOG_CI_START="-0.13323502730509712" LOG_EFFECT_SIZE="0.006368786738377846" MODIFIED="2011-12-28 11:06:17 +0000" MODIFIED_BY="tingting Yuan" ORDER="238" O_E="0.0" SE="0.16400794283832365" STUDY_ID="STD-ASCLEPIOS-1990" TOTAL_1="120" TOTAL_2="114" VAR="0.02689860531405884" WEIGHT="7.192992310452451"/>
<DICH_DATA CI_END="1.2176136484476676" CI_START="0.9434511318941734" EFFECT_SIZE="1.071801742318861" ESTIMABLE="YES" EVENTS_1="275" EVENTS_2="257" LOG_CI_END="0.0855095075377719" LOG_CI_START="-0.02528059014488096" LOG_EFFECT_SIZE="0.03011445869644548" MODIFIED="2011-12-28 11:06:17 +0000" MODIFIED_BY="tingting Yuan" ORDER="235" O_E="0.0" SE="0.0650786517986186" STUDY_ID="STD-TRUST-1990" TOTAL_1="607" TOTAL_2="608" VAR="0.004235230919925845" WEIGHT="26.40135819864527"/>
<DICH_DATA CI_END="1.3642571070596832" CI_START="0.9092120853803934" EFFECT_SIZE="1.1137320365800552" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="83" LOG_CI_END="0.13489622490617373" LOG_CI_START="-0.04133480020274899" LOG_EFFECT_SIZE="0.04678071235171239" MODIFIED="2011-12-28 11:06:17 +0000" MODIFIED_BY="tingting Yuan" ORDER="236" O_E="0.0" SE="0.10351897650662473" STUDY_ID="STD-FIST-1990" TOTAL_1="166" TOTAL_2="165" VAR="0.01071617849697912" WEIGHT="14.96972051943167"/>
<DICH_DATA CI_END="3.405859213276469" CI_START="0.39557056492806414" EFFECT_SIZE="1.1607142857142858" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5322266917296774" LOG_CI_START="-0.40277603245636695" LOG_EFFECT_SIZE="0.0647253296366552" MODIFIED="2011-12-28 11:06:17 +0000" MODIFIED_BY="tingting Yuan" ORDER="243" O_E="0.0" SE="0.549225228525012" STUDY_ID="STD-Heiss-1990" TOTAL_1="14" TOTAL_2="13" VAR="0.30164835164835163" WEIGHT="0.7324713808858937"/>
<DICH_DATA CI_END="1.8621052572547978" CI_START="1.0031737177872617" EFFECT_SIZE="1.3667534722222223" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="24" LOG_CI_END="0.2700042262441098" LOG_CI_START="0.0013761455266291813" LOG_EFFECT_SIZE="0.1356901858853695" MODIFIED="2011-12-28 11:06:17 +0000" MODIFIED_BY="tingting Yuan" ORDER="242" O_E="0.0" SE="0.15779346434389324" STUDY_ID="STD-INWEST--1990" TOTAL_1="96" TOTAL_2="47" VAR="0.02489877738964751" WEIGHT="7.686459823808531"/>
<DICH_DATA CI_END="2.1123931866731938" CI_START="0.9321383331068318" EFFECT_SIZE="1.403225806451613" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="31" LOG_CI_END="0.3247747580424526" LOG_CI_START="-0.030519631801723287" LOG_EFFECT_SIZE="0.14712756312036468" MODIFIED="2011-12-28 11:06:17 +0000" MODIFIED_BY="tingting Yuan" ORDER="244" O_E="0.0" SE="0.20870168333006317" STUDY_ID="STD-Kaste-1994" TOTAL_1="176" TOTAL_2="174" VAR="0.043556392624801966" WEIGHT="4.686728867185014"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="29.28187594827067" CI_END="1.1362057158347565" CI_START="0.9808351229570715" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0556658907984622" ESTIMABLE="YES" EVENTS_1="1738" EVENTS_2="1224" I2="28.283283362382328" I2_Q="37.96771502915766" ID="CMP-003.02" LOG_CI_END="0.055456969723188664" LOG_CI_START="-0.008403990793309814" LOG_EFFECT_SIZE="0.02352648946493939" METHOD="MH" MODIFIED="2012-01-27 15:16:22 +0000" MODIFIED_BY="tingting Yuan" NO="2" P_CHI2="0.10739701738402407" P_Q="0.20420199527031624" P_Z="0.14870850957783044" Q="1.612063783350944" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.00702896720160179" TOTALS="YES" TOTAL_1="3724" TOTAL_2="2951" WEIGHT="100.0" Z="1.4441083147200542">
<NAME>Publication status</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favors treatment group</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favors control group</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="24.92401893673295" CI_END="1.1243502962453462" CI_START="0.9447850697484327" DF="17" EFFECT_SIZE="1.0306645298349169" ESTIMABLE="YES" EVENTS_1="1484" EVENTS_2="1052" I2="31.792701477427272" ID="CMP-003.02.01" LOG_CI_END="0.05090163865766139" LOG_CI_START="-0.024666978410103135" LOG_EFFECT_SIZE="0.013117330123779095" MODIFIED="2012-01-04 07:49:59 +0000" MODIFIED_BY="tingting Yuan" NO="1" P_CHI2="0.09642334220824622" P_Z="0.49623361647885444" STUDIES="18" TAU2="0.00854241339383348" TOTAL_1="3289" TOTAL_2="2598" WEIGHT="77.8516313178374" Z="0.6804278181477107">
<NAME>Primary outcome in published trials</NAME>
<DICH_DATA CI_END="3.7086562974712898" CI_START="0.11983975024794946" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.569216586623787" LOG_CI_START="-0.9213991047351496" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="290" O_E="0.0" SE="0.8755950357709131" STUDY_ID="STD-Bogousslavsky-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.7666666666666666" WEIGHT="0.18187623306161313"/>
<DICH_DATA CI_END="1.2507592153141303" CI_START="0.6469643540996552" EFFECT_SIZE="0.8995535714285714" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="42" LOG_CI_END="0.09717371135183471" LOG_CI_START="-0.18911964706590384" LOG_EFFECT_SIZE="-0.04597296785703457" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="291" O_E="0.0" SE="0.16817013590955968" STUDY_ID="STD-Canwin-1993" TOTAL_1="96" TOTAL_2="93" VAR="0.028281194611839772" WEIGHT="3.9851657482524145"/>
<DICH_DATA CI_END="1.3642571070596832" CI_START="0.9092120853803934" EFFECT_SIZE="1.1137320365800552" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="83" LOG_CI_END="0.13489622490617373" LOG_CI_START="-0.04133480020274899" LOG_EFFECT_SIZE="0.04678071235171239" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="292" O_E="0.0" SE="0.10351897650662473" STUDY_ID="STD-FIST-1990" TOTAL_1="166" TOTAL_2="165" VAR="0.01071617849697912" WEIGHT="7.929878391217204"/>
<DICH_DATA CI_END="0.728799715585044" CI_START="0.043552861743284196" EFFECT_SIZE="0.1781609195402299" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.13739180551896332" LOG_CI_START="-1.3609833033776908" LOG_EFFECT_SIZE="-0.7491875544483271" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="293" O_E="0.0" SE="0.718743702717815" STUDY_ID="STD-Gelmers-1984" TOTAL_1="29" TOTAL_2="31" VAR="0.5165925101965148" WEIGHT="0.26873773039906984"/>
<DICH_DATA CI_END="1.092074862157147" CI_START="0.4562598347969956" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="34" LOG_CI_END="0.0382524104450592" LOG_CI_START="-0.3407877611063574" LOG_EFFECT_SIZE="-0.15126767533064908" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="294" O_E="0.0" SE="0.22265007304841153" STUDY_ID="STD-Gelmers-1988" TOTAL_1="93" TOTAL_2="93" VAR="0.04957305502846299" WEIGHT="2.4860745584710653"/>
<DICH_DATA CI_END="1.3638514450460373" CI_START="0.7423542664302464" EFFECT_SIZE="1.0062111801242235" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="63" LOG_CI_END="0.13476706818680004" LOG_CI_START="-0.1293887911652377" LOG_EFFECT_SIZE="0.002689138510781192" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="295" O_E="0.0" SE="0.15516645937597937" STUDY_ID="STD-German_x002d_Austrian-1994" TOTAL_1="230" TOTAL_2="243" VAR="0.024076630115277456" WEIGHT="4.523843281023208"/>
<DICH_DATA CI_END="3.405859213276469" CI_START="0.39557056492806414" EFFECT_SIZE="1.1607142857142858" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5322266917296774" LOG_CI_START="-0.40277603245636695" LOG_EFFECT_SIZE="0.0647253296366552" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="282" O_E="0.0" SE="0.549225228525012" STUDY_ID="STD-Heiss-1990" TOTAL_1="14" TOTAL_2="13" VAR="0.30164835164835163" WEIGHT="0.45587038253555484"/>
<DICH_DATA CI_END="1.549988410037078" CI_START="1.0292433953115954" EFFECT_SIZE="1.2630579297245963" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="54" LOG_CI_END="0.19032845076657462" LOG_CI_START="0.012518088796623928" LOG_EFFECT_SIZE="0.10142326978159924" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="283" O_E="0.0" SE="0.10444668679663607" STUDY_ID="STD-INWEST--1990" TOTAL_1="195" TOTAL_2="100" VAR="0.010909110382794593" WEIGHT="7.844589073835965"/>
<DICH_DATA CI_END="2.1123931866731938" CI_START="0.9321383331068318" EFFECT_SIZE="1.403225806451613" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="31" LOG_CI_END="0.3247747580424526" LOG_CI_START="-0.030519631801723287" LOG_EFFECT_SIZE="0.14712756312036468" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="284" O_E="0.0" SE="0.20870168333006317" STUDY_ID="STD-Kaste-1994" TOTAL_1="176" TOTAL_2="174" VAR="0.043556392624801966" WEIGHT="2.7817702178472694"/>
<DICH_DATA CI_END="1.2881524554389447" CI_START="0.1485897489787242" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.1099672656927676" LOG_CI_START="-0.8280111509761034" LOG_EFFECT_SIZE="-0.3590219426416679" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="285" O_E="0.0" SE="0.5509731650193398" STUDY_ID="STD-Limburg-1990" TOTAL_1="12" TOTAL_2="14" VAR="0.3035714285714286" WEIGHT="0.4530478690278482"/>
<DICH_DATA CI_END="1.4422893385463413" CI_START="0.4873415074756402" EFFECT_SIZE="0.8383838383838383" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.15905239320522538" LOG_CI_START="-0.31216659764817745" LOG_EFFECT_SIZE="-0.07655710222147603" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="286" O_E="0.0" SE="0.27679636779891276" STUDY_ID="STD-Martinez_x002d_Vila-1990" TOTAL_1="81" TOTAL_2="83" VAR="0.076616229226671" WEIGHT="1.6823063778067024"/>
<DICH_DATA CI_END="1.1359784548030891" CI_START="0.9002883040792722" EFFECT_SIZE="1.011290322580645" ESTIMABLE="YES" EVENTS_1="475" EVENTS_2="155" LOG_CI_END="0.055370094536212784" LOG_CI_START="-0.045618391871287696" LOG_EFFECT_SIZE="0.0048758513324625415" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="287" O_E="0.0" SE="0.05932113681683583" STUDY_ID="STD-Mohr-1992" TOTAL_1="800" TOTAL_2="264" VAR="0.003518997273241756" WEIGHT="13.340663761219664"/>
<DICH_DATA CI_END="1.0911833709352186" CI_START="0.8209456033333303" EFFECT_SIZE="0.9464682724738903" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="211" LOG_CI_END="0.03789773894170851" LOG_CI_START="-0.08568561870861255" LOG_EFFECT_SIZE="-0.023893939883451995" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="288" O_E="0.0" SE="0.07259347603128512" STUDY_ID="STD-NEST-1993" TOTAL_1="437" TOTAL_2="443" VAR="0.005269812762304767" WEIGHT="11.441528983943275"/>
<DICH_DATA CI_END="2.112849075188671" CI_START="0.5726864328404293" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.3248684756828304" LOG_CI_START="-0.2420831053663803" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="289" O_E="0.0" SE="0.33303016516389455" STUDY_ID="STD-NIMPAS-1999" TOTAL_1="25" TOTAL_2="25" VAR="0.1109090909090909" WEIGHT="1.1931419736630358"/>
<DICH_DATA CI_END="2.1189352691236043" CI_START="0.10123727637314173" EFFECT_SIZE="0.4631578947368421" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3261176897491048" LOG_CI_START="-0.9946595473544253" LOG_EFFECT_SIZE="-0.33427092880266035" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="281" O_E="0.0" SE="0.77583108702738" STUDY_ID="STD-Paci-1989" TOTAL_1="19" TOTAL_2="22" VAR="0.6019138755980862" WEIGHT="0.23108383502335794"/>
<DICH_DATA CI_END="1.2176136484476676" CI_START="0.9434511318941734" EFFECT_SIZE="1.071801742318861" ESTIMABLE="YES" EVENTS_1="275" EVENTS_2="257" LOG_CI_END="0.0855095075377719" LOG_CI_START="-0.02528059014488096" LOG_EFFECT_SIZE="0.03011445869644548" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="280" O_E="0.0" SE="0.0650786517986186" STUDY_ID="STD-TRUST-1990" TOTAL_1="607" TOTAL_2="608" VAR="0.004235230919925845" WEIGHT="12.492398118890142"/>
<DICH_DATA CI_END="2.0964042004014067" CI_START="0.9503957371917446" EFFECT_SIZE="1.4115288220551379" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="30" LOG_CI_END="0.3214750211933707" LOG_CI_START="-0.022095520298755573" LOG_EFFECT_SIZE="0.14968975044730756" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="279" O_E="0.0" SE="0.20181503677408394" STUDY_ID="STD-VENUS-1999" TOTAL_1="133" TOTAL_2="128" VAR="0.04072930906812486" WEIGHT="2.9464389926773027"/>
<DICH_DATA CI_END="1.3654657792336078" CI_START="0.677868258077594" EFFECT_SIZE="0.9620841487279843" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="28" LOG_CI_END="0.13528082049461665" LOG_CI_START="-0.16885470192843588" LOG_EFFECT_SIZE="-0.01678694071690962" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="278" O_E="0.0" SE="0.17865071136641736" STUDY_ID="STD-Wimalaratna-1994" TOTAL_1="146" TOTAL_2="69" VAR="0.03191607667172696" WEIGHT="3.6132157889427026"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.4609536045395473" CI_END="1.2961637503240757" CI_START="1.0021800862393666" DF="3" EFFECT_SIZE="1.139732204985067" ESTIMABLE="YES" EVENTS_1="254" EVENTS_2="172" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.11265987141865624" LOG_CI_START="9.457688691593729E-4" LOG_EFFECT_SIZE="0.056802820143907806" MODIFIED="2012-01-04 07:50:04 +0000" MODIFIED_BY="tingting Yuan" NO="2" P_CHI2="0.48238922972299414" P_Z="0.046245024385004385" STUDIES="4" TAU2="0.0" TOTAL_1="435" TOTAL_2="353" WEIGHT="22.148368682162598" Z="1.9931499991782735">
<NAME>Primary outcome in unpublished trials</NAME>
<DICH_DATA CI_END="1.399499026749544" CI_START="0.7358087918133415" EFFECT_SIZE="1.0147727272727274" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="44" LOG_CI_END="0.1459726007818528" LOG_CI_START="-0.13323502730509712" LOG_EFFECT_SIZE="0.006368786738377846" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="299" O_E="0.0" SE="0.16400794283832365" STUDY_ID="STD-ASCLEPIOS-1990" TOTAL_1="120" TOTAL_2="114" VAR="0.02689860531405884" WEIGHT="4.147566035242404"/>
<DICH_DATA CI_END="1.401303642403668" CI_START="0.9365586636491369" EFFECT_SIZE="1.1456016177957533" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="43" LOG_CI_END="0.14653225086904367" LOG_CI_START="-0.028465014336607967" LOG_EFFECT_SIZE="0.05903361826621785" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="298" O_E="0.0" SE="0.10279425983223325" STUDY_ID="STD-Bridgers-1991" TOTAL_1="138" TOTAL_2="66" VAR="0.010566659854456682" WEIGHT="7.997262443439122"/>
<DICH_DATA CI_END="2.1571053063633716" CI_START="1.0130498460326902" EFFECT_SIZE="1.4782608695652173" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="23" LOG_CI_END="0.33387134716845807" LOG_CI_START="0.005630814880866398" LOG_EFFECT_SIZE="0.16975108102466221" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="297" O_E="0.0" SE="0.19281011348257088" STUDY_ID="STD-Lowe--1989" TOTAL_1="56" TOTAL_2="56" VAR="0.03717573986116186" WEIGHT="3.183300077622552"/>
<DICH_DATA CI_END="1.3720978980720941" CI_START="0.8686175200592556" EFFECT_SIZE="1.0917088776326314" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="62" LOG_CI_END="0.13738509903523813" LOG_CI_START="-0.06117141514380901" LOG_EFFECT_SIZE="0.038106841945714544" MODIFIED="2011-12-23 12:29:54 +0000" MODIFIED_BY="Jing Zhang" ORDER="296" O_E="0.0" SE="0.11663307929936899" STUDY_ID="STD-Yordanov-1984" TOTAL_1="121" TOTAL_2="117" VAR="0.013603275186852896" WEIGHT="6.820240125858521"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-03-16 11:13:11 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-03-16 11:13:07 +0000" MODIFIED_BY="[Empty name]" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: primary outcome at end of follow-up.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-03-16 11:13:09 +0000" MODIFIED_BY="tingting Yuan" NO="2" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: death at end of treatment period.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2012-03-16 11:13:10 +0000" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.03" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: death at end of follow-up.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2012-03-16 11:13:11 +0000" MODIFIED_BY="tingting Yuan" NO="4" REF_ID="CMP-001.05" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: adverse events (all) during treatment period.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-03-16 11:13:34 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-03-05 12:16:27 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-07-31 02:51:29 +0100" MODIFIED_BY="[Empty name]">Appendix 1</TITLE>
<APPENDIX_BODY MODIFIED="2012-03-05 12:16:27 +0000" MODIFIED_BY="[Empty name]">
<P>MEDLINE (Ovid)<BR/>1. cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or exp brain ischemia/ or carotid artery diseases/ or carotid artery thrombosis/ or intracranial arterial diseases/ or cerebral arterial diseases/ or exp "intracranial embolism and thrombosis"/ or exp stroke/<BR/>2. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or attack$)).tw.<BR/>3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.<BR/>4. 1 or 2 or 3<BR/>5. exp Calcium Channel Blockers/<BR/>6. Calcium/ai<BR/>7. (calcium adj3 (antagonist$ or block$ or inhibitor$)).tw.<BR/>8. (amlodipine or amrinone or azelnidipine or bencyclan$ or bepridil or AT877 or AT 877 or cilnidipine or cinnarizine or conotoxin$ or daropidine or diltiazem or efonidipine or felodipine or fendiline or flunarizine or gallopamil or isradipine or lacidopine or lidoflazine or magnesium sul$ or mibefradil or nicardipine or nifedipine or nimodipine or nisoldipine or nitrendipine or perhexiline or prenylamine or verapamil).tw.<BR/>9. 5 or 6 or 7 or 8<BR/>10. Randomized Controlled Trials as Topic/<BR/>11. random allocation/<BR/>12. Controlled Clinical Trials as Topic/<BR/>13. control groups/<BR/>14. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or clinical trials, phase iv as topic/<BR/>15. double-blind method/<BR/>16. single-blind method/<BR/>17. Placebos/<BR/>18. placebo effect/<BR/>19. Drug Evaluation/<BR/>20. Research Design/<BR/>21. randomized controlled trial.pt.<BR/>22. controlled clinical trial.pt.<BR/>23. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.<BR/>24. random$.tw.<BR/>25. (controlled adj5 (trial$ or stud$)).tw.<BR/>26. (clinical$ adj5 trial$).tw.<BR/>27. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.<BR/>28. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.<BR/>29. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.<BR/>30. (coin adj5 (flip or flipped or toss$)).tw.<BR/>31. placebo$.tw.<BR/>32. sham.tw.<BR/>33. (assign$ or alternate or allocat$).tw.<BR/>34. or/10-33<BR/>35. 4 and 9 and 34<BR/>36. limit 35 to humans</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-03-15 16:03:14 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-07-31 02:56:39 +0100" MODIFIED_BY="[Empty name]">Appendix 2</TITLE>
<APPENDIX_BODY MODIFIED="2012-03-15 16:03:14 +0000" MODIFIED_BY="[Empty name]">
<P>EMBASE (ovid) </P>
<P>1. cerebrovascular disease/ or cerebral artery disease/ or cerebrovascular accident/ or stroke/ or vertebrobasilar insufficiency/ or carotid artery disease/ or exp carotid artery obstruction/ or exp brain infarction/ or exp brain ischemia/ or exp occlusive cerebrovascular disease/<BR/>2. stroke patient/ or stroke unit/<BR/>3. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or attack$)).tw.<BR/>4. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.<BR/>5. 1 or 2 or 3 or 4<BR/>6. exp calcium antagonist/<BR/>7. (calcium adj3 (antagonist$ or block$ or inhibitor$)).tw.<BR/>8. (amlodipine or amrinone or azelnidipine or bencyclan$ or bepridil or AT877 or AT 877 or cilnidipine or cinnarizine or conotoxin$ or daropidine or diltiazem or efonidipine or felodipine or fendiline or flunarizine or gallopamil or isradipine or lacidopine or lidoflazine or magnesium sul$ or mibefradil or nicardipine or nifedipine or nimodipine or nisoldipine or nitrendipine or perhexiline or prenylamine or verapamil).tw.<BR/>9. 6 or 7 or 8<BR/>10. Randomized Controlled Trial/<BR/>11. Randomization/<BR/>12. Controlled Study/<BR/>13. control group/<BR/>14. clinical trial/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/ or controlled clinical trial/<BR/>15. Double Blind Procedure/<BR/>16. Single Blind Procedure/ or triple blind procedure/<BR/>17. placebo/<BR/>18. drug comparison/ or drug dose comparison/<BR/>19. "types of study"/<BR/>20. random$.tw.<BR/>21. (controlled adj5 (trial$ or stud$)).tw.<BR/>22. (clinical$ adj5 trial$).tw.<BR/>23. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.<BR/>24. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.<BR/>25. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.<BR/>26. (coin adj5 (flip or flipped or toss$)).tw.<BR/>27. placebo$.tw.<BR/>28. sham.tw.<BR/>29. (assign$ or alternate or allocat$).tw.<BR/>30. or/10-29<BR/>31. 5 and 9 and 30<BR/>32. limit 31 to human</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-03-16 11:13:34 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-07-31 02:57:48 +0100" MODIFIED_BY="[Empty name]">Appendix 3</TITLE>
<APPENDIX_BODY MODIFIED="2012-03-16 11:13:34 +0000" MODIFIED_BY="[Empty name]">
<P>The Cochrane Central Register of Controlled Trials</P>
<P>#1. MeSH descriptor cerebrovascular disorders this term only</P>
<P>#2. MeSH descriptor basal ganglia cerebrovascular disease this term only</P>
<P>#3. MeSH descriptor brain ischemia explode all trees</P>
<P>#4. MeSH descriptor carotid artery diseases this term only</P>
<P>#5. MeSH descriptor carotid artery thrombosis this term only</P>
<P>#6. MeSH descriptor intracranial arterial diseases this term only</P>
<P>#7. MeSH descriptor cerebral arterial diseases this term only</P>
<P>#8. MeSH descriptor intracranial embolism and thrombosis explode all trees</P>
<P>#9. MeSH descriptor stroke explode all trees</P>
<P>#10. (ischaemic in Title, Abstract or Keywords or ischemic in Title, Abstract or Keywords)</P>
<P>#11. (stroke* in Title, Abstract or Keywords or apoplex* in Title, Abstract or Keywords or (cerebral in Title, Abstract or Keywords and vasc* in Title, Abstract or Keywords) or cerebrovasc* in Title, Abstract or Keywords or cva in Title, Abstract or Keywords or attack* in Title, Abstract or Keywords)</P>
<P>#12. (#10 and #11)</P>
<P>#13. (brain in Title, Abstract or Keywords or cerebr* in Title, Abstract or Keywords or cerebell* in Title, Abstract or Keywords or vertebrobasil* in Title, Abstract or Keywords or hemispher* in Title, Abstract or Keywords or intracran* in Title, Abstract or Keywords or intracerebral in Title, Abstract or Keywords or infratentorial in Title, Abstract or Keywords or supratentorial in Title, Abstract or Keywords or (middle in Title, Abstract or Keywords and cerebr* in Title, Abstract or Keywords) or mca* in Title, Abstract or Keywords or (anterior in Title, Abstract or Keywords and circulation in Title, Abstract or Keywords) )</P>
<P>#14. (ischemi* in Title, Abstract or Keywords or ischaemi* in Title, Abstract or Keywords or infarct* in Title, Abstract or Keywords or thrombo* in Title, Abstract or Keywords or emboli* in Title, Abstract or Keywords or occlus* in Title, Abstract or Keywords or hypoxi* in Title, Abstract or Keywords)</P>
<P>#15. (#13 and #14)</P>
<P>#16. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #12 or #15)</P>
<P>#17. MeSH descriptor Calcium Channel Blockers explode all trees</P>
<P>#18. MeSH descriptor calcium this term only with qualifiers: AI</P>
<P>#19. calcium in Title, Abstract or Keywords</P>
<P>#20. (antagonist* in Title, Abstract or Keywords or block* in Title, Abstract or Keywords or inhibitor* in Title, Abstract or Keywords)</P>
<P>#21.(#19 and #20)</P>
<P>#22. (amlodipine in Title, Abstract or Keywords or amrinone in Title, Abstract or Keywords or azelnidipine in Title, Abstract or Keywords or bencyclan* in Title, Abstract or Keywords or bepridil in Title, Abstract or Keywords or AT877 in Title, Abstract or Keywords or (AT in Title, Abstract or Keywords and 877 in Title, Abstract or Keywords) or cilnidipine in Title, Abstract or Keywords or cinnarizine in Title, Abstract or Keywords or conotoxin* in Title, Abstract or Keywords or daropidine in Title, Abstract or Keywords or diltiazem in Title, Abstract or Keywords or efonidipine in Title, Abstract or Keywords or felodipine in Title, Abstract or Keywords or fendiline in Title, Abstract or Keywords or flunarizine in Title, Abstract or Keywords or gallopamil in Title, Abstract or Keywords or isradipine in Title, Abstract or Keywords or lacidopine in Title, Abstract or Keywords or lidoflazine in Title, Abstract or Keywords or (magnesium in Title, Abstract or Keywords and sul* in Title, Abstract or Keywords) or mibefradil in Title, Abstract or Keywords or nicardipine in Title, Abstract or Keywords or nifedipine in Title, Abstract or Keywords or nimodipine in Title, Abstract or Keywords or nisoldipine in Title, Abstract or Keywords or nitrendipine in Title, Abstract or Keywords or perhexiline in Title, Abstract or Keywords or prenylamine in Title, Abstract or Keywords or verapamil in Title, Abstract or Keywords)</P>
<P>#23. (#17 or #18 or #21 or #22) #24.(#16 and #23)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>